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Abstract 
 
Introduction: The mismatch repair system plays an important role in maintaining the genome 
integrity as it functions to correct mismatches during DNA replication. Heterozygous mutations 
in one of the mismatch repair (MMR) genes e.g. MLH1, MSH2, MSH6 and PMS2 cause the 
dominant adult cancer syndrome termed Lynch syndrome (or hereditary non-polyposis 
colorectal cancer). In our South African cohort, the MLH1 exon 13 c.1528C>T mutation is the 
most common Lynch syndrome-causing variant in the Mixed Ancestry population.  Recently, a 
patient homozygous for this mutation, diagnosed with Constitutional mismatch repair deficiency 
(CMMR-D) syndrome was described within this extended cohort. CMMRD syndrome results in an 
increased predisposition to a range of cancers, most commonly brain and hematological tumours 
in early childhood. The aims of this thesis were: (i) to determine the rate of extra-colonic cancers 
in the cohort of Lynch syndrome families in our colorectal cancer registry, (ii) to determine if 
MLH1 c.1528C>T is a founder mutation, and (iii) to focus on the CMMR-D syndrome as a branch 
of Lynch syndrome and to potentially use the hypermutability-status in CMMR-D to understand 
the diverse carcinogenesis in Lynch syndrome.   
Methods: The registry consisting of Lynch syndrome families was interrogated and analysed to 
address the aim (i).  Haplotype analysis was performed using microsatellite markers around the 
MHL1 c.1528C>T mutation to determine founder effect for aim (ii). For aim (iii) whole exome 
sequencing was also performed in a Lynch/ CMMR-D syndrome family in order to investigate the 
extent of hypermutability in CMMR-D syndrome, and to develop a working hypothesis for 
carcinogenesis in CMMR- D and Lynch syndromes.  
Results: From the analysis of the registry it was noted that 396 individuals carried a disease-
causing mutation in either MLH1 or MSH2; females have a relatively later age of onset (for 
cancer) than males and MLH1 mutation carriers develop cancers relatively earlier in life than in 
individuals with MSH2 mutations.  The most common extra-colonic cancers were endometrial 
and breast in females; in males small bowel cancer was most common, after CRC.  The cohort 
study revealed a large founder effect with the MLH1 c.1528C>T mutation, with the most common 
inferred (disease-associated) haplotype found in 25 of the 30 subjects tested; the disease-
associated haplotype was not present in controls.  The mutation aging analysis traced the 
mutation to be ~225 years old. The WES investigation of the nuclear family within which the 
CMMR-D patient, including acquired and germline mutations in tissues from the child with 
CMMR-D, revealed a range of pathways including the extracellular matrix, WNT signaling, TGFβ 
and p53 as acquiring  significant numbers of variants as a result of the MMR deficiency.   
Discussion and Conclusion: The results which are indicative of the need to improve the Lynch 
syndrome mutation testing and management for all patients, also suggests the need to develop 
surveillance programs for extra-colonic cancers, which will improve compliance and disease-free 
survival.  WES investigation of the nuclear family containing a child with CMMR-D point to the 
potential involvement of a range of pathways associated with cancer development which may be 
indirectly invoked in the process of tumorigenesis by the wide range of variants acquired as a 
result of mismatch repair deficiency.  It is likely that some of these processes are also involved in 
the emergence of extracolonic cancers in individuals affected with Lynch syndrome (i.e. 
heterozygous for mutations in MMR genes). 
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1. Chapter 1: Introduction to Cancer 
1.1 Cancer in general 
Cancer is the most common death-causing disease in the world, with more 
people dying of cancer than Acquired Immune Deficiency Syndrome (AIDS), 
tuberculosis and malaria combined. In 2012, 14.1 million new cases were 
diagnosed and an estimated 8.2 million people died of cancer 
(http://canceratlas.cancer.org/ the-burden/). Cancer occurs as a result of the 
accumulation of multiple mutations that promote clonal selection of cells with 
increased aggressive growth (Fearon 1997). However, over the years it has been 
established that both biology and the environment play an important role in the 
process of carcinogenesis (Fearon 1997). Biologically, the development of cancer 
has been described as a series of steps, known as hallmarks of cancer (discussed 
in the section below), which involve genetic alterations that transform a cell 
from normal to cancerous. This process has made an enormous contribution to 
the understanding of cancer. Additionally, technological developments in 
molecular genetics have not only allowed for the identification of the genetic 
factors associated with disease initiation, but have also led to the discovery of 
markers of disease progression and prognosis.  
1.2 Hallmarks of cancer  
Over a decade ago, Hanahan and Weinberg (2001) first described the process 
which became known as the ‘hallmarks of cancer’ (Figure 1.1). The process 
starts with the acquisition of an initiating mutation (either germ-line or somatic) 
and the subsequent accumulation of further mutations.  These mutations lead to 
changes in gene activity which in turn, provide the growing population of cells 
the ability to: disregard the normal control of proliferation, evade growth 
suppressors, activate invasion/metastasis, enable replicative immortality, induce 
angiogenesis and resist cell death (Hanahan and Weinberg, 2011).  As cancer 
progresses, the surrounding microenvironment also changes allowing the cells 
to proliferate (Pietras and Ostman, 2010), evading the typical control of territory 
and proliferation (Ponder, 2001). In 2011, Hanahan and Weinberg added 
‘emerging hallmarks’, such as deregulating cellular energetics and avoiding 
immune destruction, as well as ‘enabling characteristics’; which included 
tumour-promoting inflammation and genome instability.  Of interest is the role 
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of the enabling characteristics in tumorigenesis, particularly genome instability.  
Genomic instability has been described previously as being able to both initiate 
the development and facilitate the progression of tumours (Negrini et al.,  2010). 
This process leads to the accumulation of mutations, which often compromise 
the important repair systems. These mutations often occur in the caretaker 
genes that function as: 1) damage/alteration detectors, 2) employers of 
mechanisms of correction, and 3) inactivating mutagenic molecules before the 
damage occurs. This characteristic is important in inherited cancers and will be 
discussed further in the next section.  
 
Figure 1.1: Hallmarks of Cancer [described by Hanahan and Weinberg (2011)].  The figure depicts 
the six original hallmarks of cancers as well as the four, later described, enabling characteristics and 
emerging hallmarks. https://commons.wikimedia.org/wiki/File:Hallmarks_of_cancer.svg 
 
1.3 Genomic instability and cancer development     
Chromosomal instability (CIN) (which is a component of genomic instability) is 
described as the high rate of change in chromosomal structure over time in 
neoplastic cells, compared to normal cells (Arends, 2013). The other form of 
genomic instability is microsatellite instability (MSI/ MIN) characterised by the 
changes in the number of nucleotide repeats per microsatellite sequence 
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(Arends, 2013). In inherited cancers, genomic instability has been associated 
with the accumulation of germline mutations in the DNA repair genes (Negrini et 
al.,  2010).  DNA repair genes encode for proteins that form part of the mismatch 
repair system, whose function is to correct mistakes or alterations, which occur 
during the DNA replication process (Corcos, 2012; Martín-López and Fishel, 
2013).  
 
Negrini et al., (2010) suggested that in inherited cancers, genomic instability is 
probably the initiating event, which then facilitates the establishment of all of the 
other hallmarks. In accordance with the mutator phenotype, the presence of 
genomic instability precedes acquisition of mutations in oncogenes and tumour 
suppressor genes. For instance, the deactivation of the mismatch repair (MMR) 
system can lead to the genome-wide accumulation of DNA replication errors 
generally, or at specific runs of nucleotide sequences resulting in microsatellite 
instability (MSI) (Corcos, 2012; Martín-López and Fishel, 2013). One of the most 
commonly inherited cancer syndromes associated with this phenomenon is 
Lynch syndrome.  
 
 1.4 MMR deficiency – Introduction to Lynch Syndrome  
Lynch syndrome (OMIM: 120435) is the most common form of inherited cancer 
(Loeb, 2001). Warthin first described this syndrome about a century ago, after 
observing a large family with several cases of colorectal cancers (CRC) which 
manifest without the premonitory polyps characteristic of familial polyposis 
(Warthin, 1925; Lynch et al., 2009; Boland and Lynch, 2013).  This syndrome is 
characterized by an increased risk of cancer, most commonly CRC.  While 
individuals diagnosed with Lynch syndrome have about 70% - 85% lifetime risk 
of developing CRC, they also have an increased risk of developing other cancers 
(Lynch et al., 2003; Barrow et al., 2013; Lynch et al., 2015).  Since CRC is the most 
common type of cancer in Lynch syndrome, much research has been conducted 
in understanding the factors including pathways, involved in disease 
development. A subset of these pathways will be discussed further in the next 
section.  
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1.4.1 Pathways involved in the development of CRC 
Several pathways involved in colorectal carcinogenesis have been identified over 
the years (Arends, 2013). Three main contributors to the disease progression 
are: 1) chromosomal instability (CIN), 2) microsatellite instability (MSI), and 3) 
CpG island methylation-mutator phenotype (CIMP) (resulting in gene silencing). 
The chromosomal instability or CIN, often associated with mutations in the 
Adenomatous Polyposis Coli (APC) gene, is the major pathway.  The gene product, 
APC, is an authentic gatekeeper of cell proliferation in the colonic epithelium. 
Microsatellite instability or MSI is often associated with a defective or altered 
DNA repair pathway.  The CIMP, which involves the hyper-methylation of the 
promoters of genes leads to the transcriptional silencing of potentially a number 
of genes, representing the key epigenetic mechanism of inactivation of tumour 
suppressor genes.  
 
1.4.1.1 Chromosomal instability (CIN) 
CIN is often associated with mutation of the APC gene. The most commonly 
identified mutations lead to a truncated inactive APC protein. APC inactivation 
represents a major pathway of adenoma formation in CRC. The APC protein 
regulates WNT signalling by interacting with β-Catenin. As a result of the 
defective APC protein,  β-Catenin is not degraded, resulting in the accumulation 
of this latter molecule. The accumulation of β-Catenin leads to activation of the 
WNT/APC/β-Catenin signalling pathway.  The WNT signalling pathway has 
many targets  - it is involved in many processes (including cell proliferation), 
which are affected by these changes, and which may result in cancer 
development (Fearon, 1997; Chung, 2010; Arends, 2013).  
1.4.1.2 Microsatellite instability (MSI) 
As mentioned previously, the presence of MSI is a result of mutations in any one 
of the DNA MMR genes. Mutations in any of the DNA MMR genes (DNA MMR 
pathway), result in the mutator phenotype, which renders the genome ‘error 
prone’.  Repetitive regions, such as microsatellite sequences, have been shown to 
preferentially accumulate these alterations, resulting in expansions or 
contractions of the sequences, hence the appellation ‘microsatellite instability’ 
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(Dietmaier et al., 1997; Imai and Yamamoto, 2008; Jiricny and Pen, 2015). This 
phenomenon is often observed in inherited CRC or MMR-deficient cancers.  
1.4.1.3 The CpG island methylator phenotype 
In sporadic CRC, MSI is often a result of the hyper-methylation of the MLH1 
promoter, which affects gene expression, and which is an example of the CIMP 
(Hitchins et al., 2005; Hitchins, 2013; Lynch et al., 2015). However, methylation 
of other promoters have been identified for genes such as MGMT, PTEN, and 
DNMT3B involved in the WNT/APC/β-Catenin signalling pathway – and known 
to be involved in colorectal carcinogenesis (Fearon, 1997; Felsberg et al., 2011; 
Arends, 2013).  
1.4.1.4 Other CRC-associated pathways  
Other associated pathways include the sessile neoplasia pathway, which involves 
the transition of hyperplastic polyps to serrated adenomas then to 
adenocarcinomas, with most lesions appearing in the right or proximal bowel 
(often also associated with Lynch syndrome) due to mutations or promoter 
hyper-methylation (Bansidhar and Silinsky, 2012).  The serrated neoplasia 
pathway referred to as the ‘traditional serrated neoplasia pathway’ is associated 
with the CIN/KRAS mutations (Arends, 2013) (Figure 1.2). 
 
                    
KRAS-activation mutations occur early on in the adenoma progression. These 
mutations affect the enzymatic function of this protein, reducing the cleavage of 
termination of the phosphate group. Failure to dephosphorylate this compound 
leads to locking of the KRAS protein into the active state, mediating the excessive 
signalling through the RAS/RAF/MEK/ERK signalling pathway, which then 
drives cell proliferation (Arends, 2013). However, KRAS also feeds into the PI3K 
pathway with activation of serine/threonine kinase (AKT) signalling which 
supresses apoptosis. This pathway can also be activated by PIK3CA-activating 
mutations or it may be inactivated by deletions, mutations or promoter 
methylation of PTEN (Arends, 2013).  
 
Another important role player in colorectal carcinogenesis is the p53 and TGF-β 
signalling pathway. Both p53 and TGF-β are key tumour suppressors, which 
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regulate a number of cellular responses (Pardali and Moustakas, 2007). TGF-β 
signals via the SMAD signal-transduction pathway, while p53 and SMAD 
physically interact and work together to induce transcription of a number of key 
tumour suppressor genes. Ultimately, mutant p53 generally subverts tumour 
suppressive TGF-β responses, diminishing transcriptional activation of key TGF-
β target genes. Mutant p53 can also interact with SMAD and this enables complex 
formation and blocks p53-mediated activation of metastasis-suppressing genes 
to promote tumour progression (Baker et al., 2006; Arends, 2013). All of these 
pathways play important roles in colorectal carcinogenesis; however, they are 
also involved in the development of cancers in other organs and tissues, some of 
which form part of the Lynch syndrome spectrum (of cancers).  
 
 
Figure 1.2 Molecular pathways to CRC: The figure depicts the four most common pathways associated 
with the development of CRC. Firstly, the APC pathway, which involves KRAS (loss of heterozygosity) and, 
lastly, p53 resulting in chromosomal instability but microsatellite stable CRC.  The KRAS and BRAF 
pathways, which both involve promoter methylation and p53 inactivation, result in conventional and 
serrated dysplasia pathways, respectively. The final pathway involves BRAF CpG methylation, which also 
involves the MLH1 promoter methylation causing a Lynch syndrome-like phenotype which is often  
microsatellite (high) unstable (MSI-H) CRC.  
 
1.4.2 Molecular basis of Lynch syndrome  
Lynch syndrome occurs as a result of a deficient MMR system.   The MMR system 
has proof reading functionality, recognizes and repairs errors which occur 
during DNA replication. Mutations of the genes coding for components of the 
MMR system can lead to suboptimal post-replication error detection and repair 
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(Kosinski et al., 2010), resulting in the embedding of a higher than normal rate of 
errors into the genome (Fearon, 2011).  
 
Many types of mutations in MMR genes have been identified and implicated in 
predisposition to Lynch syndrome (Tang et al., 2009; Borràs et al., 2010; Barrow 
et al., 2013; Lynch et al., 2015). These mutations include the frame-shift, 
nonsense and splicing mutations, which result in truncated proteins. The 
International Society of Gastrointestinal and Hereditary Tumours (InSIGHT) 
have created a database which catalogues most reported mutations (Peltomaki 
2003; http://insight-group.org ). Alterations in five genes within the MMR 
system have been associated with Lynch syndrome, including the MutS homolog2 
(MSH2), MutS homolog6 (MSH6), MutL homolog1 (MLH1), MutL homolog3 (MLH3) 
and Post-meiotic Segregation increased2 (PMS2) (Cheah 2009; Peltomäki 2001; 
Peltomaki 2003). However, mutations in just MLH1 and MSH2 account for over 
90% of disease-causing mutations in Lynch syndrome (Peltomaki 2003; Clarens, 
2004).  
 
In the MMR system, to initiate the repair process, the MutS proteins, namely 
MSH2 and MSH6, or MSH2 and MSH3, form a heterodimer (MutS-α), which 
recognizes (DNA) single base-pair mismatches (insertions and deletions) 
(Figure 1.3). Two to four base pair mismatches (insertions and deletions) are 
recognized by a heterodimer of MSH2 and MSH3 (Rustgi, 2007).  Following the 
recognition of the mismatch, the MSH2/MSH6 complex binds to the DNA base-
pair mismatch, the heterodimer recruits other complexes, such as the MLH1 and 
PMS2, which in turn trigger a series of events which lead to the excision of the 
mutated strand (Rustgi, 2007).  Exonuclease 1 (EXO1) is involved in binding the 
heterodimers together during this process (Rustgi, 2007).  A defective MMR 
system would result in the accumulation of somatic mutations in the rest of the 
genome during replication; such a mutation within either a tumour suppressor 
or oncogene leads to  the subsequent development of Lynch syndrome-
associated cancers (Calvert and Frucht, 2002; Martín-López et al., 2012).  
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Figure 1.3 Schematic representation of the MMR model in repairing DNA damage. A) Depicts the key 
MMR proteins involved in correcting single base-pair errors; while B) Depicts those involved in the 
correction of 2-4 bp insertions and deletions (together with single base-pair mismatches).  
1.4.3 MMR genes 
 The DNA MMR system is conserved in bacteria and humans, indicative of its 
evolutionary importance in the functioning of most life forms. There are a 
number of eukaryotic homologs of bacterial MutS and MutL.  In prokaryotes 
MutS-homologs include; MSH1, 2, 3, 4, 5 and 6.  The MutL-homologs include: 
MLH1, PMS1, MLH2 and MLH3. The human homologs for these proteins include 
MSH2, MSH6, MSH3, MLH1 and PMS2 for MutS and MutL, respectively (Iyer et al., 
2006). The difference between the prokaryotes and eukaryotes is in how these 
proteins perform their functions. In prokaryotes, the MutL and MutS systems 
seem to function as homo-dimers, whereas in eukaryotes they function as 
heterodimers. For instance, MutS α consists of the heterodimer formed between 
MSH2 and MSH6. The MutS β is made up of MSH2 and MSH3.  A similar 
functional need has been reported for the MutL α, where a heterodimer between 
MLH1 and PMS2 is formed in order for the protein to perform its function. The 
MutS α, binds to the DNA mismatches and short insertion/deletion loops (IDLs), 
and MutS β binds to the larger IDLs. The MutL α is a mismatch-specific 
endonuclease, and is the intermediary for activation of the down-stream 
mismatch gap repair (Iyer et al., 2006).    
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1.4.3.1 MutL α (PMS2 and MLH1)  
 Post-meiotic segregation increased-2 (PMS2) is a post replicative DNA 
mismatch-repair protein. The primary function of PMS2 involves its heterodimer 
formation (MutL α) with the MLH1 protein, and this complex then interacts with 
other complexes bound to the mismatched bases. The process of repair for these 
proteins is initiated by the MutS α or MutS β, binding to the double-stranded 
DNA. MutL α is recruited to the hetero-duplex. The assembly of the MutL-MutS 
hetero-duplex ternary complex in the presence of Replication Factor C Subunit 1 
(RFC1), a five subunit DNA polymerase accessory protein, and Proliferating Cell 
Nuclear Antigen (PCNA), a cofactor of DNA polymerase delta, is sufficient to 
activate the exonuclease activity of PMS2, which introduces single-strand breaks 
near the mismatch, thereby facilitating new entry points for EXO1 for the strand 
containing the mismatch. PMS2 and MLH1 interact physically with other 
subunits of DNA polymerase III suggesting that they may play a role recruiting 
the polymerase to the site of the mismatch (http://www.genecards.org/). 
 
1.4.3.2 MutS α (MSH6 and MSH2)  
 Both MSH6 and MSH2 proteins help with the recognition of mismatched 
nucleotides prior to their repair.  These proteins contain a conserved region of 
about 150 amino acids called a “Walker-A-adenine” nucleotide-binding motif. 
The encoded proteins hetero-dimerize with each other to form a MMR-
recognition complex (MutS α). This heterodimer functions as a bidirectional 
molecular switch, exchanging the ADP and ATPase; resulting in a conformational 
transition that converts MutS α into a sliding clamp capable of hydrolysis-
independent diffusion. This transition is crucial for MMR.  MutS α may also play a 
role in DNA homologous-recombination repair (http://www.genecards.org/ ).  
 
1.5 Cancer risk in Lynch syndrome  
Lynch syndrome-related CRC accounts for about 1-5% of all CRC, worldwide 
(Barrow et al., 2013).  Characteristically, these cancers develop on the ascending 
or right side of the colon.  In addition, Lynch syndrome-related CRC may be 
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synchronous, meaning two or more histologically distinct primary cancers 
developing at the same time, or metachronous, i.e. separate multiple primary 
cancers developing over time. Histologically, these tumours are mucinous with 
signet ring cells; they have poorly differentiated cell types and have infiltrating 
lymphocytes; these characteristics possibly influence the survival advantage of 
MMR-related CRC patients compared to those that are sporadic, or non MMR-
related (Novelli, 2014; Lynch et al., 2015; Walsh, 2015).  Although cancers of the 
colorectum and endometrium are the most common in Lynch syndrome, the risk 
of developing other (extra-colonic) cancers is significantly higher than in the 
background population (Win et al., 2012).  
 
 
1.5.1 Lynch syndrome spectrum of cancers  
Individuals diagnosed with Lynch syndrome have about a 70 to 85% chance of 
developing CRC throughout their lives. Endometrial cancers, which are the most 
common extra-colonic cancers in the Lynch syndrome spectrum (females have a 
30-40% lifetime risk) occur at a higher rate than in the background population 
(Kamat, 2013). Other cancers such as small bowel cancer are considered rare (1-
4% lifetime risk) in Lynch syndrome, but are significant when compared to an 
almost 0.01% lifetime risk in the background population (Win et al., 2012; Win 
et al., 2013).  Other cancers suggested to be part of the Lynch syndrome 
spectrum include pancreatic, breast, prostate and rare adrenocortical tumours, 
as these have been reported to occur at a higher frequency in MMR-mutation 
positive individuals compared to the background population (Win et al., 2012; 
Win et al., 2013). 
1.6 Diagnosis of Lynch syndrome  
A number of guidelines have evolved to ensure optimal diagnosis and 
management of Lynch syndrome, mostly towards early detection of neoplasms in 
those at highest risk. Initially, the Amsterdam criteria (Table 1.1) did not include 
presence of extra-colonic cancers and MSI.  Following the identification of the 
molecular basis of Lynch syndrome in 1994, the criteria were reviewed and 
revised (Lynch et al., 2009).  In 1996, the Bethesda criteria was introduced and 
included all clinical characteristics of Lynch syndrome; i.e. early age of onset, 
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MSI, extra-colonic tumours, trend of first- and/or second-degree relatives 
diagnosed with Lynch syndrome-related cancer at an early age.  Table 1.1 shows 
the list of characteristics used to select patients for mutation analysis (Lynch et 
al., 2009). Currently, only when a mutation in one of the MMR genes is identified, 
will the individual be diagnosed with Lynch syndrome, and blood relatives 
considered to be at risk.  
 
Table 1.1 Amsterdam I, Amsterdam II, and Bethesda Guidelines for diagnosis of Lynch syndrome 
(Vasen et al., 1999; Rodrrguez-Bigas et al., 1997; Umar et al., 2004) 
Amsterdam I Criteria  
1. An affected individuals should be a first-degree relative of other two other affected relatives 
2. At least two successive generations are affected 
3. At least one of the relatives with CRC is diagnosed at <50 years of age 
4. FAP has been excluded 
Amsterdam II Criteria  
1. An affected individual should be a first-degree relative of two other affected relatives 
2. At least two successive generations are affected 
3. At least one of the Lynch syndrome‐associated cancers should be diagnosed at <50 years of age 
4. FAP should be excluded in any CRC cases 
5. Tumours should be verified by pathology whenever possible 
Bethesda Guidelines for testing of colorectal cancers  
1. CRC diagnosed in a patient who is <50 years of age; 
2. Presence of synchronous or metachronous colorectal or other LS-associated tumours, regardless of age; 
3. CRC with MSI-high (MSI-H) histology diagnosed in a patient who is <60 years of age; 
4. CRC or Lynch syndrome‐associated tumour diagnosed <50 years of age in at least one first‐degree relative 
 
The description of the molecular basis of Lynch syndrome has revolutionized the 
understanding and diagnosis of this disorder. For instance, the role of 
characteristics such as MSI associated with tumours and the use of 
immunohistochemistry (IHC) to detect the (lack of) expression of MMR proteins 
in tumour tissue have made the diagnosis more accurate and specific (Boland 
and Lynch, 2013; Zhang and Li, 2013). Together, these molecular tests (i.e. 
protein expression and MSI testing) provide an indication of the gene most likely 
to harbor a pathogenic mutation. For IHC, the loss of expression of one of the 
proteins implies the presence of a pathogenic mutation in that particular gene 
(Stone, 2001). For instance, loss of expression of PMS2 and MSH6 is indicative of 
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the possible pathogenic mutation in either gene, respectively. However, a dual 
loss of expression of MLH1 and PMS2 would suggest a mutation in MLH1 as PMS2 
is destabilized by the absence of the MLH1 protein (Mohd et al. 2006; Lynch et al. 
2015). A similar principle applies to the dual loss of MSH2 and MSH6, where the 
corresponding mutation will most likely be in MSH2, because the absence of the 
MSH2 protein destabilizes MSH6 (Lynch et al., 2015).  
 
Although MSI is generally reflective of mutations in an MMR gene, a proportion 
of sporadic cancers may also manifest this feature. These sporadic tumours are 
sometimes the result of somatically acquired hyper-methylation of the 
promoters of either MLH1 or MSH2 (Hitchins et al., 2005; Hitchins et al., 2011; 
Hitchins, 2013); other sporadic cancers may  also be associated with the 
presence of somatically-acquired mutations within the proto-oncogene, Serine-
threonine kinase (BRAF) and Epithelial Adhesion Molecule (EPCAM) genes 
(Rajagopalan et al., 2002; Hitchins et al., 2005; Hitchins, 2013). However, the 
diagnosis of Lynch syndrome is normally confirmed by the presence of germline 
mutations in the MMR genes and presence of significant familial clustering 
(Boland and Lynch, 2013); in this instance, sporadically-acquired mutations 
resulting in MSI tumours are excluded. 
 
1.7 Treatment of cancers associated with Lynch syndrome  
Patients with Lynch syndrome may be treated with radiation and/or 
chemotherapy as an adjuvant to reduce the tumour mass before the surgery. 
Opinions about the usefulness of 5 Flurouracil (5FU) as an adjuvant 
chemotherapy have been contradictory (Zhang et al., 2015), with most reports 
showing that microsatellite stable tumours respond better to the administration 
of 5FU, compared to MSI tumours (Ribic et al., 2003; Sargent et al., 2010; 
Sinicrope et al., 2011). A recent report suggested that the combination of 5FU 
with one of the platinum-based drugs (e.g. Oxaliplatin) as an adjuvant, increased 
cancer-free survival period in patients with MSI tumours (Lynch et al., 2015).  
However, more studies need to be done to assess the effectiveness of the various 
drugs between the hereditary MMR-related and sporadic cancers.  
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From a preventative perspective, aspirin has been shown to significantly delay 
the onset of neoplasms in patients with Lynch syndrome (Macrae et al. 2008; 
Burn et al., 2010; Barrow et al., 2013; Boland, 2013). Regular use of aspirin in 
combination was reported to reduce the risk of developing CRC and adenomas 
(Barrow et al., 2013). Furthermore, aspirin has shown promising results with 
regards to reducing development of metastatic CRC in individuals at risk of 
developing CRC (Rothwell et al., 2010; 2011). Current trials are aimed at 
determining the minimal and optimal doses particularly because of the major 
side effect of high doses of aspirin resulting in gastrointestinal bleeding (Lynch 
et al., 2014). Thus, for the moment, the recommendation of   aspirin should be 
taken with caution.  
1.7.1 Surveillance and management of Lynch syndrome  
A few measures are recommended for families with Lynch syndrome with the 
aim of preventing or reducing tumour development. These measures have been 
divided into longitudinal surveillance programs and surgical prophylaxis (Table 
1.2). For monitoring purposes, a colonoscopic surveillance program for those 
testing mutation positive has been the most successful, as reflected by a number 
of studies that have shown early detection and an extended cancer-free survival 
period (Stupart et al., 2009; Barrow et al., 2013; Zhang et al., 2015; Leenen et al., 
2016). For extra-colonic cancers, a range of surveillance programs have been 
proposed (Lindor et al., 2006). For instance, for gynaecological tumours, which 
are the most common in females, recommended examinations include trans-
vaginal ultrasound, hysteroscopy and endometrial biopsy, at two yearly intervals 
(Dreyer et al., 2012).  However, there is not enough evidence to support the 
benefits of performing any of the latter procedures (Lindor et al., 2006).   
Table 1.2 Lynch syndrome cancer surveillance recommendations (Adapted from a 
systematic review by  Zhang et al., 2015 & Lynch and de la Chapelle 2003) 
Cancer Recommendations  From Age  
Colon cancer  
  
Colonoscopy every 1–2 years 20–25 years 
Prophylactic colectomy generally not recommended 
Endometrium/ovary Consider prophylactic TAH/BSO After childbearing is complete 
Upper urinary tract Annual urinalysis 30–35 years  
Upper GI tract Other Consider EGD every1–2 years 30–35 years  
Other  
  
  
Annual physical exam  21 years  
  
  
ROS for related cancers 
Skin exam 
TAB= Total abdominal hysterectomy; BSO= Bilateral salpingo oophorectomy;  
EGD= Esophogogastroduodenoscopy; ROS= Reactive oxygen species 
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For gastric cancers, gastroscopy is recommended once every two years, from the 
age of 30-35 years (Zhang et al., 2015). For surgical prophylaxis, subtotal 
colectomy or segmental resection is advised for individuals diagnosed with 
Lynch syndrome-associated CRC (Stupart et al., 2011; Vasen et al., 2014). Total 
colectomy has been recommended as an option for individuals who find it hard 
to bear the pain and discomfort of the colonoscopy. Total colectomy has been 
advised for young individuals (less than 45 years) who have developed primary 
CRC, to reduce the development of a secondary CRC (Barrow et al., 2013). For 
other cancers, prophylactic hysterectomy is advised for individuals who have 
passed childbearing age (Lindor et al., 2006).  This is to reduce the risk of 
developing both ovarian and endometrial tumours.  
 
1.8 Lynch syndrome in South Africa (S.A.) 
In S.A., Lynch syndrome as a disease is not common. However, cancers that are 
related to Lynch syndrome are common. For instance, CRC is among the top six 
cancers leading to deaths in this country. The incidence of CRC for males, 
according to the 2010 (S.A.) National Cancer Registry report, ranges from 8 to 
more than 50 per 100 000, within the age range of 45-75 years, and from 4 to 25 
per 100 000 for females in the same age range (http://www.nioh.ac.za 
/assets/files/NCR_Final_2010_tables(1).pdf; National Cancer registry 2010). 
Although most of the reported cases of CRC may be of the sporadic (not 
inherited) form, a recent study of MMR deficiency-associated CRC in the 
Northern Cape Province of S.A. indicated that there was a significantly high 
proportion (21.8%) of tumours with MMR deficiency (Vergouwe et al., 2013). 
This report is indicative of a possible increased rate of inherited/ MMR-deficient 
CRC within the low incidence disease areas.  
 
Other Lynch syndrome-related cancers, such as endometrial cancer, are yet to be 
more fully investigated in S.A.  Although, in general, the incidence of endometrial 
cancer was estimated to be about 4/100 000, the cases diagnosed seem to 
increase with age, from 10/ 100 000 at the age of 50 years to approximately 32/ 
100 000 by the age of 74 years.  In Lynch syndrome, the cancers generally 
develop at a much younger age than their sporadic counterparts. Thus, 
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understanding what types of cancer and how they develop within Lynch 
syndrome will not only benefit those who are at risk of inherited cancers, but 
may also have an implication for sporadic forms of cancers within the Lynch 
syndrome spectrum.  It is thought that the research in this area is likely to 
provide knowledge towards strategizing how resource-limited countries, such as 
S.A., may reduce morbidity and mortality associated with cancers. 
 
1.9 Motivation for study 
The Division of Human Genetics at the University of Cape Town (UCT) in S.A. 
together with Groote Schuur Hospital (GSH) have developed a registry of 
patients with early-onset CRC (i.e. diagnosed at 50 years of age, or younger). This 
project began in the 1980s with the aim of identifying the genetic factors 
associated with early onset inherited cancer in the Northern and Western Cape 
regions of S.A. The registry and its associated bio-repository capture clinical 
information on these subjects relating to their medical history, population 
demographics, pedigree (or family history), disease-causing or predisposing 
mutation, colonoscopic surveillance, history of neoplasms and related pathology, 
radiation or chemotherapeutic treatment and general follow-up history, together 
with biological material (ideally venous blood and tumour tissue).  To date 
(January 2017), the registry has captured details and biological material from 
more than 700 families who have been recruited. A number of disease-causing 
mutations have been identified in some of these individuals, including a S.A.-
specific mutation (c.1528C>T) in exon 13 of the MLH1 gene.  In addition, this is 
the mutation which has been identified in the homozygous state (c.1528C>T: 
c.1528C>T) in a child, who was later diagnosed with Constitutional Mismatch 
Repair Deficiency (CMMR-D) syndrome, and - described later in Chapter 3 of this 
dissertation. The number of individuals who had developed the various kinds of 
cancers, due primarily to the c.1528C>T mutation in MLH1, provided the 
opportunity to interrogate potential pathways involved in disease and rate at 
which mutations accumulate in the presence of this specific mutation.  
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The aim of this research was to provide a better understanding of the genetic 
factors associated with both Lynch and CMMR-D syndromes.   
The objectives were:  
1. To determine the rate of extra-colonic cancers in a cohort of Lynch 
syndrome families  
2. To provide evidence for the founder effect of the MLH1 c.1528C>T 
mutation  
3. To focus on the CMMR-D syndrome as a branch of Lynch syndrome and 
determine the genomics surrounding this phenomenon   
The objectives were carried out to address the aim using the workflow in Figure 
1.4.  
 
Figure 1.4 Illustration of the strategy and workflow of the research described in this 
dissertation.  
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Chapter 2: Lynch Syndrome - The Cohort Study 
2.1 Brief background  
Previously, Lynch syndrome was thought to manifest as two clinical subtypes; 
Lynch syndrome type I and type II (https://www.omim.org/entry/120435). 
Lynch syndrome type I was characterised by autosomal dominantly inherited 
nonpolypotic CRC with an early age of onset. The CRC was generally site specific 
(mostly in the ascending/ or right-hand side of the colon) and was observed in 
multiple generations. Lynch syndrome type II was characterized by families in 
which other types of malignancy (i.e. extracolonic), such as endometrial and 
urinary tract cancers occurred, in addition to CRC.  The most common types of 
cancer following CRC in type II Lynch syndrome were those of the endometrium, 
stomach, ovaries, small intestine, pancreas, urinary tract (i.e. kidney, ureter or 
bladder), bile duct, skin (usually sebaceous adenomas), and brain.  More 
recently, however, and as data has accumulated longitudinally – it has been 
recognised that extracolonic cancers are a general feature of Lynch syndrome 
(Vasen et al., 1999), and that the type I classifier may have had to do with the 
mode of ascertainment i.e. through a gastroenterologist or related specialist – 
since CRCs are most common in Lynch syndrome, and due to limited pedigree 
sizes.  
 
2.1.1 Cancer risk  
As previously described, mutations in the MMR genes increase the risk of 
developing a range of cancers in carriers. Over the years there have been a 
number of studies on genotype-phenotype correlations, where some mutations 
have been shown to confer a much higher risk of specific cancers within the 
Lynch syndrome spectrum.  However, apart from a high risk for CRC, especially 
in MLH1 and MSH2 mutation-carriers, there is no clear correlation between the 
MMR gene, the nature/domain affected by the mutation and the range of cancers 
–especially when one looks at the larger pedigrees or patient collections, 
internatonally.   
 
In one such study  (involving patients from Denmark, Holland, Finland and 
U.S.A.) Watson et al., (2008) investigated the incidence of cancers in 6041 
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individuals with MLH1 and MSH2 mutations. The most common type of 
malignancy, after CRC and endometrial cancer, were urologic cancers with an 
overall lifetime risk of 8.4% in males; and these were more likely to occur in 
MLH1 mutation carriers (Watson et al., 2008).   
 
In a separate study of 147 families (55 with mutations in MLH1, 81 with 
mutations in MSH2 and 11 with mutations in MSH6), the cumulative risk for 
cancer development was 66% in males and 42% in females (Stoffel et al., 2009). 
CRC occurred more often in males (68.3%) than in females (56.6%) with MLH1 
mutations, and 5.1% of the females had endometrial cancer (at a median age of 
47.5 years). Lifetime-risk for CRC and endometrial cancer in MMR-mutation 
carriers was high even after adjusting for an ascertainment bias (Stoffel et al., 
2009). In a more recent study of 2118 cases of MMR-mutation carriers, the seven 
most common cancers observed in this cohort were those of the stomach, small 
bowel, urinary tract, breast, ovary and prostate (Engel et al., 2012).  
 
Risk of primary cancers in Lynch syndrome has been the focus of research for 
many years. However, considering that individuals with this disorder are at risk 
of developing multiple cancers throughout their lives, it is of value to determine 
the risk of developing extracolonic cancers.  As already mentioned, there is some 
contention that the range of cancers may be dependent on the actual gene or 
specific mutation, or a range of modifier factors (both environmental and 
genetic) (Bansidhar and Silinsky, 2012). 
 
In a cohort of 46 mutation-positive individuals from 22 different families with 
Lynch syndrome the manifestation of the range of cancers (whether site specific 
or affecting a wide range of organs) seemed to depend on the actual gene that 
was mutated, rather than the type of mutation in the gene (Pérez-Cabornero et 
al., 2013). Similarly, Geocke et al., (2006) observed that MSH2 mutations were 
associated with multiple extra-colonic cancers whereas MLH1-mutation carriers, 
and specifically males, had a relatively younger age at diagnosis, (Goecke et al., 
2006).  In addition, and relatively speaking, there is an increased risk of CRC in 
MLH1 and MSH2 mutation carriers when compared to the other MMR genes, for 
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example MSH6 (Pérez-Cabornero et al., 2013). Lastly, individuals with mutations 
in MSH6 generally have a later age of onset/diagnosis - almost 10 years later 
than both MLH1 and MSH2 mutation carriers (Pérez-Cabornero et al., 2013) . 
 
In Africa, Lynch syndrome is one of the most understudied disorders, there is not 
much literature regarding the spectrum of extra-colonic cancers in African 
populations, which is why the selected background literature mostly focuses on 
the reported North American and European cases. Work published on a 
Congolese cohort of 89 individuals with early onset (median age of 35 years) 
CRC found that 38.2% of the cases had abnormal immunohistochemistry staining 
for both MLH1 and MSH2 (Poaty et al., 2017). No specific mutations were 
reported in this study and most of the tested cases were that of CRC and no 
extra-colonic cancers.  In a Tunisian study conducted in 2014, it was reported 
that of all the suspected Lynch syndrome cases, only 30% of the tested samples 
were MSI while the 70% were MSS. The loss of expression in these cases was 
seen in all the common MMR genes (MLH1, MSH2, MSH6 and PMS2) (Amira et 
al., 2014). In another study from Tunisia, Sana et al. (2014), identified 10 
germline mutations in CRC cases in 11 of the 31 HNPCC cases. Most of these 
mutations were in MLH1 and MSH2, similar to what we have seen here in South 
Africa and what has been reported internationally (Sana, et al., 2014).  
Another recent study by Ziada-Bouchaar (2017), identified 3 novel variants in 
the MLH1 gene, 4 variants MSH2, a large exon1 deletion in MSH6; none of the 
identified mutations have been seen in our population. Of interest in this cohort 
was the fact that there was similar age of onset regardless of the gene that was 
mutated. This is slightly different from what has been reported elsewhere, where 
MLH1 and MSH2 have an earlier age of onset compared to other MMR genes, 
such as MSH6 (Pérez-Cabornero et al., 2013).  Often the HNPCC/Lynch Syndrome 
studies in African cohorts have CRC as the most common cancer, however cases 
of endometrial cancer have been reported as well, but little is known about other 
Lynch syndrome-related extra-colonic cancers in African cohorts. 
Although there are no absolute phenotypes for Lynch syndrome, family history 
plays an important role in identifying cases for this disorder. It is true that the 
set of Bethesda criteria (Chapter 1; Table 1.1) is an important tool for 
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identifying these families; however, some of the extra-colonic cancers have only 
relatively recently been seen in the very large cohorts, and had not previously 
been included as part of the Lynch syndrome spectrum of cancers.  Such cancers 
include adrenocortical adenocarcinoma, thyroid carcinoma, peritoneal 
mesothelioma, malignant fibrohistiocytoma, rhabdomyo-sarcoma, 
dermatofibrosarcoma, leiomyosarcoma, liposarcoma, carcinoid tumour, non-
Hodgkin lymphoma, malignant melanoma, and those of the pancreas, prostate 
and breast (Lynch, 2003; Lynch et al., 2009). The list that has been included in 
the Lynch syndrome spectrum of tumours are often those which conceivably 
have a significantly increased risk as a result of MMR deficiency.  
 
2.1.2 The MLH1 c.1528C>T mutation 
A founder mutation or variant is a genetic change that is observed at a higher 
frequency in geographically or culturally isolated populations.  The frequency of 
Lynch syndrome in the Cape Mixed Ancestry population, specifically in the 
Western and Northern Cape Provinces of S.A. is high compared to other parts of 
the country or in other populations. In addition, the observation of a relatively 
high frequency of the MLH1 c.1528C>T mutation among the Cape Mixed 
Ancestry population raises the issue of whether this particular site of the 
genome is prone to mutagenesis or whether it may be the result of a founder 
effect, which leads to questions about its origin and distribution in the southern 
African population.  
 
Hundreds of MLH1 mutations have been identified in patients with Lynch 
syndrome in populations around the world, mostly, in Europe (Moisio et al., 
1996; Borràs et al., 2010; Pinheiro et al., 2011; Tomsic et al., 2012; Borelli et al. 
2014).  Many of these mutations have suggested a founder effect due to their 
frequencies in specific populations. Borreli et al., (2014) investigated 11 
unrelated Lynch syndrome families to evaluate the clinical consequence of the 
MLH1 exon19 c.2252_2253delAA terminal mutation and to determine if this was 
a possible founder.  The index and a further approximately 300 cases, identified 
over a period of 12 years, were investigated with 7 SNP and 10 microsatellite 
markers to determine whether they shared a common origin (or a founder 
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mutation).  The same mutation was previously observed to share founder status 
in disparate geographic locations including Australia, Germany, the United 
Kingdom and Denmark (Borreli et al., 2014). The analysis of all accessible 
individuals with this particular mutation showed a shared haplotype of over 
1.7Mb in at least eight of the 11 families and was deemed to be a founder.   
 
Several other founder mutations in MLH1 have been identified in a number of 
global populations which explains the widespread geographic occurrence of 
Lynch syndrome. However, these geographically widespread founder mutations 
have been described as ‘heterogeneous’ in function and frequency.  Most of the 
mutations result in a truncated protein, which are almost always confirmed to be 
pathogenic.  However, with the introduction of the next generation sequencing 
platforms, many more potential mutations have been identified with unknown 
pathogenicity (i.e. variants of unknown significance), and will prove interesting 
in understanding the extent of founder mutations and associated phenotypes in 
future.  
 
A separate study characterised two relatively frequent MLH1 mutations 
(c.306+5G>A and c.1865T>A) among Spanish families with Lynch syndrome 
(Borras et al., 2010). In some Lynch syndrome families around Europe, one of the 
two mutations was reported to be responsible for 28% of all MLH1 mutations 
and represented 17% of all families with mutations in this gene in the Ebro Basin 
region (which is geographically isolated). Borras et al., (2010), showed that 
families with specific mutations clustered in specific regions because of 
geographic isolation. One mutation, MLH1 c.306+5G>A, was estimated to be 
about 2000 years old while the other, MLH1 c.1865T>A, was found to have arisen 
relatively recently (~384 years) (Borras et al., 2010).  
 
In 2009, Tang et al., investigated 93 Taiwanese Lynch syndrome families.  Among 
the identified mutations was the MLH1 c.793C>T mutation, in 13 of the families. 
Genetic analysis showed that the mutation occurred on two separate extended 
haplotypes, with a shared region of about only 30kb, perhaps suggestive of a 
distant common origin. The ancestry for this particular mutation was traced 
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back to mainland China, and was further confirmed by the fact that this 
particular mutation had been previously reported in mainland Chinese Lynch 
syndrome patients (Tang et al., 2009).  
 
Other MMR gene mutations, have been observed at relatively high frequencies in 
specific populations such as Finland (Nyström-Lahti et al., 1994), China (Chan et 
al., 2004), U.S.A. (Wagner et al., 2003), Canada (Froggatt et al., 1999), Sweden 
(Cederquist et al., 2005), Korea (Shin et al., 2004) and Italy (Caluseriu et al., 
2004).  Interestingly, even if the mutations may be shared in these 
geographically and ethnically diverse populations, the profile of Lynch 
syndrome-related cancers in these patients may differ slightly. For instance, 
gastric cancer was the most common extra-colonic cancer in the 93 Taiwanese 
families, consistent with the reports from other Asian countries (such as Japan, 
Korea and China), while in Europe the most common extra-colonic cancer is 
endometrial cancer (Tang et al., 2009). 
2.1.2.1 MutL-Homolog1 (MLH1) 
The MLH1 gene was mapped to chromosome 3p21.3 in 1994 (Bronner et al., 
1994) followed by a description of the structure of the gene (Han et al., 1995). 
The gene consists of 19 coding exons, spanning about 100kb. This gene codes for 
a protein, which forms a heterodimer with PMS2 (Figure 1.3, Chapter 1) to 
form a Mut-L α complex, a component of the post-replicative DNA MMR-system. 
The MLH1 gene was identified as frequently mutated in HNPCC consistent with 
the alterations detected in microsatellite sequences.   Common conditions 
associated with this gene also include Muir-Torre syndrome (OMIM: 158320), 
Turcot syndrome (OMIM: 276300) and the more recently described, CMMR-D 
syndrome (OMIM: 276300). MLH1 is involved in many biological pathways 
including, the cell cycle, DNA repair, mismatch repair, meiosis and mitosis 
(Ellison et al., 2004; Cohen et al., 2006).  One of the listed functions of this 
protein includes, ATP-, ATPase- and protein- binding; it also contributes to MutS 
α complex binding (Plotz et al., 2002, 2006). In addition to the functions already 
described, this protein is also involved with a number of processes such as 
double stranded-break repair via non-homologous end joining and in the 
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intrinsic apoptotic-signalling pathway in response to DNA damage (Schofield and 
Hsieh, 2003). 
 
Of particular interest is the exon 13 codon 510 mutation, also referred to as 
rs63749923 (NM_0002493: c.1528C>T nonsense). The change in base (C>T) 
results in a premature stop codon, leading to a truncated transcript. This 
mutation is one of more than 1000 ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/?term=mlh1%5Bgene%5D) MLH1 
mutations, also recognized by InSIGHT (https://www.insight-
group.org/variants/databases/), as a Lynch syndrome predisposing mutation  
(Vasen, 2004).  
 
2.1.2.2 MLH1 c.1528C>T Mutation  
The history of the ascertainment of families with the MLH1 exon 13 c.1528 C>T 
mutation began in 1987, when a 30-year old male with a family history of CRC 
was identified. The CRC seemed to be autosomal dominantly inherited but 
affecting only males (Goldberg et al., 1998).  However, this was largely due to an 
ascertainment error, since the medical records ascertained from the hospital in 
the diamond-mining village of Kleinzee in the Northern Cape Province, treated 
only the workers on the mine – who were generally only men who were bussed 
in to the mine from a village some 50 kilometres away.  In due course with 
tracking family lineages through to the place of residence of the miners, both 
males and females were found to have manifest CRC in previous generations.  
The family fitted the Amsterdam criteria for HNPCC. Molecular genetic studies 
led to the identification of the pathogenic mutation in exon 13 of MLH1 in 1994 
(subsequently described by Goldberg et al., 1998).  The discovery of this 
mutation has led to the introduction of a programme of genetic counselling and 
genetic testing for individuals closely related to those previously affected by 
disease. This programme is aimed at early detection of neoplastic lesions 
through colonoscopic surveillance of those carrying the disease-causing 
mutation, and the exclusion from surveillance of those with no risk (mutation 
negative) for this familial condition. For mutation carriers, colonoscopic 
 35 
surveillance has been offered with the objective of increasing the cancer-free 
survival period.   
 
2.1.3 Objectives of this section:  
1. To analyse the registry with regards to the risk of MMR-mutation carriers 
developing a range of Lynch syndrome associated cancers 
2. To perform survival analysis on the data  
3. To investigate whether the MLH1 exon 13 c.1528C>T mutation is due to a 
founder mutation. 
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2.2 Method  
2.2.1 Study cohort 
Although the main research focus was to be on the MLH1 exon13 c.1528C>T 
mutation positive individuals/families, in the first instance, data on the whole 
cohort of MMR-mutation positive individuals/families was accessed and 
analysed.  As with all other Lynch syndrome cases, the same mutation may have 
a variable penetrance in individuals between and within families.   However, this 
c.1528C>T subset of the cohort was thought to be relatively homogenous, which 
theoretically ought to put them at similar risk of developing disease.  
 
For this section of the study, research ethics approval was previously obtained 
for the access to patient demographic data and clinical information, which 
included, disease information, age at onset, and the type of cancer, as well as the 
pathology reports (pertaining to diagnosed cancers or biopsies of neoplastic 
tissue). 
 
The third section of this study, investigated the possibility of the c.1528C>T 
mutation as a founder in 30 probands, each of whom was from a distinct ‘family’  
or ‘lineage’ with no obvious connection to any of the other pedigrees/families,  
from the Northern and Western Cape provinces of S.A. segregating the 
c.1528C>T mutation. Ethical clearance was obtained to genotype probands with 
this mutation for five previously selected microsatellite markers flanking the 
mutation in order to determine the haplotypes of these cases. In addition, 98 
healthy controls were also genotyped for all the markers to determine their 
haplotypes. The controls consisted of “unaffected” individuals of Mixed Ancestry 
from the Western Cape, unrelated to the Lynch syndrome families.  
2.2.2 Statistical analysis  (R) 
R version 3.1.3 is an open source statistical and graphic computing software 
environment.  This programme is available with a number of codes and scripts 
written and ready to be used; these are stored in a number of packages on CRAN 
(https://cran.r-project.org/web/packages/), which is easily accessible and can 
be installed and used freely.  Currently, the CRAN package repository consists of 
more than 9000 packages available for use.  The package “survival” was 
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downloaded and installed for use for this part of the study.  Survival analysis is a 
non-parametric method used to estimate the survival function from data using 
several analysis features where the outcome variable is the time until the 
occurrence of the event of interest, which can, for example, be disease or death, 
amongst other factors.  The Cox proportional hazard model analysis allows for 
the estimation of risk of an event (cancer development) for individuals given the 
prognostic variables (https://cran.r-project.org/web/packages/survival/ 
survival.pdf). For survival analysis, status was set as the “development of cancer” 
and the gender as well as type of cancer were analysed as independent variables.  
2.2.3 Microsatellite genotyping and haplotype testing  
Microsatellite genotyping was performed to measure the potentially shared 
region flanking the MLH1 c.1528C>T mutation.  Five markers flanking the 
c.1528C>T mutation (Table 2.1) were identified and selected for use based on 
their distribution either 5’ or 3’ to the disease-causing mutation.   Following 
marker identification, the relevant marker-related primers were designed to 
amplify the fragments of interest using standard PCR, and genotyped.  For 
subsequent resolution on a ABI3130xl Genetic Analyzer  (Applied Biosystems; 
Foster City, CA), one of the primers (per pair) was designed to incorporate a 
fluorescent label 
 
Table 2.1 Microsatellite Markers with marker positions relative to the mutation 
NC_000003.12 GRCh38 accessed 2014-07-18 
 
Marker name Position with respect to mutation  
D3S3512 34594179 
D3S1561 36484119 
c.1528C>T* 37028881 
D3S1611 37068501 
D3S3623 37443531 
D3S3527 39345373 
*Mutation (MHL1 c.1528C>T) 
 
2.2.3.1 Polymerase Chain Reaction (PCR)  
The PCR is a method used to amplify regions of interest in the genome. The 
locus-specific primers were used to initialize the synthesis of DNA using the 
thermo-stable DNA (Taq) polymerase, derived from the organism, Thermus 
aquaticus.  The reagents required to perform PCR included: template DNA at a 
concentration of 100ng/µL, 1x GoTaq buffer (Promega, Madison, WI, U.S.A.) at a 
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pH of 8.5 and MgCl2 (concentration of 1.5mM), 5Units/μL GoTaq DNA 
polymerase (Promega®, Madison, WI, U.S.A.), 200μM of each deoxynucleoside 
triphosphate (dNTPs) (BIOLINE, London, UK), a final concentration of 0.4µM 
primer per reaction and distilled water (Sabax, Adocock Ingram, JHB, S.A.), in a 
total reaction volume of 25µL in a 0.2mL microfuge tube.  The reaction was 
conducted in a thermal-cycler (BioRad, Hercules, CA, U.S.A.), comprising of cycles 
of denaturation, primer annealing and extension of the product under conditions 
set out in Table 2.2 (Schochetman et al., 1988). All reactions were conducted in 
multiplex format. 
 
Table 2.2 Thermo-cycler conditions for standard PCR 
 
 
 
 
 
2.2.3.2 Automated capillary electrophoresis  
Subsequent to PCR, genotyping was performed on the 3130xl Genetic Analyzer 
(Applied Biosystems; Foster City, CA).  In a standard capillary electrophoresis 
reaction, a 1 in 10 dilution of the PCR product was made for all amplicons, 1 µL of 
this was added to 8μL Hi-Di™ formamide (HiDi) (Applied Biosystems, Foster City, 
CA), the formamide was used to keep the DNA as a single strand (Sambrook and 
Russell, 2001a). Results were analysed using the GeneMapper® software 
(Applied Biosystems, Foster City, CA).  
2.2.3.3 Statistical analysis PHASE II 
PHASE is freely available statistical software that implements a Bayesian 
statistical method for reconstruction of haplotypes using genotype data (Stephen 
and Donelly, 2003). This software allows the user to input data generated from 
SNPs, microsatellites and other multi-allelic loci. For the analysis, data is 
generated and input files prepared; the analysis can be performed on case only 
 Step  Temp (˚C) Duration 
Initial step 
Denaturation 95 5 min 
25-30 cycles 
Denaturation 94 30 sec 
Primer annealing 50-60 30 sec 
Extension 72 40 sec 
Final Step 
Final extension 72 7 min 
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or case-control data. This regression model could be estimated through Markov 
Chain Monte Carlo (MCMC) methods. To implement an MCMC simulation, the 
process starts at some value for the parameter of interest, which can be defined 
by the user. In order to determine this starting point, a number of ‘burn-in’ 
iterations was specified, which is a grace period during which the Markov Chain 
wanders to the most probable region of the sample space. The samples obtained 
during the burn-in are discarded. After the burn-in, the simulation will continue 
to generate samples from the distributions of the parameters of interest for the 
specified number of iteration times.  For example, an MCMC model was run with 
300 iterations and a burn-in of 30, indicating 330 iterations; but the first 30 were 
discarded.  The challenge of using MCMC is specifying an appropriate number of 
iterations and appropriate burn-in. For the analysis, the run was conducted for 
five microsatellite markers and results were analysed for both cases (30 
probands) and controls (98 controls). The run was set to have 1000 burn-in 
iterations, followed by 1000 iterations and recorded after one hundred 
iterations.  
2.2.4 Estimating the time of origin or age of c.1528C>T mutation  
To estimate the age of the South African (Cape Mixed ancestry) MLH1 c.1528C>T 
mutation the DMLE+2.3 software program (www.dmle.org) was used. This 
programme was designed for high resolution mapping of disease mutation and 
estimation of its age. The method is based on the observed linkage 
disequilibrium between the five markers (relative to the mutation) in both cases 
and controls. The software uses the MCMC algorithm (Hamra et al., 2013) to 
allow Bayesian estimation of the mutation age, based on parameters including; 
the observed haplotypes, in samples of unrelated cases or controls, distances 
between genotyped markers and position of the mutation, the estimated 
population growth rate and an estimation of the proportion of disease-causing 
mutation.  Following the haplotypic phasing of all 30 probands using Phase 
version 2.1, the chromosome map distances were obtained from the NCBI 
(https://www.ncbi.nlm.nih.gov). The population growth rate was obtained from 
the Statistics S.A. report 
(https://www.statssa.gov.za/publications/P0302/P03022014.pdf). A 25-year 
intergenerational interval was used to calculate number of years per generation.  
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2.3 Results  
2.3.1 Cohort demographics 
 
The Division of Human Genetics at the UCT, with the Division of 
Gastroenterology at GSH have maintained a registry, which consists of probands 
and  families with early onset (50 years of age or younger) CRC. These families, 
predominantly from the Northern and Western Cape provinces of S.A., have been 
enrolled in this research study. The on-going search of the individuals at risk in 
the Northern and Western Cape provinces, has led to the identification of almost 
400 individuals with more than 20 different disease-causing mutations in just 
two of the MMR genes, namely MLH1 and MSH2.  This cohort is sub-divided into 
those carrying mutations in either MSH2 (Figure 2.1) or MLH1  (Figure 2.2).  
The MLH1/MSH2 schematic representations show the list of mutations, the 
domains of the protein affected by the mutation, and types of cancers observed 
in the cohort.   As is evident from Figure 2.2, most individuals in this cohort have 
a mutation in exon13 of the MHL1 gene.  
 
Figure 2.1 Site of cancers associated with the mutations in the MSH2 gene in the cohort 1. 
Indicated are exons (in mauve), domains (orange, pink and yellow), specific genotype of 
mutations and the type of  cancers observed in this cohort. C=coding region, p. =amino acid, N= 
the N-terminal, C=the N-terminal, Y= yes.  
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Figure 2.2 Site of cancers associated with the mutations in the MLH1 gene in the cohort 1. 
Indicated are exons (in mauve), domains (orange, pink and yellow), specific mutations and the 
types of  cancers observed in this cohort.  C=coding region, p. =amino acid, N= the N-terminal, 
C=the N-terminal, Y= yes.   
In total, there were 396 mutation positive individuals identified in the UCT/GSH 
cohort (cohort 1). Of those, 309 individuals were confirmed to have the MLH1 
exon 13 (c.1528C>T) mutation (from here on referred to as cohort 2).  To date, 
this mutation has only been reported in the Mixed Ancestry population of S.A., 
specifically located in the Northern and Western Cape Provinces of S.A. The 
mutation-carrying individuals form part of 30 different families. In the registry, 
the MLH1 c.1528C>T sub-cohort  (cohort 2) is comprised of 53% females and 
47% males.  Lynch syndrome has been described to cause early onset disease 
(cancer), usually in individuals younger than 50 years of age.  In cohort 2, the 
majority of individuals (62%) are under the age of 50 years 
 
Cohort 3 (carrying mutations other than the MLH1 exon 13 mutation) accounted 
for 86 cases in 23 families diagnosed with Lynch syndrome (from hereon 
referred to as cohort 3). The most common mutation after the MLH1 c. 1528C>T 
is the MSH2- exon8 c.1340InsGG mutation, in two families with 27 mutation-
positive individuals. This is followed by the MSH2 c.1219delCT mutation (in 
exon7), which has been identified in 15 individuals from five families (Table 
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2.3). Cohort 3 was made up of 61 females and 25 males, of whom 37 (43%) have 
developed cancers; these are made up of more than half of the mutation-carrying 
males and 40% of the mutation-carrying females. As expected, the most common 
malignancy is CRC accounting for about 60% of the individuals who have been 
diagnosed with cancer. However, there are a significant number of cases with 
multiple cancers, with extra-colonic cancers making up 24% of cancers 
diagnosed in cohort 3. The most common of the extra-colonic cancers observed 
in cohort 3 is that of the endometrium and breast. Other cancers observed, 
included cancers of the small bowel, and the stomach, amongst others. 
 
 
Table 2.3 Cohort demographics for Lynch syndrome registry 
Cohort demographics  
 **Cohort 3 *Cohort 2 
Gender    
Males 25 147 
Females  61 162 
   
MMR gene mutation   
MLH1 14 309 
MSH2 73 0 
   
Age   
Age range 17-88 years 4-96 years 
   
Cancer 37 111 
CRC/ CRC+other 28 95 
CRC only  23 73 
Extra-colonic  cancers (only) 9 16 
*cohort 2: individuals carrying the MLH1 c. 1528C>T; 
** cohort 3: individuals carrying any of the other mutations in MLH1 and MSH2 
 
In cohort 2 consisting of 309 individuals, 104 have been diagnosed with 
cancer(s). In most instances, probands had been treated, usually for CRC, before 
the disease pre-disposing mutation was identified in their particular family. 
Again, as expected, the most common cancer observed in cohort 2 was CRC.   
 
In addition, about 30% of the individuals with CRC have had secondary extra-
colonic cancers, including cancers of the liver, small bowel, endometrium and 
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breast (Figure 2.3 and 2.4).  Overall, 43% of the individuals who are affected in 
cohort 2 have developed extra-colonic cancers. Perhaps understandably, most 
extra-colonic cancers in this cohort have been reported in females (62%).  
Analysis of the cohort data shows more cases of small bowel cancer in males 
(35% of the reported extra-colonics); the most common type of extra-colonic 
cancer in females is that of the endometrium observed in 29% of all extra-colonic 
cancers (12/41), with an age range of 50 to 64 years.  This was followed by 
breast cancer which was observed in 24% (10/41) of the affected individuals 
with an age range of 35 to 72 years.  These latter two types of cancers  together 
accounted for over 50% of the reported extra-colonic malignancies in females.  
 
 
Figure 2.2 Bar graph showing the range of extra-colonic cancers in males with mutations in MLH1 (in 
red) and MSH2 (in green). The most common cancers observed were in small bowel for both MLH1 and 
MSH2 mutation carriers. No cases of prostate or liver cancer were observed in individuals with a mutation 
in the MSH2 gene.  
 
Figure 2.3 Bar graph showing the range of extra-colonic cancers in females with mutations in MLH1 
(red) and MSH2 (green).  The most common cancers observed were those of the endometrium and breast. 
Most of the other cancers were only seen in MLH1 mutation carriers.  
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The average age at diagnosis for cohort 1 was approximately 48 years for males 
and 49 years for females (all cancers) (Table 2.4). However, MLH1 c.1528C>T 
mutation carriers, had a younger age at onset for CRC (Figure 2.5) compared to 
the background population (66 years) as reported in the National Cancer 
registry 2010 (http://www.nioh.ac.za 
/assets/files/NCR_Final_2010_tables(1).pdf;).  
 
Table 2.4 Average ages at onset for cancer in mutation positive cases 
                                                                                 Average age of onset (in years) 
Type of cancers Males Females 
CRC 44.19 46.5 
Other cancers* 52.8 53.54 
MLH1-CRC 43.13 45.2 
MLH1-other cancers  53.15 45.6 
MSH2-CRC 45.2 49.1 
MSH2-other cancers  52.5 56.42 
 
 
 
 
Figure 2.5 Distribution of age at onset/diagnosis for CRC in Lynch syndrome patients in 
cohort 2.  The mean age is 44 years. Indicated is the number of observations per age grouping. 
The age range was from 17 to 69 years for (CRC cases only) 
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2.3.2 Survival Analysis  
Survival analysis was performed for cohort 2, consisting only of individuals with 
the MLH1 c.1528C>T mutation. The cohort was also stratified by gender and type 
of cancer to determine if there was a significant difference in the survival period 
amongst those who had developed cancer and those who had not developed 
cancer.  
 
There was no significant difference in cumulative survival for the individuals 
who have developed cancer versus those who had not (data not shown). When 
the cohort was stratified by gender, there was no significant difference in overall 
survival (p=0.15); neither was there a significant difference (p=0.209) in cancer-
free survival period between males and females (Figure 2.6). However, when 
individuals were divided by cancer type (Figure 2.7), there was a trend towards 
significance (p=0.0782), with individuals who had developed CRC having a 
better survival compared to those with extra-colonic cancers.  
 
 
 
Figure 2.6 Kaplan Meier Survival analysis for cohort 2 showing males vs. females (Red: 
males, Blue: Females) 
X axis: Survival time in days, Y axis = cumulative survival 
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Figure 2.7 Kaplan Meier Survival analysis of cohort 2 by cancer type (Red: CRC, Blue: Extra-
colonic) 
X axis: Survival time in days, Y axis = cumulative survival 
 
Even though not significantly different, there is a seemingly better survival 
period recorded for males when compared to females (Figure 2.6). However it is 
noteworthy that there are more cases of CRC in males (than in females), and 
more extra-colonic cancers in females (than in males). That said, it is likely that, 
historically, extra colonic cancers were not part of the routine surveillance – and 
they may be diagnosed at a relatively advanced stage – with a drop in their 
cancer-free survival period (Figure 2.7). This becomes clearer specifically when 
observing survival comparing CRC and extra-colonic cancers; a better survival 
margin was noted for individuals with CRC compared to those with extra-colonic 
cancers.  
2.3.3 Founder mutation phase analysis  
A founder effect is expected to result in shared polymorphisms in cis closest to 
the mutation of interest. To test whether the c.1528C>T mutation represented a 
founder effect, five-microsatellite markers  (listed in Table 2.5) around the 
MLH1 gene were genotyped and analysed. Phase II 
(http://stephenslab.uchicago.edu/phase/download.html ) was used to construct 
the haplotypes. The haplotype analysis was performed in 30 probands and 98 
controls. The most common inferred haplotype  (1-6-c.1528C>T-8-1-6) (for 
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markers: D3S3512, D3S1561, c.1528C>T, D3S1611, D3S3623, and D3S3527) 
was observed in 25 of the 30 probands.  The other five individuals shared the 
alleles closest to the mutation (Table 2.5) but had a different extended 
haplotype. To determine the prevalence of the haplotype (1-6-c.1528C>T-8-1-
6), 98 Cape Mixed Ancestry, unrelated controls were genotyped for the same 
markers. The observed haplotype was not observed in the control population.  
 
Table 2.5: Microsatellite marker results relative to the c.1528C>T mutation for the 30 
probands. 25 of the 30 probands had the same haplotype, whilst the five remaining cases 
(indicated in red) share only parts of the haplotype on either side of the mutation.   
PROBAND D3S3512 D3S1561 c.1528C>T D3S1611 D3S3623 D3S3527 
NC_000003.12 34594179 36484119 37028881 37068501 37443531 39345373 
n1 1 6 c.[1528C>T] 8 1 6 
n10 1 6 c.[1528C>T] 8 1 6 
n100 1 6 c.[1528C>T] 8 1 6 
n101 1 6 c.[1528C>T] 8 1 6 
n102 1 6 c.[1528C>T] 8 1 6 
n103 1 6 c.[1528C>T] 8 1 6 
n104 1 6 c.[1528C>T] 8 1 6 
n105 1 6 c.[1528C>T] 8 1 11 
n106 1 6 c.[1528C>T] 8 1 6 
n106 1 6 c.[1528C>T] 8 1 6 
n107 1 6 c.[1528C>T] 8 3 3 
n108 1 6 c.[1528C>T] 8 1 6 
n109 1 6 c.[1528C>T] 8 1 6 
n11 1 6 c.[1528C>T] 8 1 6 
n111 1 6 c.[1528C>T] 8 1 6 
n44 1 6 c.[1528C>T] 8 1 6 
n45 1 6 c.[1528C>T] 8 1 6 
n62 1 6 c.[1528C>T] 8 1 6 
n8 1 6 c.[1528C>T] 8 1 6 
n87 1 6 c.[1528C>T] 8 1 6 
n9 1 6 c.[1528C>T] 8 1 6 
n90 7 5 c.[1528C>T] 8 1 6 
n91 1 6 c.[1528C>T] 8 3 3 
n92 1 6 c.[1528C>T] 8 1 6 
n93 1 6 c.[1528C>T] 8 1 6 
n94 1 6 c.[1528C>T] 8 1 6 
n95 1 6 c.[1528C>T] 8 1 6 
n96 1 6 c.[1528C>T] 8 1 6 
n97 5 8 c.[1528C>T] 8 1 6 
n98 1 6 c.[1528C>T] 8 1 6 
n99 1 6 c.[1528C>T] 8 1 6 
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In the present study the probable carrier frequency was calculated for the MLH1 
c.1528C>T mutation in the selected geographical areas in the Northern and 
Western Cape provinces of S.A. To estimate the prevalence of mutation carriers 
in a random sample, the carrier frequency of heterozygotes was estimated 
(Table 2.6). The theoretical probability of a homozygous mutation carrier is 
even lower. However, considering how small and how remote these 
communities are, the probability of a homozygous case with CMMR-D-syndrome 
may be less than 1 in 18000 of mutation positive in some of these communities 
(Table 2.6).  
 
Table 2.6: Carrier frequency estimations for c.1528C>T in the Northern Cape populations 
Location Population  
Number of 
Carriers 
Frequency 
(het) 
Frequency 
(Hom) 1 in:  
Northern Cape  1166700 137/309 0.000011 0.000000000121 826 446 280 
Hondeklipbaai 543 4 0.0073 0.000053 18867 
Komaggas 3116 23 0.0073 0.000053 18867 
Kleinzee 728 5 0.0068 0.000046 21739 
Buffelsrivier  1123 7 0.0062 0.000038 26315 
Steinkopf 7842 9 0.0011 0.0000012 83333 
Garies 2105 6 0.0028 0.0000078 128205 
Aggeneys 2262 6 0.0026 0.0000067 149253 
Okiep 6304 11 0.0017 0.0000029 344827 
Port Nolloth 6092 9 0.00016 0.000000025 4000000 
 
 
2.3.4 Estimating the time of origin or age of c.1528C>T mutation  
The founder mutation (c.1528C>T) age was estimated using the DMLE+2.3 
program (Reeve and Rannala, 2002). A total of 10 000 000 real iterations were 
performed with 1 000 000 burn-in iterations. The population growth was set at 
1.1% in accordance with the current statistics in the Northern Cape province of 
S.A.   The age analysis of the founder mutation showed a range from minimum to 
nine generations (95% credible set 8.14-9.5) when calculated using the 
haplotype frequencies (Figure 2.8). The results were obtained by algorithmic 
metric mean of two simultaneous runs shown in Figure 2.8. Therefore, if the 
generation span is considered to be 25 years (Fenner, 2005) and that 2014 is the 
year study/sampling, the mutation dates  back to between 1789 and 1814. 
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Figure 2.8: Age estimation of the MLH1 c.1528C>T mutation. The probability distribution 
plots (obtained by two simultaneous runs) of the mutation (in generations), as estimated by the 
software DMLE+2.3. The analyses were conducted with haplotype frequencies. The blue 
rectangle shows the age values with the highest probability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of generations (1 generation = 25 years)  
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2.4 Discussion  
 
The objectives of this chapter involved a detailed analysis of all cases with Lynch 
syndrome in the UCT Human Genetics registry, and to investigate whether the 
MLH1 exon 13 c.1528C>T mutation is due to a founder effect. Mutations in both 
MLH1 and MSH2 contribute to the entire cohort of Lynch syndrome cases (396) 
in the registry. These families have been followed up for over three decades and 
records of the oldest family in the registry spans several generations.  As 
mentioned previously, the most commonly occurring malignancies in Lynch 
syndrome are CRC and endometrial cancers. Other malignancies which occur at a 
higher frequency within Lynch syndrome compared to the general population; 
include small bowel, gastric, urothelial/renal, brain, biliary, pancreatic and skin 
cancers.  Overall, of the total of 111 cancers in cohort 2, 95 (or 85%) were CRC 
(range of age at disgnosis: 17-69 years). In cohort 3, CRC was observed in 28 of 
37 (76%) individuals (range of age at diagnosis: 25-59 years). This observation 
of an overwhelming number of CRCs is a feature of most larger collections of 
Lynch syndrome (Lynch et al., 2009; Pérez-Cabornero et al., 2013; Boland and 
Lynch, 2013).  For males; extra-colonic sites for cancers included the small 
bowel, stomach and prostate; while for females cancers of the endometrium, 
ovary, small bowel, liver and cervix were observed, although in smaller numbers.  
 
The most common extra-colonic cancer observed in males was that of the small 
bowel. Cases of liver cancer were also observed, however reports on the 
incidence of liver cancer in Lynch syndrome are inconsistent (Levine and Allen, 
2014), with further clarification required with regards to whether liver cancer 
was a primary or metastatic neoplasm.  Small bowel cancers have an estimated 
lifetime risk of 0.01% in the general population (Aarnio et al., 1995; Bansidhar, 
2012) while individuals with Lynch syndrome have a lifetime risk of 1 to 4% ( 
Kate et al., 2007; Bansidhar, 2012). In cohort 1, small bowel cancer was 
diagnosed in 7 of 21 (33%) (age range: 33- 69 years) cases of mutation positive 
extra-colonic cancers in males.  
 
For females, the most commonly observed extracolonic cancers in the entire 
study cohort were those of the endometrium (29%) and breast (24%). A lifetime 
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risk of endometrial cancer in women with MLH1 or MSH2 mutations has been 
reported to be approximately 30~40 %, with a median age at diagnosis of 49 
years (Barrow et al., 2013). In a study of women with Lynch syndrome who 
developed both a colon and a gynaecologic cancer, Lu and Daniels (2013) found 
that 50 % of cases first presented with a gynaecologic cancer. Bonaı et al. (2013) 
investigated 537 French families with Lynch syndrome or MMR gene mutations 
and reported a lifetime risk of 35% for endometrial cancer with the highest risk 
predicted for women with MLH1 mutations. In the present study (cohort 2), 12 
of 41 extra-colonic cancer cases in females were that of the endometrium, which 
is similar to that reported in the literature. 
 
Breast cancer was the second most common extracolonic cancer in females (24% 
of the cases) in the overall study cohort (cohort 1). The incidence is relatively 
high considering that this type of cancer had not previously been considered part 
of the Lynch syndrome spectrum of cancers.   The breast cancers in the present 
cohort have been immunohistologically shown to have the loss of staining of the 
relevant MMR gene product.  There has been considerable debate as to whether 
breast cancer should be added to the list of the Lynch syndrome spectrum. There 
have also been several studies documenting MSI in breast tumors, as well as a 
loss of MMR-gene product staining, histologically, thereby confirming their 
status as an important feature of Lynch syndrome.  Because of the evidence of 
breast cancer being a feature in our Lynch syndrome cohort, over the past four 
years, the non-profit organization, Pink Drive (www.pinkdrive.co.za), which 
advocates screening for breast cancers, has been part of the annual clinical 
surveillance trip to remote regions of the Western and Northern Cape provinces.  
This clinical surveillance trip was previously wholly focused on colonoscopic 
examination of MMR mutation carriers. 
 
A number of studies have shown conflicting results regarding the relative risk of 
breast cancer among individuals with MMR deficiency (Walsh, 2010; Win et al., 
2012; Win et al., 2013).  Most of the previously conducted studies were 
retrospective, however, recently a prospective study (Win et al., 2012) showed 
that women with MMR deficiency had a four fold increase (4-fold) in the risk of 
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developing breast cancer compared to the background population.  Since the 
presence of an MMR gene mutation leads to deficiency in the functioning of the 
protein in correcting all MMR-related errors, it is possible that the individuals 
with MMR deficiency may have an accumulation of mutations in genes involved 
in breast cancer (such as BRCA1, BRCA2,  CHEK2 or ATM, amongst others). The 
accumulation of these mutations may well accelerate tumour development.  As 
with the range of Lynch syndrome cancers, the development of the disease may 
not necessarily be the primary result of MMR deficiency, but rather as a 
secondary effect of the increase in the number of genome-wide mutations which 
are not efficiently repaired. The suggested modest increase of breast cancers in 
Lynch syndrome is important to confirm, given that breast cancer is a common 
disease. In South Africa the age specific incidence of breast cancer in 2012 was 
about 25/ 100 000 individuals between the ages of 35 and 40 years,  
(http://www.nioh.ac.za/assets/files/NCR%202012%20results.pdf). This is 
relatively high compared to other cancers. A lack of prospective studies, and 
differences in population ethnicity, and a range of environmental and other risk 
factors makes it difficult to estimate the role of genetic factors contributing 
towards the disease development.  
 
Win et al. (2012) calculated that as much as 50% of breast cancers in families 
with MMR gene mutations showed evidence of MMR-deficiency. Some 
histopathological features such as poor tumour differentiation and presence of 
tumour-infiltrating lymphocytes, specifically in CRC and endometrial cancers 
have been reported in the breast cancers in mutation-positive individuals in 
families with Lynch syndrome (Win et al., 2012; 2013).  In addition, some of the 
breast cancers with MMR deficiency have an increased incidence of mucinous 
differentiation, another characteristic of cancers with MMR-deficiency. 
Interestingly, a separate study by Walsh et al. (2013),which investigated the MSI 
status of MMR-deficient breast cancers, reported these cancers as predominantly 
of higher nuclear grade, in situ, supporting the aberrations of MMR functioning 
and that they may lead to a more aggressive  type of breast cancer. The 
indication that 50% of the cases of breast cancer in Lynch syndrome families did 
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not have classic MMR deficiency was no surprise since they may be part of the 
population burden of a reasonably common cancer (Win et al., 2012). 
 
A study which investigated 90 families with occurrence of both CRC and breast 
cancer cases, found that about 60% of the families had a mutation in an MMR 
gene (Walsh et al., 2010).  In the observed breast cancer cases, 18/107 cases had 
abnormal IHC results for MMR gene products. Usually for Lynch syndrome 
testing, the negative IHC result is indicative of the presence of a mutation in the 
gene of interest. In this particular study, there was an over representation of the 
MLH1 mutation positive cases who had developed breast cancer (Walsh et al., 
2010).  This has been observed in other cohorts, where individuals with MLH1 
mutations have an increased risk of developing breast cancer when compared to 
individuals with mutations in other MMR genes. The Brazilian study found 
breast cancer was one of the most common extra-colonic cancers, even 
exceeding endometrial cancers in their cohort (Oliveira-Ferreira et al., 2004).  
 
A higher lifetime risk of CRC for males was observed in the UCT/GSH cohort 
(cohort 1)– this is similar to that reported in other MMR cohorts (Lynch et al., 
2009). However, what was evident in the UCT/GSH cohort was that males had a 
relatively better survival compared to females; this is indicative of the need to 
develop and employ improved methods of surveillance and /or management of 
the extracolonic cancers, especially those affecting females. The results showed 
that individuals with an MLH1 mutation have a younger age of onset/diagnosis 
for cancer (Table 2.6). This is in accordance with the literature – but may well 
reflect that this cohort is under better surveillance, and the neoplastic lesions are 
possibly being detected and treated earlier. Also noted is the age and gender 
difference in the UCT/GSH cohort, where female MSH2 mutation carriers have a 
later age at onset/diagnosis especially for extra-colonic cancers. Again, this may 
be explained by a lack of adequate surveillance for the extracolonic cancers in 
this cohort.  Even though this is the case, there was no significant difference in 
survival for MHL1 or MSH2 mutation carriers.  
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A number of factors determine the frequency of Lynch syndrome related 
cancers; these include: geography, ethnicity, gender, the underlying range of 
somatic mutations and the specific germ-line mutation (Bansidhar and Silinsky, 
2012).  Many studies have been conducted with the aim of identifying some of 
the modifier effects which may impact on Lynch syndrome-related cancers. 
Talseth-Palmer et al. (2013a) identified candidate modifiers as follows: 1) 
xenobiotic clearance and micronutrient metabolism, 2) cell cycle control, 3) DNA 
repair, 4) immunological function, 5) growth factors, 6) other modifiers which 
included the role of the MTHFR gene and the DNA (cytosine-5-)-
methyltransferase-3-beta (DNMT3B) gene.  
 
The search for modifier genes that influence disease expression in Lynch 
syndrome has revealed a number of potential candidates. By identifying and 
including modifier genes/loci in risk algorithms it would be possible to tailor 
individualized surveillance options for patients, allowing for better outcomes 
and possibly reducing morbidity and mortality (Felix et al., 2006; Scott et al., 
2012; Bellido et al., 2013; Talseth-Palmer et al., 2013a). 
 
The region around the c.1528C>T variant, spanning 4.8 Mb, was characterised by 
genotyping the microsatellite markers; D3S3512, D3S1561, D3S1611, D3S3623 
and D3S3527.  Based on the allele frequencies for the five markers, one hundred 
and eighty seven different haplotypes were inferred for 98 (apparently healthy) 
‘control’ individuals from the Cape Mixed Ancestry population and 30 probands 
harboring the c.1528C>T DNA variant.  The most common inferred extended 
haplotype was observed in 83% of the probands. This disease-associated 
haplotype was not inferred for any of the persons tested from the background 
Cape Mixed Ancestry population.  Thus, it can be concluded that the disease-
associated haplotype is not on a common haplotype present in the relevant 
population.  The mutation age was estimated to be between 8 and 9 generations, 
which is approximately between 200 and 225 years old (1789-1814). The South 
African Mixed Ancestry population makes up about 9% of the entire South 
African population. This population group has its origins in the late 1700s, with 
the colonization of the Western Cape (De Wit et al., 2010).  The mutation has not 
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been identified anywhere else in the world, suggesting that it originated here in 
S.A. perhaps more recently than the arrival of European immigrants. 
 
The carrier frequency of this mutation (c.1528C>T) is not high in the Cape Mixed 
Ancestry population, although it is very likely that the numbers are 
underestimated. It is to be noted that only 98 persons (background control) 
were genotyped to determine the carrier frequency of this mutation. In South 
Africa, mixed ancestry individuals account for just over 8% of the population (~ 
5 million), thus to accurately determine the carrier frequency for this mutation, 
more individuals will need to be genotyped. Future studies should address this 
limitation. The c.1528C>T mutation has only ever been observed in the South 
African Cape mixed Ancestry population. This is one of the most admixed 
populations in South Africa. The population has genetic contributions from 
indigenous Africans such as Khoesan (or Khoisan) and Xhosa (Bantu speaking 
populations), Europeans (German, Dutch, French and British) and Asians (De Wit 
et al., 2010). Thus determining the origin of this mutation will require the 
haplotype analysis of the genetic markers flanking the c.1528C>T mutation in 
other populations, perhaps indigenous communities in S.A. and abroad.   
Nonetheless, since the mutation has not been reported in international disease-
specific databases, it is reasonable to presume a local African origin. 
 
Lastly, admixture mapping is a valuable method that can be used to help study 
the relationship of the admixture of disease risk and to control for admixture as a 
confounder. McKeingue et al. (2000) described the method to analyse data from 
an admixed population that allows the effects of linkage and population 
structure to be distinguished.  However, this analysis could not be performed in 
the current study because of the limited number of individuals genotyped, in 
addition, only one population was included in the current study. Thus, future 
work should determine the genotypes for the selected markers (in other 
populations that may have contributed to this admixed population) in order to 
estimate the level of admixture in this population, but also to accurately 
determine the markers associated with disease.  
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Chapter 3: Constitutional Mismatch Repair- Deficiency (CMMR-
D) Syndrome  
 
3.1 Introduction to CMMR-D syndrome 
 
Heterozygous mutations within the DNA mismatch repair (MMR) genes cause 
Lynch syndrome.  In 1999, homozygous mutations in the DNA mismatch repair 
genes were described in another cancer syndrome:  “CMMR-D syndrome” 
(OMIM: 276300) (Wimmer and Etzler, 2008; Wang et al., 1999; Ricciardone and 
Tayfun, 1999).  This disorder manifests as a result of constitutional 
biallelic/homozygous or compound heterozygous mutations in the genes 
encoding MMR proteins (Leung et al., 1998; Menko et al., 2004; Poley et al., 2007; 
Amayiri  et al., 2015; Amayiri et al., 2015; Elhasid et al., 2015; Lavoine et al., 
2015; Li et al., 2015). Unlike Lynch syndrome, this disorder presents 
predominantly in paediatric patients, most of whom do not survive the disease. 
 
CMMR-D syndrome was only recognised relatively recently as a ‘component’ of 
Lynch syndrome – it is likely that earlier cases were classified as another disease, 
since CMMR-D patients have similar characteristics to other paediatric cancer 
syndromes.  The original report by Ricciardone and Tayfun (1999) described 
three affected children of consanguineous Turkish parents who, although 
unaffected, both carried the same cancer-predisposing mutation in one of their 
MMR genes, MLH1.  The pedigree information revealed that both parents had a 
family history of hereditary non-polyposis colorectal cancer (HNPCC -OMIM: 
120435). Each of the three offspring had developed haematological cancers by 
the age of three years and had characteristics of neurofibromatosis type 1 
(NF1:OMIM; 162200) e.g. café-au-lait (CAL) spots. Results of mutation testing in 
each of the children revealed an inherited homozygous mutation in MLH1.  
Mutation testing to understand the presence of NF1 symptoms revealed somatic 
and not germline mutations in the NF1 or Neurofibromin gene on chromosome 
17. The presence of the haematological malignancies also suggested that these 
cases were not traditional NF1 patients.  It was speculated that homozygous 
mutations in MLH1 may have created a mutator phenotype, which resulted in 
somatic mutations in the relatively large NF1 gene on chromosome 17 (374,244 
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base pairs in length) (Genecards: http://www.genecards.org/cgi-
bin/carddisp.pl?gene=NF1).  
 
Soon after this report, Wang et al. (1999) also described paediatric patients with 
similar phenotypes, where the parents were first cousins. The children had 
constitutional homozygous mutations in the MLH1 gene and the extended family 
was from North Africa, with a confirmed history of cancer.  The family 
characteristics were consistent with the Amsterdam criteria of HNPCC, wherein 
eight family members developed cancer before the age of 50 years. In the family, 
there were cases of both neoplastic (indicative of cancer growth in a tissue) and 
non-neoplastic diseases.  The first case of CMMR-D in this family was that of a 
child, who developed malignant non-Hodgkin’s lymphoma (OMIM: 605027) at 
the age of two years.  Subsequently, her sister was diagnosed with acute myeloid 
leukaemia  (OMIM: 61626) at the age of six years, followed by medulloblastoma 
(OMIM: 155255) at the age of seven years.  Both sisters had developed CAL 
dermatologic macules with no previous family history of NF1. Parents had 
heterozygous mutations in MLH1 previously described as pathogenic and disease 
causing.  Genetic testing in one of the children confirmed the presence of the 
homozygous mutation in MLH1 (Wang et al., 1999).  
 
One of the main characteristics of MMR deficiency is the presence of MSI in the 
repeat (microsatellite) sequences of the genome. MSI testing of DNA from buccal 
mucosal cells of one of the affected sisters showed evidence of MSI (Wang et al., 
1999).  Although no DNA was available for testing for the other sibling – the 
observation that the children had similar characteristics and disease 
presentations led the authors to conclude that both children had inherited the 
MLH1 mutation homozygously from their parents. Based on these cases, the 
authors suggested that penetrance for CMMR-D was 100% by the age of five 
years.  It was speculated that signs of NF1 could be due to the accumulation of de 
novo mutations in the neurofibromin gene during the cell/genome replication 
process due to the mutator phenotype, and that this was simply a function of the 
relatively large size of the NF1 gene.  It was plausible that the absence of the 
MLH1-associated post-replication DNA repair system resulted in the embedding 
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of these non-repaired mutations in the NF1 gene, resulting in the ‘acquired’ NF1 
features in these subjects.  
 
The first two reported cases of CMMR-D had homozygous MLH1 mutations, and 
their parents were related. In 2002, the first case of a homozygous mutation in 
another MMR gene, MSH2, was reported (Whiteside et al., 2002). The mutation 
was novel and resulted in exon skipping. The patient presented with acute 
lymphoblastic leukaemia (OMIM: 613065) and signs of NF1 (OMIM: 162200). 
Phenotypically, the subject described in this report did not meet the more 
comprehensive criteria for an NF1 diagnosis. The parents were not related and, 
interestingly, there was no family history of cancer, which added to the 
complexity of understanding the aetiology of the disease.  To date, this syndrome 
has shown a variable phenotype and it is possible that some features and 
phenotypes are yet to be described.  
3.1.1 Epidemiology of CMMR-D syndrome 
In 2008, a report of 78 cases of CMMR-D syndrome from 46 different families 
was published (Wimmer and Etzler, 2008). Subsequently, a comprehensive 
report by Wimmer et al. (2014), reviewed 146 cases from 91 different families.   
Most of the cases reported to date are from North America and Europe, although 
more recent reports from countries in the Middle East and Africa have emerged 
(Leung et al., 1998; Kratz et al., 2009; Bruwer et al., 2013; Bakry et al., 2014; 
Antelo et al., 2015; Shlien et al., 2015).  
 
In Saudi Arabia, the numbers of CMMR-D cases were higher than expected, 
possibly due to cultural practices of consanguinity in that region (Uddin et al., 
2013). A retrospective study covering a ten-year period identified 42 cases that 
met the CMMR-D syndrome criteria (Amayiri et al., 2015).  Of those, 39% were 
diagnosed with high-grade gliomas, approximately 80% of which had negative 
IHC staining, indicating the loss of expression of more than one MMR protein. 
From this data, the authors concluded that CMMR-D occurs in approximately 
51% of childhood gliomas (Amayiri et al., 2015). 
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3.1.2 Clinical features associated with CMMR-D  
The neoplastic phenotypes associated with CMMR-D consist of four categories; 
(i) haematological malignancies, (ii) brain tumours, (iii) gastric cancers 
(including the Lynch syndrome spectrum of cancers), and (iv) others (Baas et al., 
2013). As with most cancer syndromes, these tumours manifest early in life. The 
age range for brain tumours in CMMR-D was estimated at five and a half to eight 
years, while the age of onset for the Lynch syndrome spectrum of cancers in 
CMMR-D syndrome, was estimated at about 15 -30 years (Jasperson et al., 2011).  
 
As mentioned previously, individuals diagnosed with CMMR-D also present with 
signs of NF1, such as CAL macules on the skin. NF1 is an autosomal dominant 
disorder, which results from mutations in the NF1 gene. This large tumour-
suppressor gene, comprising of 60 exons has a high mutation rate (Campos et al., 
2013).  Although NF1 is usually an inherited disease, for individuals with CMMR-
D syndrome, the signs of NF1 are quite distinct, comprising largely of e.g. CAL 
macules on the skin.  In CMMR-D there is hyperpigmentation of the CAL macules 
with spots of hypo-pigmented borders; the skin lesions are more diffuse and 
irregular when compared to the classic CALs in inherited NF1.  The number of 
skin lesions in CMMR-D varies, ranging from mostly one to two focal areas, and 
sometimes more areas of skin pigmentation (Whiteside et al., 2002). From the 
cases that have been published, there is no evidence of systemic disease as one 
would see in NF1 which is the result of inherited mutations in the NF1 gene 
(Wang et al., 2003).   
 
Since CMMR-D syndrome is relatively rare, one of the ways in which researchers 
have begun to investigate it, has been through research consortia. A consortium 
is an association of several entities, which in this case includes a 
multidisciplinary team including paediatric and adult oncologists from different 
countries, working together with other clinicians and scientists to identify, 
evaluate and investigate the causes of the various phenotypes within the 
syndrome, to develop relevant monitoring and surveillance modalities, and to 
develop new treatments for children and young adults with CMMR-D. To date, 
two international consortia have been established, namely, the Biallelic 
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Mismatch Repair Deficiency (BMMRD) syndrome consortium 
(www.sickkids.ca/MMRD) and the Care for Constitutional Mismatch Repair 
Deficiency (C4CMMRD) consortium (Wimmer et al., 2014), both of which have 
similar goals.  In a recent report by Bakry et al. (2014), 97% of CMMR-D patients 
who were followed up as part of the BMMRD consortium, had developed CAL 
macules (Bakry et al., 2014).  
 
However, it should be noted that because of the shared characteristics with 
many other inherited syndromes, in some instances, individuals with CMMR-D 
syndrome are misdiagnosed or misclassified. As noted above, the specific 
features of the CAL macules differ from the classic NF1 – however this may only 
be evident when highly experienced clinicians at tertiary and quaternary health-
care facilities see patients. The CMMR-D-related NF1 skin phenotype consists of 
distinct irregular hyper- and hypo-pigmented lesions (Rauen et al., 2014).  
 
The non-recognition or misdiagnosis of CMMR-D also means that appropriate 
surveillance measures are not engaged with timeously and individuals end up 
dying of potentially preventable malignancies. Another challenge with CMMR-D 
is that individuals who survive the first malignancy, usually develop other 
tumours soon afterwards.  For these individuals, the progression from adenoma 
to adeno-carcinoma is rapid with most individuals likely going unnoticed until 
the cancer has progressed to an advanced stage.  Turcot syndrome is an 
additional rare childhood MMR-deficiency syndrome, which further complicates 
CMMR-D diagnosis.  The disorder is characterised by multiple polyps and 
adenomas of the colon, and an increased risk of both colon and brain cancers, 
specifically medulloblastoma in children.  In OMIM (http://www.omim.org) 
Turcot syndrome is classified under the broad category of all MMR cancer 
syndromes (OMIM: 276300), together with CMMR-D.  When it was initially 
described in 1959, Turcot syndrome was divided into dominantly and 
recessively inherited types (Hamilton and Liu, 1995). The dominantly inherited 
type is marked by the presence of heterozygous mutations in the APC gene 
(OMIM: 611731), which is primarily associated with FAP (OMIM: 175100), 
another colon cancer-predisposing disease. A number of distinct features have 
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been identified between these two syndromes, including: type of tumour 
developed, presence of NF1-like characteristics and haematological cancers for 
CMMR-D (Järvinen et al., 2000). Of note is that cases of Turcot syndrome, due to 
APC gene mutations, often develop medulloblastomas compared to those that 
have MMR deficiency, most of whom develop glioblastomas (Mori et al., 1994; 
Hamilton and Liu, 1995; Huang et al., 2000). Following the description of CMMR-
D syndrome, some of the previously described cases of Turcot syndrome have 
been re-classified as CMMR-D.  
3.1.3 Spectrum of tumours in CMMR-D  
3.1.3.1 Haematological malignancies  
In general, haematological malignancies are a group of heterogeneous 
conditions, which originate from bone marrow and plasma cells (Rodriguez-
Abreu et al., 2007; Hall et al., 2013) and are divided into leukaemias, lymphomas 
and plasma cell neoplasms (Hall et al., 2013). According to Wimmer & Etzler 
(2008) , the most prevalent of haematological cancers in CMMR-D are non-
Hodgkin’s lymphoma and acute lymphoblastoid leukaemia. Non-Hodgkin’s 
lymphoma is a lymph-proliferative disease with distinct clinical and histological 
characteristics (Evans and Hancock, 2003). This type of cancer is heterogeneous 
and 85-90% of the cases arise from B-lymphocytes, which can occur in lymph 
nodes and white blood cells (Evans & Hancock, 2003; Shankland et al., 2012). 
Acute lymphoblastoid leukaemia is also a heterogeneous cancer, derived from 
both B and T lymphoid progenitors.  Sporadic cases of this leukaemia have been 
observed in both children and adults ( Onciu, 2009; Inaba et al., 2013).  It has 
been proposed that development of other types of haematological malignancies, 
such as acute myeloid leukaemia might be secondary, due to the administration 
of chemotherapy and/or the development of NF1 (of which acute myeloid 
leukaemia is a feature) in the CMMR-D cases (Wimmer and Etzler, 2008). 
3.1.3.2 Brain tumours 
Brain tumours are the most common malignancy in CMMR-D cases. These 
include high-grade gliomas (HGG), primitive neuroectodermal tumours and 
medulloblastomas.  In a recent study of 18 individuals with CMMR-D, Barky et al. 
(2014) reported the presence of brain tumours in 74% of cases. The most 
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prevalent type of brain tumours are the glioblastomas (Wimmer and Etzler, 
2008). Glioblastomas are one of the most common brain cancers in young 
children, and these may develop from lower grade astrocytic tumours (mostly, 
the secondary type), while the primary glioblastomas most commonly occur de 
novo (Lee et al., 2008; Huse and Holland, 2010; Epple et al., 2012; Archer et al., 
2013). This type of brain tumour displays a highly heterogeneous cellular 
composition, which in turn increases the invasiveness of the tumour (Epple et al., 
2012; Archer et al., 2013).  
 
One type of brain cancer reported as part of the CMMR-D spectrum is 
medulloblastoma, also a relatively common brain malignancy in children (Huse 
and Holland, 2010). Medulloblastomas are believed to arise in the cerebellum 
because of an aberrant activation of the Sonic hedgehog (SHh) pathway. The 
Hedgehog pathway is a signalling system, which regulates a number of important 
processes such as cell differentiation and cell proliferation, amongst others.  An 
inappropriate activation of this pathway has been implicated in a number of 
cancers including those of the lung, breast and brain (Kool et al., 2008; Gupta et 
al., 2010).  Other types of brain tumours, which have been reported as part of the 
syndrome, are listed in Table 3.1  (Wimmer et al., 2008).  
 
3.1.3.3 Lynch syndrome-related tumours 
Not many instances of the Lynch syndrome  spectrum of cancers have been 
reported in individuals with CMMR-D although, when present, these cancers 
develop at an earlier age e.g. in childhood or adolescence (mean age: 17 years) 
(Wimmer and Etzler, 2008). Individuals with gastrointestinal tumours often 
present with polyps.  CRC is also seen in these cases, with a mean age of about 
16.4 years at diagnosis (range from 8 to 35 years), with most cases being 
paediatric. Like Lynch syndrome, individuals with CMMR-D often have CRC 
diagnosed in the ascending colon (Levi et al., 2015). Compared to other CMMR-D 
cancers, the CRC cases often occur in relatively older individuals with an age 
range of 23-35 years (Wimmer and Etzler, 2008; Wimmer et al., 2014). A low 
occurrence of renal and bladder cancers have also been reported in CMMR-D, in 
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individuals ranging from 19 to 21 years of age (Wimmer et al., 2014). Other 
cancers within this syndrome are also classified under ‘emerging phenotypes’, 
including hepatic carcinomas, neuroblastomas, Wilms tumor and 
rhabdomyosarcoma (Wimmer et al., 2014). 
 
Table 3.1 Spectrum of cancers reported in CMMR-D syndrome  
Table adapted from (Wimmer and Etzler, 2008) 
Type of cancer Median age at onset in years 
(age range where available) 
Haematological Malignancies  
Acute lymphoblastoid leukaemia 4 
Acute myeloid leukaemia 9 
Lymphomas 5 
Atypical chronic myeloid leukemia 1 
Overall average age 5.5 
Brain Tumours  
Glioblastoma and other astrocytic tumours 8 
Supratentorial primitive neuroectodermal tumour 8 
Medulloblastoma  7 
Unspecified  23-24 
Overall average age  8 
Lynch Syndrome-associated Tumours  
CRC 16(8-35) 
Endometrial carcinoma 24(23-35) 
Duodenum/jejunum carcinoma 16(11-41) 
Ureter/renal pelvis carcinoma 15 
Overall average age  16 
Other Cancers  
Neuroblastoma  13 
Wilms tumour 4 
Ovarian neuroectodermal tumour  21 
Infantile myofibromatosis  1 
Rhabdomyosarcoma  4 
Mamma carcinoma 35 
Sarcoma 65 
 
3.1.4 Family history and CMMR-D 
Consanguineous parents are a relatively common feature of CMMR-D cases.  In 
some instances, CMMR-D families may already have a history of the Lynch 
syndrome spectrum of cancers, or at least meet the Amsterdam criteria. 
However, from a review of the literature thus far, parents of offspring with 
CMMR-D are often unaffected. This observation may be due to CMMR-D-related 
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cancer diagnosis in very young children (e.g. <5 years of age) where parents may 
well be in their  third (20s) or fourth (30s) decade of life, prior to any signs or 
clinical diagnosis of Lynch syndrome.  It is also possible that there is a decreased 
penetrance associated with certain genes and mutations (Drost et al., 2013). 
Only a few studies have been performed to assess the penetrance of disease in 
individuals with PMS2, which only account for about 10% of all cases of Lynch 
syndrome, compared to other MMR genes, such as MLH1 and MSH2.  In one such 
study, of 377 PMS2-mutation-positive cases from more than 2000 European 
families: the lifetime risk for disease development was estimated to be about 
19% and 11% for CRC in males and females, respectively, and about a 12% risk 
for endometrial cancer in females.  The estimated risk of a malignancy with PMS2 
mutations was still higher compared to the background population, but was 
relatively lower when compared to MLH1- and MSH2-mutation carriers.  This 
could, at least to some extent, explain the lack of a clear dominant family history 
among individuals who harbour biallelic PMS2 mutations and who manifest with 
CMMR-D. 
3.1.5 Genetics of CMMR-D syndrome 
3.1.5.1 Mutations associated with CMMR-D syndrome 
Biallelic mutations in the genes coding for the four main MMR proteins, namely 
MLH1, PMS2, MSH6 and MSH2 have been associated with CMMR-D syndrome. All 
four of these genes play an important role in MMR activity (Chapter 1, section 
1.4.2). Mutations (including monoalleic) in these genes result in the suboptimal 
functioning of the DNA post replication-repair mechanism and repair efficiency. 
This biological compromise has been associated with many cancers and cancer 
syndromes as previously described. The “InSight” variant website 
(http://insight-group.org) maintains a database of all mutations in these MMR 
genes that have previously been reported to be associated with cancers. As 
would be expected, not all of the thousands of mutations reported in the MMR 
genes have been associated with CMMR-D. The mutations reported in association 
with CMMR-D are listed in Table 3.2. Most of these are compound heterozygous 
mutations located in the PMS2 gene. Mutations reported in the MLH1 and MSH2 
genes are mostly homozygous and indels, respectively.  
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Table 3.2 List of mutations associated with CMMR-D syndrome (CompHet = compound heterozygote) 
 
No. Gene Zygosity  Sequence change Protein change 
1 MLH1 Homozygous c.676C>T ARG2265STP 
2 MLH1 Homozygous c.199G>T GLY67TRP 
3 PMS2 CompHet c.2113G>A GLU705LYS 
  PMS2 CompHet C del-upstream codon 1 p.? 
4 PMS2 CompHet c.400C>T AGR134STP 
  PMS2 CompHet c.delAAG LYS-DEL618 
5 PMS2 CompHet c.1221delG THR408LEU 
  PMS2 CompHet c.2361delCTTT p.? 
6 PMS2 Homozygous c.1169ins20 p.? 
8 MSH2 Homozygous c.1662-1G>A (exon skipping) p.? 
9 MSH2 CompHet c.exon3 deletion p.? 
  MSH2 CompHet c.153-1del1bp (exon3) p.? 
10 MLH1 Homozygous c.1943C>T P648S 
11 MLH1 Homozygous c.2059C>T ARG687TRP 
12 MLH1 Homozygous nonsense mutation GLU268GLY 
13 PMS2 Homozygous   R802STP 
14 MSH6 Homozygous c. 3386-3388delGTG p.? 
15 MSH6 CompHet c.3609-3612del HIS1203GLN 
  MSH6 CompHet c.3073G>A p.? 
16 PMS2 CompHet c.1951 C>T Q643STP 
  PMS2 CompHet c.161C>T S46I 
17 MSH2 Homozygous c.2006-5T>A GLY669ASP 
18 MLH1 CompHet c.677G>A R226STP 
  MLH1 CompHet c.2146G>A V716M 
19 PMS2 Homozygous    R802STP 
20 MSH6 CompHet c.3226C>T CYT1076ARG 
  MSH6 CompHet c.3991C>T ARG1331STP 
21 MSH2 CompHet c.229G>A C765W 
  MSH2 CompHet   V878A 
22 MSH6 CompHet c.642C>G Y214STP 
  MSH6 CompHet c.458-1 G>A(splice site) p.? 
23 PMS2 Homozygous c.400kb del. (exon9-15) p.? 
24 MSH6 CompHet c.1596-1597T GLU533fs 
  MSH6 CompHet c.3261delC PRO1087fs 
25 MLH1 CompHet c.595delAG(frameshift) p.? 
  MLH1 CompHet c.104T>G MET35ASN 
26 MSH2 Homozygous c.226C>T Q76X 
27 MSH2 Homozygous c.1906G>C ALA63PRO 
28 PMS2 Homozygous c.1306dupA SER436LYSfs 
29 MSH6 Homozygous c.4002-3_4002_8 indel p.? 
30 PMS2 Homozygous c.182delA TRY61LEU 
  PMS2 Homozygous c.234A>G(exon4) p.? 
  PMS2 Homozygous c.2340C>T(unclassified) (p.?) r.2340c>u 
31 PMS2 Homozygous c.182delA TRY61LEU 
32 MSH6 CompHet c.1806-1809delAAG GLU604LEU 
  MSH6 CompHet c.3226C>T ARG1076CYS 
33 PMS2 Homozygous   P1590STP 
34 PMS2 Homozygous   G271V 
35 PMS2 CompHet c.1408C>T LYS614STP 
  PMS2 CompHet c.1454C>A THR485LYS 
36 PMS2 Homozygous del  Exon7 p.? 
37 PMS2 Homozygous c.137G>A S46N 
38 PMS2 Homozygous c.989-1G>T p.? 
39 PMS2 CompHet del Exon 1-6 p.? 
  PMS2 CompHet c.1A>G Met1? Met1? 
40 PMS2 Homozygous c.219A>T CYS73STP 
41 PMS2 CompHet c.137G>T SER46ILE 
  PMS2 CompHet c.804-2A>G(splice site) p.? 
42 MSH6 CompHet c.1634-1635AAdel LYS545ARG 
  MSH6 CompHet c.357-3958insTCAAA… p.? 
43 MSH6 Homozygous c.691delG VAL231STP 
44 MSH6 CompHet c.3226C>T R1076C 
  MSH6 CompHet c.1422insTG GLN475CYS 
45 PMS2 Homozygous c.989-1G>T p.? 
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No Gene Zygosity  Sequence change Protein change 
46 MSH6 Homozygous c.326insC F1088L 
47 PMS2 CompHet c.1687C>T R563STP 
  PMS2 CompHet Maternal allele dropout p.? 
48 PMS2 CompHet c.137G>T SER46ILE 
  PMS2 CompHet c.736_741del6insTGTG… PRO246fs 
49 PMS2 CompHet c.1239dupA LYS413fs 
  PMS2 CompHet c.1927C>T GLN643STP 
50 PMS2 Homozygous c.2174+1G>A(intron12) p.? 
51 PMS2 CompHet c.137G>T SER46ILE 
  PMS2 CompHet c.2174+1G>A(intron12) p.? 
52 PMS2 CompHet del PMS2 p.? 
  PMS2 CompHet c.736-741insGTGTG… PRO246CYSfs 
53 PMS2 CompHet c.137G>A SER46ILE 
  PMS2 CompHet c.2174+1G>A(intron12)(aberrant splicing) p.? 
54 PMS2 CompHet del Exon1-11 p.? 
  PMS2 CompHet del Exon3-7 p.? 
55 PMS2 Homozygous c.2174+1G>A(intron12) p.? 
56 PMS2 CompHet c.delExon7-14 p.? 
  PMS2 CompHet c.delExon7-11 p.? 
57 PMS2 CompHet c.1687C>T ARG563STP 
  PMS2 CompHet r.2007_2445del439(delExons12-14) p.? 
58 PMS2 CompHet c.325dupG p.? 
  PMS2 CompHet r.804_825del(silent premature stop-RNA) ILE269ALA(STP) 
59 PMS2 CompHet c.1221delG THR408LUE(STP) 
  PMS2 CompHet c.2361_2364delCTTC PHE788CYS 
60 PMS2 Homozygous c.1169_1170ins20(frame shift) p.? 
61 PMS2 CompHet c.137G>T SER46ILE 
  PMS2 CompHet c.1927C>T GLN643STP 
62 PMS2 CompHet c.137G>T SER46ILE 
  PMS2 CompHet c.1730dupA; 1732C>T ARG578VAL 
63 PMS2 CompHet c.400G>T ARG134STP 
  PMS2 CompHet c.2184-2185del LEU729GLN 
64 PMS2 CompHet c.2361-2364del PHE788CYS 
  PMS2 CompHet c.1221delG THR408LUE(STP) 
  PMS2 Homozygous c.1169_1170ins20(frameshift) p.? 
65 PMS2 Homozygous c.2407C>T ARG802STP 
  PMS2 Homozygous c.1768del ILE590PHE 
66 PMS2 Homozygous c.812G>T GLY271VAL 
67 PMS2 Homozygous c.1840A>T LYS614STP 
68 PMS2 Homozygous del Exon7 p.? 
69 PMS2 CompHet c.2249G>A GLY750ASP 
  PMS2 CompHet del PMS2 p.? 
70 PMS2 CompHet c.1A>G Met1?(5'trancation) Met1? 
  PMS2 CompHet del Exon9-10 p.? 
71 PMS2 CompHet c.1A>G Met1?(5'trancation) Met1? 
  PMS2 CompHet c.614A>C GLN205PRO 
72 PMS2 CompHet c.1A>G Met1?(5'trancation) Met1? 
  PMS2 CompHet c.251A>G(aberrant splicing) p.? 
73 PMS2 Homozygous c.949G>T GLN317STP 
74 MLH1 CompHet c.1852-1853CC>GG LYS618ALA 
  MLH1 CompHet c.546A>G(aberrant splicing) ARG182SER 
75 MLH1 Homozygous c.2059C>T ARG687TRP 
76 MLH1 Homozygous c.806C>G SER269STP 
77 MLH1 CompHet c.2146G>A VAL716MET 
  MLH1 CompHet c.676C>T ARG226STP 
78 MSH2 Homozygous c.2006-5T>A(aberrant splicing) GLY669ASP 
79 MSH2 Homozygous c.1906G>C ALA636PRO 
80 MSH2 CompHet del Exons1-6 p.? 
  MSH2 CompHet c.1A>G (5'trancation) Met1? 
81 MSH6 Homozygous c.3386-3388del CYS1129_VAL1130indelLEU 
82 MSH6 Homozygous c.3635dupT ASP1213GLY 
83 MSH6 CompHet c.2633T>C VAL787ALA 
  MSH6 CompHet c.2295C>G CYS765TRP 
84 MSH6 CompHet c.3226C>T ARG1076CYS 
  MSH6 CompHet c.3991C>T ARG1331STP 
85  MLH1 Homozygous  c.1528C>T  GLN510STP 
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3.1.6 Genotype/Phenotype correlation 
Wimmer et al. (2014) recently reviewed 146 reported cases of CMMR-D from 91 
different families, globally.  These subjects ranged in age from about six months 
to 39 years.  A total of 145 of the 146 cases already had malignancies or 
neoplasias following ‘mutational’ diagnosis.    PMS2 and MSH6 were by far the 
most commonly mutated genes reported in patients diagnosed with CMMR-D.  As 
mentioned earlier, CMMR-D patients with MSH6 and PMS2 mutations often have 
no family history of cancer.  According to Wimmer et al. (2014), individuals with 
either MLH1 or MSH2 mutations were more likely to develop haematological 
primary malignancies, and at a much earlier age than those with mutations in 
either MSH6 or PMS2. About 60% of the PMS2 and MSH6 mutation carriers, 
compared to only about 30% of the MLH1 or MSH2 mutation carriers, developed 
brain tumours as their primary malignancy.  
Although patients with either MSH6 or PMS2 mutations were likely to survive 
their initially diagnosed malignancy, they tend to be diagnosed with secondary 
tumours relatively shortly thereafter (Wimmer et al., 2014). There is an 
emerging literature on CMMR-D syndrome – however, it is clear that more 
research is needed to establish clear genotype and phenotype correlations for 
this devastating group of diseases.  
 
3.1.7 Diagnosis of CMMR-D  
Unlike the molecular diagnosis of Lynch syndrome, which requires identification 
of a mutation in one of the alleles in one of the MMR genes, there are challenges 
associated with diagnosis of CMMR-D (Leenen et al., 2011).  Traditionally for 
Lynch syndrome, testing is performed if the individual meets the Bethesda 
criteria as previously described in Chapter 1 (literature review). For the 
individuals with CMMR-D, a family history (as defined within the Bethesda 
criteria) is not very helpful; and patients may well be identified ‘accidentally’, 
and where there is a specialist interest in e.g. Lynch syndrome.   Most studies – 
when already suspecting CMMR-D, perform three main tests; 1) IHC, 2) MSI 
testing, and 3) molecular genetic testing (Wimmer and Kratz, 2010).  
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3.1.7.1 Immunohistochemistry (IHC) 
IHC tests are performed with antibodies which check for the integrity of the 
common protein products of the MMR genes associated with the disease i.e.  
MLH1, MSH2, MSH6 and PMS2.  The tumour analysis for IHC in Lynch syndrome 
has been shown to be specific and sensitive in pointing to the respective 
‘mutated’ gene (Peltomäki and Gylling, 2011).  For IHC, the loss of expression in 
one of the genes implies the presence of a pathogenic germline mutation in that 
particular gene (with a somatic second hit occurring – and perhaps being the 
precipitating event) leading to tumorigenesis. Following IHC, sequencing of the 
indicated  gene  is performed to confirm the mutation.  
 
3.1.7.2 Microsatellite instability (MSI) 
 Tumours with MMR deficiency are often characterised by the presence of MSI. 
However, with CMMR-D, the role or presence of MSI is controversial.   A review 
of 31 brain cancers (diagnosed with CMMR-D) by the C4CMMRD consortium  in 
Europe, reported that most cases had microsatellite stable tumours. In a study by 
Giunti et al., (2009), the MSI mononucleotide marker panel was tested in gliomas 
in order to gauge whether patterns of MSI correlated with the family history of 
cancer. It was reported that the degree of instability is lower in MMR-related 
gliomas versus colon cancer cells, perhaps because of the small allelic shift in the 
CNS (where there are fewer actively proliferating cells) compared to the 
colon/CRC (Giunti et al., 2009). Thus, depending on which tissue is being tested, 
the MSI status could be uninformative and this calls for improvement in methods 
used to diagnose CMMR-D syndrome. 
3.1.7.3 Molecular genetic testing  
In Lynch syndrome, the MMR proteins shown to be compromised during IHC 
generally point to the gene which may be mutated; this gene is then screened 
through DNA sequencing to identify the causative mutation. Usually the parents 
of the affected individual will also be tested to confirm the origin of the mutation 
manifesting in the child. The identified mutations range from single base pair 
changes to insertions and deletions of larger sections of the gene. As previously 
mentioned, to date mutations in the PMS2 gene have been identified to underlie 
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cases of CMMR-D syndrome more often than in other MMR genes. Other tests 
performed are those for the mutations in the NF1 gene. This has been done 
mostly to confirm that the NF1 mutations are not germline, but somatic, 
reflecting that the NF1 features are a secondary result of the mutator phenotype, 
and a consequence of MMR mutations.  
 
3.1.8 Recommended surveillance and treatment  
 For individuals with CMMR-D syndrome, very little is known about the 
efficiency of chemotherapy for the treatment of childhood haematological 
malignancies (Ripperger et al., 2010). Regular follow-up by an oncologist 
(Leenen et al., 2011), assessment of immunoglobulin levels, colonoscopy 
(Ilencikova et al., 2011; Herkert et al., 2011), video capsule small bowel 
endoscopy from the age of eight years (Herkert et al., 2011) and magnetic 
resonance imaging (MRI) (Ilencikova et al., 2011; Leenen et al., 2011; Durno et 
al., 2012 ) may be considered options for surveillance.  There are, as yet, no 
established management surveillance programs or guidelines to monitor these 
patients to ensure optimal prognosis and survival.  
 
3.1.9 Chapter synopsis 
As reported earlier, researchers in the Division of Human Genetics at the UCT 
have found the primary predisposing gene defect in the MLH1 (7127) gene, 
which is a component of the post-replication MMR system for Lynch syndrome in 
the Mixed Ancestry population of the Northern and Western Cape Provinces of 
S.A. Currently, several communities are being managed (pre-symptomatically) 
with the use of genetic testing, genetic counselling and surveillance 
colonoscopies of MMR-gene mutation carriers.  A study by Stupart et al., (2009) 
indicated the effectiveness of this programme through improved mortality and 
morbidity.  However, more recently,  a four year old child in this S.A. cohort  
demised due to a grade IV astrocytoma in the brainstem, despite early pre-
symptomatic molecular diagnosis (Bruwer et al., 2013). This subject was the 
child of non-consanguineous parents, who were both heterozygous for the MLH1 
c.1528C>T mutation, with a history of Lynch syndrome in their respective 
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families. As indicated in the pedigree in Figure 3.1 the proband (III-1) was 
homozygous for the c.1528C>T; c.1528C>T mutation.       
 
 
Figure 3.1: Pedigree indicating clinical features in a family with Lynch syndrome and 
CMMR-D. Also indicated are the types of cancers, age at diagnosis and mutation status for family 
members. In the figure, squares represent males, and circles represent females, deceased 
individuals are indicated by a diagonal line through the square/circle. Black/shaded symbols 
represent affected individuals with the type of cancer indicated below the symbol e.g. CRC  or 
gynae for a gynaecological cancer. The specific MLH1 c.1528C>T (het= heterozygous) mutation 
has only been observed in families of Mixed Ancestry in S.A. and has not been reported in any 
other population (Ramesar et al., 2000). (Figure adapted from Bruwer et al., 2013) 
 
As discussed by Bruwer et al. (2013), the management as well as the surveillance 
applied to this patient was unsuccessful, highlighting the need to identify new 
ways to manage CMMR-D cases. The questions worthy of investigation include: 
what are the biological consequences of having a homozygous mutation in a 
MMR gene, and whether one might be able to predict which cancers to optimally 
screen for in these patients.   The clinical proximal research will be supported by 
asking the following questions:  
(i) what are the range of genes that are most susceptible to acquiring 
somatic mutations as a result of both a heterozygous and/or 
homozygous mutation in the MLH1 gene,  
(ii) which parts of these genes are most likely to be mutated i.e. 
consensus nucleotide sequence or specific domain-coding regions 
of these genes, and  
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(iii) what are the range of secondary mutations which may lead to the 
development of the different types of cancers  
 
This chapter will also provide a means of identifying the possible rate of 
mutagenesis in the mutation carrier. This chapter will also provide new channels 
to assist in understanding the pathways involved in MMR-defective 
tumorigenesis.  
 
 It is known that the transition from normal to a cancerous state is a result of 
accumulation of mutations (Frank, 2003; Frank and Nowak, 2004) and that the 
mutation rate is a key biological feature of somatic cells that determines risk for 
malignant transformation (Araten et al., 2005). An average mutation rate in a 
somatic cell in humans is about 1.02x10-9, which is 17 times higher than the 
germline rate and 3.3 times higher than the average for yeast and E. coli (Lynch, 
2010). Under normal circumstances, the repair systems are able to cope with 
such rates. However, the loss of MMR leads to a mutator phenotype for all cells 
and this loss of repair functioning does not only affect the frequency at which 
mutations occur, it also changes the pattern of mutations (Klasen et al., 2005).  
Lang et al., (2013) used yeast to generate the genome view of the rate, spectrum 
and distribution of mutations in the absence of MMR function.  Of the 19 strains 
used, they found insertions and deletions at homopolymeric sites to be more 
common (87%) and predicted that these homopolymer sites, with proximal 
repeats, host potential drivers of tumorigenesis in MMR-defective cells.   
Identification of these drivers in human cells could improve the understanding of 
the mutagenic processes which are likely to occur in the absence of MMR 
functioning, and also assist in identifying target loci that contribute to 
carcinogenesis.  
3.1.9.1 Research Aims 
 The main aim of this chapter of the study was to identify the underlying genetic 
features involved in initiation and progression of neoplasia in CMMR-D 
syndrome. The hypothesis is that there are regions in the human genome that 
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are more susceptible to accumulation of somatic mutations in the absence of 
MMR function which, as a result, enhance carcinogenesis.  
3.1.9.2 Research objectives:  
1) To determine whether CMMR-D individuals exhibit microsatellite 
instability 
2) To determine the germline mutation rate by using whole exome 
sequencing. 
3) To employ bioinformatics tools for pathway-based analysis in order to 
identify the gene clusters in existing pathways which may be involved in 
disease initiation and progression  
 
 
 
 
3.2 Methods  
3.2.1 Ethics and consent 
All subjects investigated in this study previously provided informed consent as 
part of the main study (HREC REF 225/2010) and in the case of minors, parents 
consented on behalf of the children (Appendix A). The purpose of the additional 
consent was to provide permission to use post-mortem material of the demised 
proband for research purposes. This research was approved by the Human 
Research Ethics Committee, at UCT (HREC REF333/2014) and biological 
material was collected according to the guidelines of the Declaration of Helsinki 
(World Medical Association, 2013).   
 
3.2.2 Biological material  
The biological materials for all subjects in the current study were previously 
collected with informed consent.  For this investigation, eligible subjects 
included individuals who met the following criteria: a confirmed disease-causing 
mutation in one of the MMR genes and, where applicable, knowledge of their 
mutation status following a genetic counseling session.    Several different 
biological material types were used for various aspects of this study. For the 
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germline genetic testing, DNA was isolated from both saliva and whole blood.  
For the tissue extractions to identify somatic mutations, DNA was isolated from 
formalin-fixed paraffin-embedded (FFPE) and freshly-frozen tissue. Described 
below are the methods used to isolate DNA from various biological specimens.  
 
3.2.2.1 DNA Isolation 
3.2.2.1.1 Whole-blood  
An adjusted version of the Helms’ salting-out DNA extraction method (Miller et 
al., 1988) (http://hdklab.wustl.edu/lab_manual/dna/dna2.html) was used to 
extract DNA from whole blood.  Briefly, the process involved a series of salt-
saturated buffers to separate the DNA from the rest of the blood, followed by 
protein precipitation/removal, and the precipitation of DNA. The DNA was 
hydrated in TE buffer. Subsequently, samples were stored at either -20°C (short-
term storage, or working stock) or -80°C (long-term storage).   
 3.2.2.1.2 Saliva 
 The Oragene® manual purification of DNA (prep IT.L2P) was used to isolate 
genomic DNA from 0.5mL saliva as per the manufacturer’s protocol 
(http://www.dnagenotek.com/US/pdf/PD-PR-006.pdf). Briefly, the process 
involved heating samples at 50°C to ensure adequate extraction and nuclease 
inactivation. This was followed by ethanol precipitation and removal of the co-
contaminants such as phenol and proteins. The samples were rehydrated using 
the DNA storage buffer or 1X TE buffer, then stored at either -20°C (short-term 
storage) or -80°C (long-term storage).   
3.2.2.1.3 Tissue  
DNA isolation from FFPE tissue was carried out using three methods, the 
ROCHE® DNA FFPE Tissue isolation method, Ion Ampliseq Direct FFPE DNA kit™ 
and the frozen tissue was isolated using a derivative of salting out method, each 
of which is explained briefly, below. RAN was isolated using the Quick-RNA mini-
prep Zymo kit method.  
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 3.2.2.1.3.1 ROCHE ® DNA FFPE Tissue isolation method 
The isolation was carried out as per manufacturer’s protocol and 
recommendation. The principle of isolation involved removing formalin using 
xylene, and proteinase K to lyse the cells. The samples were heated to remove 
the remaining formalin; this was followed by a series of washing steps, with 
washing buffer to remove the co-contaminants. Finally, DNA was eluted into a 
tube using an elution buffer, after which it was stored at either -20°C (short-term 
storage) or -80°C (long-term storage).   
3.2.2.1.3.2 Ion Ampliseq Direct FFPE DNA kit™  
The method was performed as per the manufacturer’s protocol (Appendix B).   
This method did not make use of deparaffinising with xylol or xylene. The 
principle of isolation involved the use of two solutions; ‘transfer solution’ and 
‘direct reagent’ (whose ingredients are proprietory). The tissue was removed 
from the microscope slide using transfer solution, in to a microfuge tube 
containing direct reagent. The tube was then incubated in a thermocycler at 65°C 
for 15 minutes and then at 20°C for 30 minutes, for the purpose of digesting the 
cell walls/membranes to release DNA.  Subsequently, the samples were stored at 
-20°C until required.  
3.2.2.1.3.3 Frozen tissue extraction (DNA)  
This method was adapted from the Helms’ salting-out DNA extraction method 
(Miller et al., 1988). The tissue was dissected into small fragments with a sterile 
scalpel and transferred into a sterile microfuge tube, followed by the addition of 
a buffer containing proteinase K and incubation at 37°C to allow for tissue lysis. 
Subsequently, the samples were subjected to a series of steps of precipitation 
with ethanol and elution using 1X TE buffer. The DNA samples were stored at -
20°C until required.  
 
3.2.2.2 DNA Quantification and Quality Control 
 To determine the quality and quantity of the DNA samples, spectrophotometry 
and/or Qubit® fluorometry and gel electrophoresis were performed.  
Spectrophotometry was performed using the NanoDrop® ND-1000 (Thermo 
Scientific, Wilmington, U.S.A.).  In addition to obtaining the concentrations of 
DNA in the stock solution, this instrument measures the purity of the solution.  
 75 
The intensity for DNA was measured at A260, whilst the wavelength of 
maximum absorbance for protein was A280, and other solvent(s) at A230.  The 
ratio of A260/A280 measures protein levels and a ratio of less than 1.8 indicated 
protein and phenol contaminants.  An A260/A230 ratio below the range of 1.6-
2.0 may indicate the presence of co-purified products such as inorganic solvents 
(http://www.nanodrop.com/Library/nd-1000-v3.7-users-manual-8.5x11.pdf).  
     
Qubit® 3.0 Fluorometry (Thermo Fisher Scientific, MA, U.S.A) is a method used 
to quantify the nucleic acid and protein concentrations in a given sample. It uses 
fluorescent dyes, each of which is specific to the type of the molecule (DNA, RNA 
or protein). The ‘free’ dyes have low fluorescence but once bound to the target, 
their fluorescence increases. At a specific level of fluorescence, signals from the 
dye and DNA mixture are directly proportional to the concentration of the DNA 
in the solution.  The Qubit®3.0 Fluorometer performs the calculations 
automatically and then produces a reading in ng/uL.  The Qubit® dsDNA HS 
(high sensitivity) Assay kit (Thermo Fisher Scientific, MA, U.S.A.) was used. The 
assay was carried out as described by the manufacturer 
(https://tools.thermofisher.com/content/sfs/manuals/Qubit_dsDNA_HS_Assay_
UG.pdf).  
 
Subsequent to spectrophotometry and/ or Qubit® readings, the DNA was 
diluted to a working concentration of 100ng/µL using sterile, distilled water, 
(Adcock Ingram, Johannesburg, South Africa).  Working solutions were stored at 
–20°C for an integrity test using gel-electrophoresis, as outlined in the following 
paragraphs.  
3.2.2.3 Integrity check: Gel electrophoresis 
Gel-electrophoresis is a method used to separate and visualize nucleic acids 
according to size.  A sample of DNA (usually 100ng/µL in distilled water) was 
loaded onto an agarose gel submerged in TBE buffer. The gel was then subjected 
to an electric field, which draws the negatively charged DNA across it. The 
molecules travel at different speeds depending on their net charge and size 
(larger fragments travel slower while smaller fragments travel faster and 
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further) and therefore end up at different positions in the gel, as a function of 
their size, after a given time. 
 
To prepare the gel, a 1% or 2% [weight per volume agarose, Seakem® LE 
Agarose Lonza (Rocklands, ME, U.S.A.)], was mixed with TBE buffer (Appendix 
C). In order to enable visualization of the DNA fragments in the gel, a nucleic acid 
stain, SYBR® Safe stain (1mg/ml) (Sigma, MO, U.S.A.), was added directly into 
the agarose gel.  The DNA stain binds to DNA by intercalating between base 
pairs, to facilitate visibility of the sample in the gel.  Five microliters (5 µL) of 
GeneRulerTM 100bp DNA Ladder Plus molecular weight marker (0.05ug/µL) 
(Fermentas®, Vilnius, Lithuania) was loaded into one of the wells on the gel in 
order to gauge the approximate size of the DNA molecules (i.e. in this case to 
check if DNA was relatively intact or degraded) (Appendix C).  Gel 
electrophoresis was conducted between 110-160 volts (V) for 30 to 40 minutes. 
The resulting gel was visualized using the Ultra-Violet trans-illuminator (UVI-
Tech, Cambridge, UK), and the image processing was performed using the UVI-
Pro software (version 12.3). 
 
3.2.3 Microsatellite genotyping 
3.2.3.1 Marker amplification  
To determine the microsatellite status (i.e. extent of microsatellite instability) in 
the germline and tumour material, the Promega (Madison, WI, U.S.A.) MSI 
analysis system, version 1.2, was used.  This assay includes labelled primers for 
co-amplification of five mononucleotide repeat markers (BAT25, BAT26, NR21, 
NR24 and MONO27) and two penta-nucleotide markers (penta C and penta D) 
(Table 3.3) 
 
The mononucleotide markers were used for MSI testing while the penta-
nucleotides were used to ensure accurate amplification and sizing and as a 
control in case of sample mix-ups and contamination. 
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Table 3.3 List of microsatellite Markers for MSI testing (Promega) 
Marker Name  GenBank® Number Size Range (bp) 
NR-21  XM_033393 94–101 
BAT26 U41210 103-115 
 BAT-25 L04143 114–124 
NR24 X60152 130-133 
 MONO-27 AC007684 142–154 
Penta C ALI38752 143-194 
 Penta D AC000014 135–201 
 
For microsatellite genotyping, the PCR involved the use of nuclease free water, 
Gold Star 10X buffer (Promega Madison, WI, U.S.A.), MSI 10X primer pair and 
AmpliTaq Gold DNA polymerase (Promega Madison, WI, U.S.A.), which is a 
specialized polymerase that performs well in multiplex PCR conditions.  The PCR 
was conducted under conditions described in Appendix D. Once the 
amplification was completed, capillary electrophoresis was carried out.   
 
3.2.3.2 Automated capillary electrophoresis  
To prepare samples for capillary electrophoresis, a mixture of an internal lane 
standard (ILS600) and Hi-Di™ formamide (HiDi), (Applied Biosystems, Foster 
City, CA) was made to maintain the DNA as a single strand (Sambrook and 
Russell, 2001a).  An internal lane standard 600 (ILS600) serves as a molecular 
weight marker during this process. The ILS600 specifically, contains 22 DNA 
fragments ranging from 60 to 600 bases in length. Each fragment is labelled and 
detected separately in the presence of the MSI during electrophoresis.  For this 
particular experiment, 1uL of ILS600 was added to 9uL of HiDi formamide, to 
make up the cocktail, and 1uL of the PCR product (of each sample) was then 
added.  
 
The combination of the sample and cocktail was denatured at 950C for five 
minutes and immediately snap frozen in ice for three minutes (this is to allow 
the DNA fragments to remain single stranded in preparation for the automated 
electrophoresis).  Results were analysed using the GeneMapper® software 
version 4 (Applied Biosystems, Foster City, CA).  
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3.2.4 Next Generation sequencing 
Next-generation sequencing (NGS) has emerged as a powerful tool to determine 
the wide range of DNA variations, from single nucleotide changes to insertions 
and deletions and other structural changes (Majewski et al., 2011).  
The workflow is divided into three major steps (Figure 3.2); sample preparation 
and sequencing, primary data analysis and secondary data processing.  
                             
Figure 3.2: NGS workflow. Indicated above are the three important stages of NGS, sample 
preparation and sequencing, primary data processing and secondary data  analysis [Image taken 
from Ku et al. 2012)] 
 
  
For the purpose of this study, the Ion Torrent, Ion Express™ sequencing platform 
was utilized to perform WES. The workflow for this platform is explained below.  
The samples used in the sequencing included NPC569.1 (father), NPC1.77 
(mother). NPC569.3 (proband) and NPC569.4 (sibling). For the parents 
(NPC569.1 and NPC1.77) DNA was extracted from whole blood, and for the 
sibling DNA was extracted from saliva.  For the proband, DNA was extracted 
from saliva, and for the subsequent experiments, DNA was extracted from 
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several tissues (adrenal, bowel, cerebellum, cerebrum, kidney, liver and spleen) 
which were obtained post mortem.   
 
3.2.4.1 Library Construction 
In preparation of the library construction, the quality checks were performed to 
ensure that the input DNA quality was good enough for library construction.  For 
Ion Torrent WES, the TaqMan RNaseP detection Reagent Kit (Thermo Fisher 
Scientific, MA, U.S.A.)  is recommended to quantify the amplifiable DNA.  For each 
exome library it was recommended that ~50-100ng of genomic DNA (gDNA) be 
used as an input.  
 
Library construction involved fragmenting the DNA into uniform sizes of about 
200 to 400 base pairs, followed by the addition of sequencing adapters (Figure 
3.3). Sequencing adapters are short pieces of DNA added to the ends of the 
fragmented DNA. During the sequencing step, these adapters were used to prime 
DNA replication. The Ion AmpliSeq™ Exome kit was used to construct the library.  
    
Figure 3.3: Library construction Ion Torrent sequencing platform. A step-by-step process 
from DNA sample to generation of libraries. The generated library for the study was bar-coded, 
and  two samples were run at the same time 
(https://tools.thermofisher.com/content/sfs/manuals/MAN0010084_AmpliSeq  
_ExomeRDY_LibraryPrep_UG.pdf) 
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3.2.4.2 Template Preparation/amplification 
Following the library construction, templates were prepared for amplification. 
This process starts with attachment of beads to the fragments generated in the 
library preparation, described above and subsequent amplification of the 
fragments using emulsion PCR (emPCR). The beads, coated with complementary 
primers, were mixed with a dilute aqueous solution containing the fragments to 
be sequenced along with the necessary PCR reagents. This solution was then 
mixed with oil to form an emulsion of micro-droplets. The clonal amplification of 
each fragment was then performed within the micro-droplets. The sample 
emPCR, emulsion breaking and enrichment were performed using the Ion X-
press template kit according to the manufacturer’s instructions (Thermo Fisher 
Scientific, MA, U.S.A.). Following amplification, the emulsion was broken by 
organic extraction and centrifugation, and the amplified beads were enriched in 
a glycerol gradient.  
3.2.4.3 Sequencing 
The Ion Torrent sequencing technology is based on the standard pyro-
sequencing chemistry. The nucleotide bases are introduced one at a time and 
incorporated by the DNA polymerase. The machine then measures the direct 
release of protons (H+) from the reaction of base introduction. Nucleotide 
incorporation into the growing complimentary DNA strand causes a release of a 
Hydrogen ion, which is sensed by a hypersensitive sensor. The technology is 
faster to run because it does not use optics and processes about 200 reads in two 
hours. Sequencing was subsequently performed using the sequencing kit v2.0 
(Thermo Fisher Scientific, MA, U.S.A.), on the Ion Torrent PGM (Thermo Fisher 
Scientific, MA, U.S.A.) for 65 cycles with barcoded samples, with two DNA 
samples/libraries per chip.  
3.2.5 Data analysis  
Data from the PGM runs were processed using the Ion Torrent platform specific 
pipeline, Torrent Suite software™ (version 4.2.1) (Thermo Fisher Scientific, MA, 
U.S.A.), to generate sequencing reads, trim the adapter sequences, filter and 
remove poor signal profile reads.  The Torrent Suite software™ (version 4.2.1) is 
a web based platform which included the analysis pipeline optimized for Torrent 
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raw data, alignments and variant calling purposes and for this process it uses a 
plug-in function Torrent variant base caller version 4.2-18/6b3fd1b, 
configuration: Generic Proton- Germline – high stringency.  The analysis was 
performed using the factory default settings. The BAM files and variant call files 
(VCF) were generated using the Torrent Suit Software with plug-in variant caller. 
The filter was set at a depth average of >100, each variant calling of >20, a 
variant frequency of each sample >5% and p value of <0.01.  
3.2.5.1 WES Analysis workflow (family analysis)  
The bioinformatics analysis for the germline DNA WES of family NPC569 (Figure 
3.4) was completed on the Torrent variant caller software version 4.2-
18/6b3fd1b using the default settings.  The BAM files and VCFs were exported 
for further analysis. VCF is a text file format (most likely stored in a compressed 
manner) consisting of a list of all variants identified from a specific genome.  
 
Figure 3.4: Analysis workflow for the NGS analysis part of the study with particular interest in 
identifying novel variants in the NPC569.3 and NPC569.4. These variants were identified by 
excluding all variants observed in both parents, then put through a pathway based analysis to 
identify the most enriched pathways. 
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3.2.5.2 Variant annotation and filtering      
Subsequent to variant calling, variant annotation was performed on each sample 
VCF file and the merged family VCF files. Variant annotation is a process 
whereby the raw recognized and data was combined to determine certain 
information such as definition of the variant and genotype call to the variants 
identified. ANNOVAR was used to independently perform gene-based annotation 
in each sample and the merged family VCF files were analysed in order to 
catalogue whether SNPs cause protein-coding changes and whether the amino 
acids are affected http://annovar.openbioinformatics.org/en/latest/.  ANNOVAR 
also predicts whether the identified variants result in any protein coding 
changes and if the affected codons may result in a change of amino acids.  
This program also performs filter-based annotation, whereby frequency of 
variants which have been previously reported in other databases, for instance, 
dbSNP, and 1000 Genomes Project are reported. Annovar is also able to calculate 
the pathogenicity score for each of the variants. The following ANNOVAR settings 
were used to annotate variants: 
I. Population frequency information for each variant were obtained from 
1000 Genomes exome (http://www.internationalgenome.org) and 
targeted exon datasets and COSMIC (http://cancer.sanger.ac.uk/cosmic),  
II. Gene function was obtained from RefGene (http://refgene.com),  
III. Functional predictions were obtained from SIFT (http://sift.bii.a-
star.edu.sg), PolyPhen 2 (http://genetics.bwh.harvard.edu/pph2/), 
MutationTaster (http://www.mutationtaster.org), MutationAssessor 
(http://www.ngrl.org.uk/Manchester/page/mutation-assessor ), LRT 
(http://www.genetics.wustl.edu/jflab/lrt_query.html), FATHMM 
(http://fathmm.biocompute.org.uk/fathmmMKL.htm), MetaSVM 
(http://bioinform.github.io/metasv/), GERP++ 
(https://omictools.com/genomic-evolutionary-rate-profiling-tool), 
MetaLR (http://annovar.openbioinformatics.org/en/latest/), PhyloP 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/phyloP46way/) and 
SiPhy (http://portals.broadinstitute.org/genome_bio/siphy/),  
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IV. Conserved and segmental duplication sites, dbSNP code and clinical 
relevance reported in dbSNP138 were also ascertained 
(https://www.ncbi.nlm.nih.gov/projects/SNP/ ) 
 
In order to identify novel variants in the proband (NPC569.3), following the 
annotation of variants, all variants observed in both parents were excluded. The 
identified variants were then put through a pathway-based analysis to identify 
the most enriched pathways. The purpose of the pathway-based analysis was to 
identify key regulators of disease related gene networks. In addition, this type of 
analysis provides a bird’s eye view of affected biological systems. 
 
The pathway-based analysis was performed using two web-based programmes, 
WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) and Consensus PathDB 
(http://consensuspathdb.org). Using both programs provided a different but 
useful approach to interpreting the data. The WebGestalt program, short for 
Web-based Gene Set Analysis Toolkit, is a combination of a functional genome, 
proteomic and large-scale genetic studies from which a list of large number of 
genes was generated.  WebGestalt incorporates information from a number of 
different sources and provides an efficient way to make sense of a seemingly 
disparate list of genes. 
 
 
The list of identified genes was uploaded to WebGestalt. For the enrichment 
analysis, Homo sapiens was selected as the organism of choice, the gene list was 
uploaded and then for the analysis, options of the type of enrichment analysis 
was selected, as were the selection ranges from GO analysis to phenotype-
analysis. First, GO analysis was performed; the statistical method used was 
hyper-geometric, which was the default method for the program. This was 
followed by the selection of the multiple testing statistical tests (and 
corrections/adjustments) to be performed, by default the program was set on 
BH, but it ranges from none to the Bonferroni adjustment for multiple testing. 
The significance level can also be selected; for the purpose of this study, it was 
left at ‘top ten’, as in the top ten results, which the program will produce 
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regardless of their p-value. This is good for eliminating the unnecessary output. 
The minimum number of genes per category was set at two by default (and left 
as that), but can range from two to 10. For this analysis, there were no results 
with less than 10 genes as an ouput.  As mentioned earlier, the program is web-
based; as soon as the results are ready, they can be accessed on the web.  The 
analysis for this study was performed using the whole list of genes identified to 
have variants, and separately, also for a list of genes that were found to have 
variants only in the proband.  
 
The second pathway-based analysis was performed using the Consensus Path DB 
(http://consensuspathdb.org) program; also a web-based program, which 
integrates networks such as binary and complex protein–protein genetic 
metabolic signaling, gene metabolic signaling, gene regulatory, and drug target 
as well as biochemical pathways.  The data is sourced from 32 different publicly-
available databases and the interactions are curated from the literature. 
Overrepresentation analysis, enrichment and induced network modules analysis 
were performed.  Although the WebGestalt is not the most up to date and does 
each analysis separately, it allows for additional analyses, whereby one can 
determine which disease or phenotype has been previously associated with any 
of the genes on the list. 
 
3.2.5.3 Sub-network analysis    
The aim of this particular part of the analysis was to identify sub-networks of 
interacting genes, generated from a list of candidate variants (workflow in 
Figure 3.5).  From the VCF files of the proband (NPC569.3), sibling (NPC 569.4), 
father (NPC569.1) and mother (NPC1.77), candidate variants were identified.   
Declared candidate variants, were those that were ranked through at least six of 
the eight algorithms (i.e. SIFT, PolyPhen 2, MutationTaster, Mutation Assessor, 
LRT, FATHMM, MetaSVM and MetaLR) predicting significant impact on  
functional significance i.e.   "deleterious" (D), "probably damaging" (D), "disease 
causing-automatic" (A) or "disease-causing"(D). The identified variants and 
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genes were investigated further to identify the phenotypes associated with these 
sub-networks. 
The protein–protein interaction (PPI) was performed using the list of candidate 
variants identified. To determine this, the protein interaction network analysis 
platform (http://cbg.garvan.unsw.edu.au /pina/) was used to generate the 
potential sub-networks (derived from the identified candidate genes) in the four 
individual samples, as well as in the merged data. The sub-networks identified 
were compared and subjected to an enrichment analysis using Enrichr 
(http://amp.pharm.mssm.edu/Enrichr/) (Chen et al., 2013; Kuleshov et al., 
2016), to identify the pathways associated with the set of genes, biological 
processes and associated human phenotypes.  Enrichr is a freely available 
comprehensive resource for curated gene sets and a search engine that 
accumulates biological knowledge for further biological discoveries. The dataset 
contains over 180 000 annotated gene sets from over 100 gene set libraries 
(Kuleshov et al., 2016; Chen et al., 2013). 
 
                                   
Figure 3.5: Analysis workflow for sub-network analysis. The variants with most damaging 
prediction scores were used to map protein-protein interactions. Followed by the mapping 
pathways they are involved in, and the biological processes as well as phenotypes they are 
associated with.  
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3.2.6 WES Analysis workflow: Mutations in different tissues  
Exome sequencing of the samples extracted from the five different tissues 
(adrenal gland, bowel, cerebrum, kidney, and saliva) from the proband was 
conducted as previously described using the Ion Torrent sequencing technology 
(Section 3.2.4). Data from the PGM runs were processed using the Ion Torrent 
platform specific pipeline, Torrent Suite software™ (version 4.2.1), to generate 
sequencing reads, trim the adapter sequences, filter and remove poor signal 
profile reads.  ANNOVAR (http://annovar.openbioinformatics.org /en/latest/) 
was used to analyse the generated VCFs.  Further analysis was conducted to 
identify variants only observed in individual tissues, and shared variants 
amongst all the tissue types.  To identify the most biologically enriched 
pathways, pathway-based analysis was carried out using EnrichR as described in 
Section 3.2.5.3.  
 
 
3.2.7 NGS panel for Lynch syndrome susceptibility genes  
In this NGS design, 13 Lynch syndrome/ cancer susceptibility genes were 
sequenced. Most of the amplicons had a mean depth of 900 per sample. This part 
of the sequencing was performed to validate some of the sequencing results 
obtained in the WES previously. The 13 genes which probes were designed for 
included: APC, BMPPR1, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, 
POLE, PTEN, STK11, TP53. To analyze the sequences; the Torrent Suite software™ 
(version 4.2.1) was used to generate sequencing reads, trim the adapter 
sequences, filter and remove poor signal profile reads.  This was followed by the 
annotation of variants using ANNOVAR http://annovar.openbioinformatics.org 
/en/latest/).  The identified variants were compared to those obtained in the 
WES analysis, for validation purposes. 
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3.3 Results  
3.3.1 DNA quantification and quality control 
Several methods were used to isolate DNA from the different types of samples. 
These methods were generally successful in yielding good quality DNA i.e. DNA 
concentrations of  >100ng/µL (Table 3.4) and good DNA integrity as indicated 
by gel electrophoresis (Figure 3.6).   
 
Table 3.4 DNA Sample quality analysis output  
Sample ID Sample 
origin 
Sample 
type 
Isolation 
Method  
Nano-drop 
concentration 
Qubit 
results *  
Gel 
Electrophoresis  
NPC569.1 Blood DNA Salting out 369ng/µL - ✓ 
NPC1.77 Blood DNA Salting out 229ng/µL - ✓ 
NPC569.4 Saliva DNA Oragene 238ng/µL - ✓ 
NPC569.3 Saliva DNA Oragene 219ng/µL - ✓ 
NPC569.3 Tumour DNA RocheDNA FFPE 
Tissue Isolation 
method 
55ng/µL - ✓ 
NPC569.3 Adrenal 
gland 
DNA Salting out 618ng/µL 55ng/µL ✓ 
NPC569.3 Bowel DNA Salting out 390ng/µL 54ng/µL ✓ 
NPC569.3 Cerebellum DNA Zymo-Spin 
column DNA 
isolation Kit 
272ng/µL 49.3ng/µL ✓ 
NPC569.3 Cerebrum DNA Salting out 152ng/µL 49.6ng/µL ✓ 
NPC569.3 Kidney DNA Salting out 465ng/µL 55ng/µL ✓ 
NPC569.3 Liver DNA Zymo-Spin 
column DNA 
isolation Kit 
404ng/µL 40.5ng/µL ✓ 
NPC569.3 Spleen DNA Zymo-Spin 
column DNA 
isolation Kit 
352ng/µL 75ng/µL ✓ 
*Qubit ® 3.0 Fluorometer DNA concentrations were only determined for samples that were subsequently 
used for sequencing.  
 
 
Figure 3.6: Agarose gel electrophoresis showing integrity of DNA from members of Family 
NPC569. MW= molecular weight marker, lane 1: NPC569.1, lane 2: NPC1.77, lane 3: NPC569.3 
and lane 4: NPC569.4.  
 
Both the Roche® and the Ion Ampliseq® Direct FFPE DNA kits failed to produce 
sufficient DNA from the FFPE sample for WES.  However, the quality of the 
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isolated DNA using the Roche® FFPE kit was satisfactory for microsatellite status 
testing.  
 
The standard salting out method for DNA isolation was performed on all seven 
samples of freshly frozen tissue (obtained post mortem) from the deceased 
subject. However, integrity checks using gel electrophoresis (Figure 3.7) 
showed that three of the seven samples were degraded to some extent and 
appeared to have protein contaminants.  These contaminants would have the 
potential to inhibit some of the downstream processing such as PCR. For this 
reason, new samples were sectioned and the Zymo-Spin® column DNA isolation 
kit (Irvine, CA, U.S.A.) was used to extract DNA for which the yield was 
satisfactory.  
 
    
Figure 3.7: Integrity gel of DNA isolated from frozen tissue from subject NPC569.3 
MWM=Molecular weight marker, Lane 1: Adrenal gland, Lane 2: Colon, Lane 3: Cerebrum,  Lane 
4: Cerebellum, Lane 5: Kidney, Lane 6: Liver, and Lane 7: Spleen.  
 
DNA concentrations measured using a Nano-drop spectrophotometer indicated 
that the samples were all satisfactory for further analysis. Subsequently, Qubit® 
3.0 Fluorometry was performed only on samples used for WES (Table 3.4).  
Since the Nano-drop and Qubit® 3.0 Fluorometer quantification methods only 
determine the concentration of the DNA, gel-electrophoresis was used to check 
the integrity of the samples.  This process determines the level of degradation 
and/or contaminants, as seen in Figure 3.6 and Figure 3.7.  
 
Degradation 
Possible Protein 
contaminants  
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The working concentration for all reactions was 100ng/µL. However, for WES, 
DNA concentrations were required to be at least 750ng/µL. For this process i.e. 
WES, additional checks were carried out to ensure quality of samples for 
amplification. These checks included: (i) the TaqMan® RNAse P detection assay 
which determined the quality of the sample prior to library preparation and, (ii) 
qPCR assay which determined the concentration of the unamplified libraries 
before sequencing.  
3.3.2 MSI genotype testing 
All markers amplified successfully for all samples. There was no significant 
difference observed in the microsatellite status between germline DNA (saliva) 
and somatic DNA (tumour) of the CMMR-D patient (NPC569.3) (Figure 3.8), i.e. 
all markers appeared stable for both the germline and somatic samples. In 
addition, when comparing germline marker status between NPC569.3, her 
sibling (NPC569.4) and both parents, (NPC569.1 and NPC1.77), (all three of the 
latter who are heterozygous for the c.1528C>T mutation), no significant 
difference in microsatellite status was observed (data not shown).  
 
Figure 3.8: Microsatellite instability analysis results. Tumour (somatic) DNA in the top 
panel versus normal (germline – as seen in DNA from saliva), in the bottom panel, of NPC 
569.3.  Seven  markers were genotyped, A: NR21, B: BAT-26, C: BAT-25, D: NR24, E: Mono-27 
(green) & Penta-C (black), F: Penta-D (blue) & Penta C (black).   
 
3.3.3 WES results of the family study  
Following WES and variant annotation, more than 25 000 variants were 
identified in each individual (Table 3.5).    Notably, the proband (NPC569.3) and 
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her mother (NPC.177) had more variants  (26 523 and 26 948, respectively) 
compared to her father (NPC 569.1) who had 24 828 and her sibling (NPC 569.4) 
who had 25 157 variants. 
 
Table 3.5 WES Variant call summary (CMMR-D proband highlighted in red) 
Sample no.  
Type of Variant 
NPC569.1 
(father) 
NPC569.3 
(proband) 
NPC569.4 
(sibling) 
NPC1.77 
(mother) 
Total variants 24 828 26 523 25 157 26 948 
Intronic  1 694 1 834 1 666 1 792 
Exonic 22 452 23 874 22 789 24 334 
UTR 479 594 492 580 
Splicing 70 64 64 80 
*Others 133 167 131 162 
Non-synonymous 10 166 10 769 10 214 10 871 
Synonymous  11 481 12 288 11 816 12 637 
Frameshift 118 131 114 113 
Non-frameshift 8 9 7 12 
Stop gain/loss 90 88 85 94 
Unknown 353 371 343 378 
N/A 2 612 2 837 2 578 2 843 
*Others= intergenic, upstream, downstream and ncRNA, N/A=”.” never been reported mapped 
variants  
 
In the first instance, WES was performed to determine if there were any obvious 
genetic differences observed between the CMMR-D proband  (NPC569.3) and 
related individuals (NPC569.4, NPC569.1 and NPC1.77). The WES was performed 
on DNA isolated from both saliva and blood, extracting DNA from FFPE samples 
(tumour DNA) for the purpose of exome sequencing was unsuccessful; all the 
samples isolated did not yield desirable amounts or quality of DNA to conduct 
high throughput sequencing. 
 
Having identified 26 523 variants in NPC569.3 (proband), who was homozygous 
for the MLH1 disease-causing mutation, the next step was to determine if there 
were regions of the genome that might have accumulated more variants 
compared to the variant distribution in the rest of her family members – each of 
whom was heterozygous for the disease-causing mutation. The gross 
distribution of variants across the genome indicated no obvious preferential 
region of variant accumulation (Figure 3.9).  Chromosome 1 and 19 had the 
most number of variants amongst all of the chromosomes, with an average of 
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more than 2000 variants per chromosome (chromosome 1 and 19) in each of the 
four individuals (Figure 3.9). There was no significant difference in the number 
of variants per chromosome between the proband and her sibling. 
 
Figure 3.9 Distribution of variants per chromosome. Variants observed in all four members 
of the family NPC569 are listed by chromosome, each bar / colour represents an individual. 
NPC569.1 (father), NPC1.77 (mother), NPC569.3 (proband) and NPC569.4 (sibling).  
 
3.3.3.1 Number of new “de novo” variants  
One of the main consequences of having a deficient mismatch repair system is 
the accumulation of mutations with every cycle of DNA replication.  It has been 
hypothesised that individuals with CMMR-D accumulate an even higher number 
of mutations/variants over time. This section of the study investigated whether 
the number of de novo variants identified in the proband, NPC569.3, is 
significantly higher than the sibling (NPC569.4) who has one defective copy 
(heterozygous form) of the MMR gene.  To do this, all variants that the proband 
inherited from her parents (i.e. all variants shared between the proband and her 
parents) were excluded for this analysis. In total, 964 of the total of 26 523 
variants (3.63%) were unique to the proband.  Similar analysis for the sibling 
revealed 755 of a total of 25 157 (3%) variants that were unique to the sibling. 
The sibling had 17.3% less variants than the proband.  Some of the de novo 
variants observed (n=185) were common to both the proband, NPC569.3, and 
the sibling, NPC569.4 (but were not in their parents). The distribution of new 
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variants indicated that NPC569.3 (in blue) had more variants compared to 
NPC569.4 (red) (Figure 3.10), across most but not all of the chromosomes 
(Figure 3.10).  
 
Figure 3.10 Distribution of new variants between NPC569.3 and NPC569.4.  Blue = proband 
(NPC569.3) and Red = sibling (NPC569.4). The figure depicts the distribution of all non-shared 
variants between the siblings across all the chromosomes.  
 
When comparing NPC569.3 and NPC569.4, there was no significant difference in 
the type of variants observed. Even though the number of variants differed, for 
both samples, 60% of the variants were made up of non-synonymous variants 
and about 2% of all the new variants had been previously reported (Figure 
3.11). 
  
 
Figure 3.11 Types of new variants in NPC 569.3 – in (germline  DNA from the) saliva sample. 
This figure indicates the types of variants observed in the proband. Most were non-synonymous 
variants accounting for 61% of all variants.  
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For NPC569.3, most (569/964) of the de novo variants had not been reported; 
whereas 369 had been reported in dbSNP previously.  Similarly, for NPC569.4, of 
all the variants, 479 did not have a dbSNP identifier. Of those that had been 
reported in both individuals, only 14 variants (Table 3.6) had been reported in 
the catalogue of somatic mutations in cancer (COSMIC) 
(http://cancer.sanger.ac.uk/cosmic). 
 
Table 3.6 List of shared COSMIC variants in NPC569.3 and NPC569.4 
Chr REF ALT GENE rs ID COSMIC ID (Type of cancer associated with variant)  
chr1 C T NOTCH2NL rs140871032 ID=COSM166701,COSM166700;OCCURENCE=1 
(haematopoietic_and_lymphoid_tissue) 
chr1 T C F5 rs6028 ID=COSM146676;OCCURENCE=1(stomach) 
chr5 C T MYO10 rs16868979 ID=COSM449271;OCCURENCE=1(breast) 
chr5 C T SPINK5 rs33920397 ID=COSM149975;OCCURENCE=1(stomach) 
chr6 T C DSP rs36087964 ID=COSM451787;OCCURENCE=2(breast) 
chr6 C A HLA-B rs1131215 ID=COSM1443267;OCCURENCE=1(colon) 
chr7 C A LAMB4 rs9690688 ID=COSM452142;OCCURENCE=1(breast) 
chr7 G A ZNF775 rs7780011 ID=COSM452592;OCCURENCE=1(breast) 
chr8 G A SBSPON rs150036727 ID=COSM1101550;OCCURENCE=1(endometrium) 
chr9 T C ROR2 rs10820900 ID=COSM1569878;OCCURENCE=1(colon) 
chr10 C T ADARB2 rs2271275 ID=COSM1560925;OCCURENCE=1(colon) 
chr11 C T MAML2 rs113349418 ID=COSM1561901;OCCURENCE=1(colon) 
chr17 C A EPN3 rs4794159 ID=COSM436852;OCCURENCE=1(breast) 
chr19 A C SRRM5 rs3815422 ID=COSM148658;OCCURENCE=1(stomach) 
Chr= chromosome, REF= reference allele, ATL= Alternate allele, rs ID= SNP identity number, COSMIC 
ID= COSMIC identification number 
 
“Mutational signature” is a concept which has been described recently, the aim of 
which is to distinguish the type of cancers by the type of mutations they 
accumulate. There have been more than 30 signatures described (and proven) to 
date (Nik-Zainal et al., 2012a, 2012b; Alexandrov et al., 2013; Alexandrov and 
Stratton, 2014). Amongst these is a ‘mismatch repair deficiency’- signature, 
which is linked to the presence of the type of changes commonly seen in MMR-
deficient tumours.  Signatures 6 and 16, associated with MMR deficiency, were 
investigated amongst the de novo variants, in germline DNA. These signatures 
are commonly seen with the predominance of the C>T and T>C changes. This 
was observed in our results (Figure 3.12).  
 94 
 
Figure 3.12 Illustration of the mutational signatures.  Relative occurrence of specific base-
pair changes amongst the de novo variants in the DNA of the proband (NPC569.3) and sibling 
(NPC 569.4)  
3.3.3.2 Pathway based analysis  
In an effort to identify whether specific genes or regions of the genome may be 
more susceptible to mutations, the purpose of this section was to analyse the 
most ‘variant-enriched’ genes and pathways. Two pathway-based analysis 
programs were used: ConsensusPathDB and WebGestalt.  The list of genes with 
unique variants was investigated using ConsensusPathDB. In total, 964 variants 
in 776 different genes were uploaded.  For the enriched pathway based set, 57 
genes were identified and the top ten enriched pathways included collagen 
biosynthesis, collagen formation and the extracellular matrix (Table 3.7).  
Table 3.7 Output of the pathway-based analysis for unique variants in subject NPC569.3 
Pathway p-value Source 
Collagen biosynthesis and modifying enzymes 4.5319822194e-08 Reactome 
Termination of O-glycan biosynthesis 2.32210853602e-06 Reactome 
Collagen formation 2.40720716677e-06 Reactome 
Protein digestion and absorption - Homo sapiens 
(human) 
3.64596367622e-06 KEGG 
O-linked glycosylation 4.89505355362e-06 Reactome 
Signalling by NOTCH 2.52534301889e-05 Reactome 
Integrin 3.76067907245e-05 INOH 
Extracellular matrix organization 0.000207526993005 Reactome 
NOTCH1 Intracellular Domain Regulated 
Transcription 
0.000240906460416 Reactome 
Extracellular matrix-receptor interaction –  
Homo sapiens (human) 
0.000274061819978 KEGG 
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For the Gene Ontology based set (Table 3.8), the extracellular matrix, complex 
collagen trimmers and proteinaceous extracellular matrix were amongst the 
most enriched Gene Ontology sets.  Lastly, for the enriched protein complex-
based sets, the extracellular matrix, integrin-signalling and ALL-1, (a histone 
methyltransferase that assembles a supercomplex of proteins involved in 
transcriptional regulation) were among the top enriched pathways.  
 
Table 3.8 Gene-Ontology Enriched based set for NPC 569.3 unique variants 
Term name p-value GO-id 
Extracellular matrix structural constituent 1.93652371537e-08 GO:0005201 
Complex of collagen trimers 1.08250495618e-07 GO:0098644 
Proteinaceous extracellular matrix 1.50391421233e-06 GO:0005578 
Structural molecule activity conferring elasticity 2.75039949804e-05 GO:0097493 
Fibrillar collagen trimer 0.00010947904853 GO:0005583 
 
The second pathway analysis program used was WebGestalt.  For this, all 
variants identified during the WES as well as the list of genes which were 
identified during the unique variants analysis were analysed.  
 
For the Gene Ontology analysis, the results were divided into three sections: 1) 
biological process, 2) molecular function, and 3) cellular component.  Under the 
rubric of ‘biological process’, genes involved in biological adhesion, detection of 
chemical stimuli, cellular adhesion, and extracellular structure and organisation 
emerged. Under ‘molecular function’, molecular adhesion, receptor activity, 
transmembrane signalling, ion binding and calcium binding, emerged.  For 
‘cellular component’, the extracellular membrane, intrinsic to membrane, cell 
membrane and proteinaceous extracellular membrane, were identified. The 
extracellular membrane was the most enriched pathway in the unique variant 
list as well, and this is a trend seen in the independent ‘molecular function’ and 
‘cellular component’ analyses.  Worthy and of note, is that the top five diseases 
associated with the list of genes are diseases of the brain/ central nervous 
system.  
 
The same analysis was performed using all of the genes that have been found to 
have variants in them, and the results showed disorders pertinent to collagen 
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and the brain   (Table 3.9) for the proband (NPC569.3), while the analysis for 
the sibling (NPC569.4) revealed disorders/processes pertinent to collagen, 
adhesion and myocardial infarction, amongst others (Table 3.10). 
 
Table 3.9 Disease-association analysis for variants in subject NPC569.3 
Disease Number of 
gene 
Statistics 
Collagen Diseases 14 C=96;O=14;E=1.61;R=8.69;rawP=8.40e-10;adjP=8.37e-07 
Brain Diseases 25 C=411;O=25;E=6.90;R=3.62;rawP=4.42e-08;adjP=4.41e-05 
Nervous System Diseases 33 C=694;O=33;E=11.65;R=2.83;rawP=1.22e-07;adjP=0.0001 
Central Nervous System 
Diseases 
24 C=438;O=24;E=7.35;R=3.26;rawP=5.48e-07;adjP=0.0005 
Mitral Valve Prolapse 6 C=21;O=6;E=0.35;R=17.02;rawP=9.60e-07;adjP=0.0010 
Tremor 8 C=54;O=8;E=0.91;R=8.82;rawP=3.20e-06;adjP=0.0032 
Genetic Predisposition to 
Disease 
33 C=808;O=33;E=13.56;R=2.43;rawP=3.45e-06;adjP=0.0034 
Myasthenia Gravis 7 C=39;O=7;E=0.65;R=10.69;rawP=3.52e-06;adjP=0.0035 
Schizophrenia 20 C=360;O=20;E=6.04;R=3.31;rawP=3.86e-06;adjP=0.0038 
Mental Disorders 26 C=564;O=26;E=9.47;R=2.75;rawP=4.59e- 
 
 
Table 3.10 Disease association analysis of variants in the sibling, NPC569.4 
Disease Number of 
genes 
Statistics 
Collagen Diseases 12 C=96;O=12;E=1.33;R=9.00;rawP=1.00e-08; adjP=5.77e-06 
Adhesion 30 C=647;O=30;E=8.99;R=3.34;rawP=1.31e-08; adjP=5.77e-06 
Myocardial Infarction 15 C=242;O=15;E=3.36;R=4.46;rawP=1.81e-06; adjP=0.0004 
Bronchial Diseases 17 C=307;O=17;E=4.26;R=3.99;rawP=1.78e-06; adjP=0.0004 
Vascular Diseases 18 C=357;O=18;E=4.96;R=3.63;rawP=3.35e-06; adjP=0.0006 
Hypertension 14 C=227;O=14;E=3.15;R=4.44;rawP=4.21e-06; adjP=0.0006 
Infarction 14 C=236;O=14;E=3.28;R=4.27;rawP=6.58e-06; adjP=0.0008 
Curvature of spine NOS 7 C=53;O=7;E=0.74;R=9.51;rawP=8.53e-06;  adjP=0.0009 
Cardiovascular Diseases 19 C=425;O=19;E=5.90;R=3.22;rawP=1.01e-05; adjP=0.0010 
Lupus Erythematosus, 
Systemic 
13 C=218;O=13;E=3.03;R=4.29;rawP=1.32e-05; adjP=0.0012 
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3.3.3.3 Sub-network analysis for predicted damaging variants 
 
In order to identify the sub-network of interactive genes and the pathways which 
they are involved in, a list of genes was compiled from the variants with the most 
damaging prediction scores (Table 3.11); also included in the list was the 
disease causing variant, MLH1 c.1528C>T (Table 3.11).  
 
This list was compiled using data from all four individuals.  Some of the variants 
identified as most damaging, were shared amongst all four individuals 
(highlighted in red in Table 3.11). There were 11 variants identified in the 
proband (NPC569.3), 13 from the sibling (NPC569.4), 9 and 12 from each of the 
parents, NPC569.1 and NPC1.77, respectively. This list of variants was utilised to 
determine the networks and interactions (Figures 3.13 and 3.14). 
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Table 3.11 List of filtered variants with most damaging prediction scores 
Sample dbSNP ID #CHROM refGene FuncGene SIFT HDIV HVAR LRT MT MA FA RI LR 
NPC569.3                  
  rs113718290 chr1 ARID1A exonic T P B D D L T T T 
  rs113576347 chr2 PLEKHH2 exonic T B B D D L T T T 
  rs2306369 chr4 KIAA1109 exonic T B B D D N T T T 
  rs33977775 chr8 NPBWR1 exonic D D D D P M D T T 
  rs17417407 chr10 PLCE1 exonic T D D N P L T T T 
  rs36006049 chr11 NAT10 exonic T B B D D M T T T 
  rs11539445 chr12 YARS2 exonic D P B D P N T T T 
  rs4778078 chr15 RGMA exonic D B B U P L D T T 
  rs112038587 chr17 FAAP100 exonic D D P N N N T T T 
  rs13047478 chr21 C21orf58 exonic D D P N P L T T T 
  rs63749923 chr3 MLH1 exonic . . . . . . . . . 
NPC569.4                  
  rs373793845 chr1 PLEKHG5 exonic T D D D D L T T T 
  rs344141 chr4 SHROOM3 exonic T D D N P M T T T 
  rs2306369 chr4 KIAA1109 exonic T B B D D N T T T 
  rs17850652 chr6 RARS2 exonic D B B D P N T T T 
  rs17417407 chr10 PLCE1 exonic T D D N P L T T T 
  rs7081076 chr10 SORBS1 exonic D D D N D N T T T 
  rs10895991 chr11 CAPN1 exonic T D D D P M D T T 
  rs34982553 chr17 RILP exonic T D D N P L T T T 
  rs144623089 chr18 DCC exonic D B B D D N T T T 
  rs13047478 chr21 C21orf58 exonic D D P N P L T T T 
  rs6151415 chr22 ARSA exonic D D P N D N D T T 
  rs375687463 chrX PHKA2 exonic D D D D D M D D D 
  rs63749923 chr3 MLH1 exonic . . . . . . . . . 
NPC569.1                  
  rs2306369 chr4 KIAA1109 exonic T B B D D N T T T 
  rs76067797 chr7 CDHR3 exonic D P P N N M D T T 
  rs17417407 chr10 PLCE1 exonic T D D N P L T T T 
  rs2277339 chr12 PRIM1 exonic D D P D P L T T T 
  rs3743398 chr15 ACAN exonic T D D N P M T T T 
  rs34745339 chr16 GALNS exonic D P B D D M D D D 
  rs144623089 chr18 DCC exonic D B B D D N T T T 
  rs10425488 chr19 OCEL1 exonic T D D N P N T T T 
  rs63749923 chr3 MLH1 exonic . . . . . . . . . 
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NPC1.77                  
  rs113718290 chr1 ARID1A exonic T P B D D L T T T 
  rs344141 chr4 SHROOM3 exonic T D D N P M T T T 
  rs33977775 chr8 NPBWR1 exonic D D D D P M D T T 
  rs7081076 chr10 SORBS1 exonic D D D N D N T T T 
  rs36006049 chr11 NAT10 exonic T B B D D M T T T 
  rs192902098 chr13 PDX1 exonic D D D D D M D D D 
  rs4778078 chr15 RGMA exonic D B B U P L D T T 
  rs8074498 chr17 ASPSCR1 exonic D D D D P M T T T 
  rs12978266 chr19 DOCK6 exonic D D P D P M T T T 
  rs13047478 chr21 C21orf58 exonic D D P N P L T T T 
  rs375687463 chrX PHKA2 exonic D D D D D M D D D 
  rs63749923 chr3 MLH1 exonic . . . . . . . . . 
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Figure 3.13 Extracted sub-network of interactions for NPC 569.3 
The extracted sub-network of interactions for the list of variants with the most damaging 
predicted scores. The identified hubs for the proband (NPC 569.3) include FANC, NAT10, UBC, 
PLEC1 and ARID1A, indicated by arrows.  *Figure key: each pie chart is colour co-ordinated according to 
the frequency of the each allele represented. The three different populations represented herein include, 
African (black), East Asian (blue) and European (red). The Mixed Ancestry population of a Western Cape are 
an admixture of these populations. 
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Figure 3.14  Extracted sub-network of interactions for NPC 569.4. The extracted sub-
network of interactions for the list of variants with the most damaging predicted scores. The 
identified hubs in the sibling NPC 569.4 include UBC, DCC, SORBS, CAPIN1, and PLCE1, indicated 
by arrows.  *Figure key: each pie chart is colour co-ordinated according to the frequency of the each allele 
represented. The three different populations represented herein include, African (black), East Asian (blue) 
and European (red). The Mixed Ancestry population of a Western Cape are an admixture of these 
populations. 
 
 
 
Several hubs were identified for both NPC569.3 (Figure 3.13) and NPC569.4 
(Figure 3.14), some of which were shared, for instance UBC (Ubiquitin C), and 
NAT10 (N-Acetyltranferase 10). However, there were also hubs, which were not 
connected to the main hubs, for example the FANC hub (top left in Figure 3.13) 
and PNA2,  (top right in Figure 3.14).  FANC (Fanconi Anemia Complementation 
group) is a cluster of Fanconi anemia-related proteins which play an important 
role in chromosomal instability and breakage, defective DNA repair mechanisms, 
and have been shown to cause a number of recessive disorders, including 
Fanconi anemia (OMIM: 227650).   
 
 
In the next step the sub-networks were characterized according to relevant 
biological pathways (Table 3.12) and biological processes (Table 3.13). The 
 102 
biological pathways associated with the top sub-network in NPC569.3, such as 
the Wnt-signalling pathway, p53 feed-back loops and TGF-β signalling pathway 
are enriched with relevant molecular functions, implicated in human cancers.   
 
 
Table3.12 Results of EnrichR Analysis for Biological Pathways in NPC569.3 
Term Overlap p-value Adjusted P-
value 
Z-score Combined 
Score 
Genes 
Wnt signaling 
pathway_ 
10/278 0.000 0.008 -1.77 8.39 SMARCE1;SMAR
CD1;SMARCC1;S
MARCB1;SMARC
C2;SIAH1;CTNN
B1;ARID1A;SMA
RCA2;SMARCA4 
p53 pathway 
feedback loops 
4/45 0.001 0.020 -1.53 5.98 NRAS;SIAH1;CT
NNB1;HRAS 
TGF-beta 
signalling 
pathway 
4/88 0.014 0.131 -1.28 2.60 SMAD2;NRAS;S
MAD3;HRAS 
p53 pathway 3/71 0.041 0.282 -1.22 1.55 SUMO1;SIAH1;S
IRT1 
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Table3.13 Results of EnrichR Analysis for Biological Processes in proband, NPC 569.3  
Term   Overlap  p-value  Adjusted p-
Value 
 z-score  Combined 
Score  
 Genes  
Chromatin 
remodelling 
(GO:0006338) 
14/118 0.00 0.00 -2.18 58.32 SMARCE1;SMARC
D1;SMARCC1;PBR
M1;SMARCC2;SM
ARCB1;BAZ1B;ARI
D1A;ARID1B;SIRT
1;SMARCA2;SMAR
CA4;KLF1;TOP1 
Protein-DNA 
complex 
disassembly 
(GO:0032986) 
7/17 0.00 0.00 -2.96 56.12 SMARCE1;SMARC
D1;SMARCC1;SMA
RCC2;SMARCB1;A
RID1A;SMARCA4 
Nucleosome 
disassembly 
(GO:0006337) 
7/17 0.00 0.00 -2.95 55.97 SMARCE1;SMARC
D1;SMARCC1;SMA
RCC2;SMARCB1;A
RID1A;SMARCA4 
Chromatin 
modification 
(GO:0016568) 
19/475 0.00 0.00 -2.40 50.02 SMARCE1;SMARC
D1;SMARCC1;PBR
M1;SMARCC2;USP
49;SMARCB1;CHD
7;SIRT7;BAZ1B;A
RID1A;ARID1B;S
MARCA2;SIRT1;SI
RT2;KLF1;SMARC
A4;CARM1;TOP1 
DNA repair 
(GO:0006281) 
14/403 0.0 0.00 -2.45 31.19 SMARCB1;FANCM
;FANCL;FANCA;FA
NCB;BAZ1B;SIRT1
;FANCG;APITD1;S
UMO1;KIAA0101;
UBC;OTUB1;FAAP
100 
Ubiquitin-
dependent 
protein catabolic 
process 
(GO:0006511) 
13/355 0.00 0.00 -2.44 29.83 USP49;CUL3;SIAH
2;CUL2;SIAH1;CU
L1;SIRT1;SIRT2;C
DC20;SOX2;ITCH;
NEDD4;UBC 
Modification-
dependent 
macromolecule 
catabolic process 
(GO:0043632) 
13/368 0.00 0.00 
 
-2.44 29.58 USP49;CUL3;SIAH
2;CUL2;SIAH1;CU
L1;SIRT1;SIRT2;C
DC20;SOX2;ITCH;
NEDD4;UBC 
       
 
The biological pathways associated with the sub-network for the proband’s 
sibling, i.e. NPC569.4, in Table 3.14 were pertinent to “angiogenesis”, VEGF-
signalling and integrin-signalling. Angiogenesis plays an important role in 
cellular growth, neoplastic progression, invasion and metastasis, all important 
hallmarks of cancers. The VEGF- (vascular endothelial growth factor) signalling 
pathway is a regulator of tumour angiogenesis. It stimulates endothelial growth, 
survival and proliferation; it also regulates the growth of specific vascular tissue 
in blood and lymph vessels. The integrin-signalling pathway functions as a cell 
surface receptor that interacts with the extracellular matrix; this pathway also 
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mediates intercellular signals in response to the extracellular matrix including 
cellular shape and mobility. Table 3.15 indicates some of the biological 
processes identified during the analysis. These included the processes of 
translational initiation and neuron projection guidance, amongst others.  
 
 
Table 3.14 Results of EnrichR Analysis for Biological Pathways in sibling, NPC 569.4 
Term Overla
p 
p-value Adjusted P-
value 
Z-score Combined 
Score 
Genes 
Angiogenesis 17/142 0.00 0.00 -1.66 14.99 SRC;F2R;PXN;STAT3;FRS2;PT
K2;CASP9;EFNB1;NRAS;CTN
NB1;MAPK1;RAF1;SOS1;PAK2
;HRAS;MAPK3;NCK1 
Integrin 
signalling 
pathway 
17/156 0.00 0.00 -1.68 14.366 ACTN2;SRC;PXN;RND2;RND3;
PTK2;RND1;COL1A1;NRAS;C
OL3A1;RAF1;SOS1;HRAS;VCL;
LIMS1;ARF6;MAPK3 
CCKR 
signalling 
map ST_Homo 
sapiens_P069
59 
16/165 0.00 0.001 -1.61 11.14 SRC;RPS6;PXN;STAT3;ARRB2;
PTK2;NFKBIA;MYC;CASP3;CT
NNB1;MAPK1;RAF1;SOS1;EIF
4E;BCL2L1;MAPK3 
VEGF 
signaling 
pathway_ 
8/54 0.00 0.005 -1.45 7.47 CASP9;NRAS;PXN;MAPK1;RA
F1;HRAS;PTK2;MAPK3 
T cell 
activation_ 
Homo 
sapiens_P000
53 
9/73 0.000 0.006 -1.20 5.98 NFKBIA;NRAS;MAPK1;SOS1;R
AF1;PAK2;HRAS;MAPK3;NCK
1 
Ras Pathway_ 
Homo 
sapiens_P043
93 
8/69 0.001 0.016 -1.15 4.72 NRAS;STAT3;MAPK1;SOS1;RA
F1;PAK2;HRAS;MAPK3 
B cell 
activation_ 
Homo 
sapiens_P000
10 
7/57 0.002 0.021 -1.03 4.01 NFKBIA;NRAS;MAPK1;SOS1;R
AF1;HRAS;MAPK3 
EGF receptor 
signaling 
pathway_ 
Homo 
sapiens_P000
18 
9/109 0.008 0.03 -0.78 2.53 NRAS;STAT3;MAPK1;SFN;RA
F1;SOS1;CBL;HRAS;MAPK3 
Interleukin 
signaling 
pathway_ 
Homo 
sapiens_P000
36 
8/86 0.006 0.035 -0.74 2.47 IL1A;NRAS;MYC;STAT3;MAPK
1;SOS1;RAF1;MAPK3 
PDGF 
signalling 
pathway 
9/112 0.009 0.042 -0.59 1.88 NRAS;MYC;STAT3;MAPK1;RA
F1;SOS1;HRAS;MAPK3;NCK1 
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Table 3.15 Results of EnrichR Analysis Biological Processes NPC569.4 
Term Overlap p-
valu
e 
Adjusted P-
value 
Z-score Combined 
Score 
Genes 
Translational 
initiation 
(GO:0006413) 
24/139 0.00 0.00 -2.18 85.78 RPL4;RPL5;EIF2B4;EIF2B2;
EIF4E3;EIF1AX;RPL23;RPS
6;RPL10A;EIF2S2;RPS4X;EI
F2S3;EIF6;RPL13;EIF3E;RP
L38;EIF2B1;EIF4E;RPS10;R
PL28;RPS24;RPS13;EIF2A;
RPS23 
 
Neuron 
projection 
guidance 
(GO:0097485) 
 
28/367 
 
0.00 
 
0.00 
 
-2.41 
 
68.31 
 
SRC;ITGB3;PITPNA;NTN1;R
ND1;EFNB1;NRAS;ABL1;M
APK1;SLIT3;HRAS;PAK2;SP
TAN1;SPTBN1;NCK1;MAPK
3;NTRK1;SEMA6A;DCC;SIA
H2;SIAH1;PTK2;COL3A1;GR
B2;EZR;RAF1;SOS1;CDK5R1 
Axon guidance 
(GO:0007411) 
28/367 0.00 0.000 -2.40 68.244 SRC;ITGB3;PITPNA;NTN1;R
ND1;EFNB1;NRAS;ABL1;M
APK1;SLIT3;HRAS;PAK2;SP
TAN1;SPTBN1;NCK1;MAPK
3;NTRK1;SEMA6A;DCC;SIA
H2;SIAH1;PTK2;COL3A1;GR
B2;RAF1;SOS1;EZR;CDK5R1 
Cellular 
response to 
organo-
nitrogen 
compound 
(GO:0071417) 
26/411 0.00 
 
0.000 -2.55 56.81 PXN;NRAS;ABL1;MAPK1;EI
F4E;HRAS;SH2B2;APPL1;M
APK3;NTRK1;PTPN1;INSR;
RPS6;STAT3;FRS2;SORBS1;
GNG12;PTK2;COL1A1;COL3
A1;CTNNB1;GRB2;LAMTOR
1;RAF1;SOS1;BCL2L1 
Cellular 
component 
disassembly 
(GO:0022411) 
25/350 0.00 0.00 -2.34 55.13 RPL4;RPL5;RPL10A;RPS4X;
CAPNS1;CASP3;FLOT1;RPL
13;RPL38;CAPN1;SPTAN1;
PAK2;RPS10;RPS13;RPL23;
RPS6;PTK2;COL1A1;COL3A
1;ADAM15;CTNNB1;VIM;R
PL28;RPS24;RPS23 
Cellular 
response to 
nitrogen 
compound 
(GO:1901699) 
26/438 0.00 0.00 -2.53 54.43 PXN;NRAS;ABL1;MAPK1;H
RAS;EIF4E;SH2B2;APPL1;M
APK3;NTRK1;PTPN1;INSR;
RPS6;STAT3;FRS2;SORBS1;
GNG12;PTK2;COL1A1;COL3
A1;CTNNB1;GRB2;LAMTOR
1;RAF1;SOS1;BCL2L1 
Response to 
peptide 
(GO:1901652) 
25/384 0.00 0.00 -2.43 53.4 PXN;INPPL1;NRAS;MAPK1;
EIF2B1;HRAS;EIF4E;SH2B2
;APPL1;MAPK3;PTPN1;EIF
2B4;EIF2B2;INSR;RPS6;STA
T3;FRS2;SORBS1;GNG12;PT
K2;COL1A1;NFKBIA;GRB2;
RAF1;SOS1 
       
 
 
 
 
To determine whether different tissues could be acquiring and embedding 
mutations at different rates, WES of DNA from adrenal gland, colon, cerebrum, 
kidney and saliva of the deceased proband NPC569.3 was performed.  The aim 
was to determine whether there were differences in the number and type of 
variants in the different tissues of the proband, and specifically whether brain 
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tissue may be more prone to certain types of mutation not seen in other tissues – 
taking into account that the proband demised as a result of a 
glioblastoma/astrocytoma.   As noted in Figure 3.15 there were no regions 
within the genome, which harboured more variants than the other, with the 
exception of both chromosome 1 and 19, which had a similar pattern in the 
family data.  
 
 
Figure 3.15 Number of variants observed per chromosome inWES analysis of five tissues 
for NPC569.3. This variant distribution was generated from the WES data using DNA extracted 
from different tissues of the proband. Only variants in the exons and splicing sites were included 
in this figure.  
 
The analysis also involved investigating the number of de-novo variants in each 
tissue. About 500 variants were unique to each tissue, although most of the 
observed variants were missense or thought to be benign. A pathway-based 
analysis for each tissue was then performed from this list of variants. The results 
indicated that the most enriched pathways in the cerebrum, which was the 
closest tissue to the tumour, which was analysed in this section, included the 
extracellular matrix among others, which was a similar finding to the previous 
analysis of variants in germline DNA.   
 
To validate some of these findings of the study we conducted a targeted gene 
panel sequencing of 13 genes that had previously been described to be 
instrumental in cancer development (Figure 3.16).  The number of variants 
observed in the panel coincided with the number of variants seen in these genes 
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on WES, with one exception. POLD1 had an average of 13 variants across the 
tissues yet, none were seen in the VCF output of the WES data.  Upon checking 
for ‘pathogenicity’, none of the 13 variants were predicted to have an impact on 
the translated protein structure.   
 
 
Figure 3.16 The number of mutations identified in the ‘cancer panel of genes’ across eight 
tissues of NPC596.3. Indicated in the figure are the list of genes (X-axis) in the panel (sequenced), 
the number of variants observed for each sample (Y-axis) and the list of tissues (from which DNA 
was sequenced), which are colour coded on the right of the bar graph.  
 
3.4 Discussion 
The main aim of this section of the study was to identify the state of mutagenicity 
associated with mismatch repair deficiency.   It was thought that at least some 
genes and pathways involved in cancers would be exposed more easily in an 
individual who was constitutionally mismatch repair deficient i.e. homozygous 
for a deleterious MLH1 mutation.   In this preliminary analysis - there were 
seemingly no specific regions within the genome which were identified to be 
more prone to accumulating mutations. However, the results presented here 
suggest that, even though most of the individual variants seem benign and not 
disease causing, some of these genes are involved in the most important known 
cancer pathways.  
 
In the first instance for CMMR-D, the intention was to determine whether 
microsatellite instability could be a feature that can be used to diagnose this 
syndrome.  There was no observed difference in the microsatellite status in 
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germline (saliva) or tumour DNA of the CMMR-D subject of the study 
(NPC569.3). This was unsurprising as other investigations have previously also 
reported microsatellite stable results for CMMR-D cases (Leenen et al. 2011; 
Baris et al. 2016).  Nonetheless, improved methodology for detection of MSI has 
been suggested (Ingham et al., 2013; Wimmer et al., 2014).  This method 
involves using a program Peak Heights 
(http://dna.leeds.ac.uk/peakheights/guide/) to determine peak ratios of 
germline MSI (gMSI) from three microsatellite markers (D2S123, D17S250 and 
D17S791). By determining the peak ratio of the markers, authors found that 
there was a significant difference in the gMSI of CMMR-D patients compared to 
the controls (Ingham et al., 2013).  
 
For the mutational signature analysis, signatures 6 and 16, associated with MMR 
deficiency, were observed in our results.   These signatures are commonly seen 
with the predominance of the C>T and T>C changes (Nik-Zainal et al., 2012a, 
2012b; Alexandrov et al., 2013; Alexandrov and Stratton, 2014).  Of interest is 
that the C>T change abundance is also present in signature 2.  Signature 2 has 
been attributed to the activity of the activation-induced Cytidine Deaminase 
(AID)/ APOBEC family of cytidine deaminase. Cytidine deaminase functions by 
deaminating the cytidine coupled with base excision repair and mismatch repair 
machinery as a natural mutator, and play an important role in adaptive 
immunity (Kumar et al., 2014). The AID expression and activity is tightly 
regulated, and its deregulation is associated with diseases including cancers 
(Kumar et al. 2014; Rogozin et al., 2016). 
 
Gene annotation and pathway analysis for the family study identified the 
potential dysregulation of several biologically important genes and pathways. 
Several cancer-related pathways including those pertinent to collagen 
biosynthesis, cellular adhesion and the extracellular matrix (organization and 
structural constituent) were over-represented in the samples.  Pathways 
involving cell adhesion and the extracellular matrix were implicated repeatedly.  
Similar results were obtained in the analysis of the exome sequencing of the DNA 
derived from the cerebrum - the most proximal tissue to where the tumour was 
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located. Both, the extracellular matrix pathway and cell substrate adhesion were 
implicated as the most enriched pathways. Together, these results could suggest 
that cell adhesion and extracellular matrix interaction pathways are 
inadequately modulated or may be dysregulated early during tumorigenesis of 
MMR-deficiency-related cancers. Similar findings were reported by Emery et al. 
(2009), who investigated the expression profiles of breast cancers, and reported 
that for Atypical Ductal Hyperplasia (ADH), the genetic changes related to 
cellular adhesion and extracellular matrix  pathways suggest that these regions 
are poorly modulated before cancer invasion and, in malignancy.  
 
The extracellular matrix is important in modulating cellular functions as it 
directly interacts with the cellular-signalling receptors, and functions as a 
provider of growth factors and signalling molecules (Venning et al., 2015).  
Extracellular matrix signalling is important for cellular migration, invasion and 
angiogenesis; these are important functions, which makes this process (i.e. 
extracellular matrix signalling) instrumental in the metastasis/spreading of 
cancer.  Since the extracellular matrix is so important in tumorigenesis, it has 
been suggested as a promising target in the development of adjuvant 
therapeutics (Emery et al., 2009; Lu et al., 2012; Venning et al., 2015; Xiong and 
Xu, 2016).  
 
A list of hubs was identified from the sub-network analysis (from the protein-
protein interactions):  for example, UBC or ubiquitin C is part of the cell cycle 
checkpoint pathway and has been implicated in diseases such as apocrine 
adenoma and congenital granular cell tumour (Hsu et al., 2003; Zerener et al., 
2013). Another identified hub, was small ubiquitin-like modifier (SUMO1), which 
is involved in translational modification and cellular processes such as nuclear 
transport, transcriptional regulation, apoptosis and protein stability. Both UBC 
and SUMO are important in maintaining genome stability (Jackson and Durocher, 
2013). 
 
 N-Acetyltranferase 10 (NAT10), also identified as a hub, is a regulator of p53 
activation, previously associated with CRC.  After DNA damage, NAT10 
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translocates into nucleoplasm and activates p53-mediated cell cycle control and 
apoptosis. This protein inhibits cell proliferation through p53 activation by 
counteracting MDM2 action, providing an alternative pathway, which in turn 
activates the p53 cellular stress (Zhang et al., 2014; Liu et al., 2016). The AT-rich 
interactive domain 1A (ARID1A) gene encodes a member of the switch/sucrose 
non-fermentable (SWI-SNF) chromatin-remodelling complex, and is considered 
to work as a tumour suppressor in concert with p53. Loss of ARID1A is more 
common in advanced gastric cancers, sporadic CRC with microsatellite instability 
and MMR deficiency of both colon cancers and endometrial cancers (Chou et al., 
2014).  Variants in the gene encoding phospholipase C epsilon 1 or PLEC1 
protein have been associated with CRC susceptibility and oesophageal cancer.  In 
addition, specific mutations have been implicated in upper gastric cancers (Malik 
et al., 2014; Xue et al., 2015).  
 
Some pathways of known cancer relevance were not prominent among the first 
gene sets which emerged in the analysis (e.g. pathways involved in maintenance 
of genomic stability, apoptosis, and damage repair), of unique variants in 
subjects NPC569.3 (proband) and NPC569.4 (sibling). However, during the sub-
network analysis, when extracting the list of variants with the most damaging 
protein prediction scores, a number of pathways associated with cancers were 
identified. These included the Wnt-signalling pathway (Ponder, 2001; Zhan et al., 
2016; Yoda et al., 2015), p53-pathway (Markowitz and Robertst, 1996; 
Vogelstein et al. 2000; ; Wakefield and Roberts, 2002; Harris and Levine 2005; 
Pardali and Moustakas, 2007; Lampropoulos et al., 2012), and the TGF-β 
pathway, suggesting that most of these pathways may be collectively involved, 
perhaps through incremental individual  effects.  
 
Even though NPC569.4 was not affected by any MMR-deficiency disorder, in the 
presence of the heterozygous MLH1 c.1528C>T variant, the germ-line variant 
analysis of her DNA showed cancer-related pathways to be most enriched. These 
included, the Integrin-signalling pathway (Guo and Giancotti, 2004), VEGF-
signalling pathway (McMahon, 2000), and the PDGF-signalling pathway (Yu et 
al., 2003; Liu et al., 2011; Heldin et al., 2013). For instance, the angiogenesis 
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pathway (which pertains to one of the main hallmarks of cancers) is very 
important in growth, progression, invasion and metastasis of cancers). Also, 
VEGF stimulates endothelial growth, survival and proliferation. In addition, the 
PDGF pathway, which has been described as a model system for growth factors, 
also regulates the biological processes such as the activity of receptor kinases 
and pathways that drive cellular responses.  Of note, also,  are previously 
mentioned pathways such as the N-RAS and CTNNB1, which have previously 
been associated with CRC  (Caluseriu et al., 2004; Haigis et al., 2008).  
 
Following the exome sequencing of the five tissues of the CMMR-D proband, 
there were on average of 60,000 variants observed for each tissue. Most of the 
variants (99%) were shared (identical for each tissue) which is expected since it 
derived from the same individual, and only 1%  (i.e. about 500) were unique to 
each tissue sample.  In addition, when characterising these variants most were 
benign with no obvious impact on translated protein.  Again, there were no 
particular regions of the genome which showed bias towards accumulation of 
these variants.  
   
For validation purposes, the panel sequencing of the 13 genes, that been 
described to be instrumental in cancer development, was performed. POLD1 had 
an average of 13 variants across the tissues yet, none were observed in the WES 
data. Upon analysis of the raw data, it was concluded that this was a result of the 
coverage for this particular region of the genome, the variants were excluded 
because the generated data did not pass the quality control process during 
filtering steps of WES analysis. POLD1 is a catalytic and proof reading subunit of 
DNA polymerase delta (Weedon et al., 2013), which is responsible for the 
synthesis of the lagging strand during DNA replication (Palles et al., 
2013;Weedon et al., 2013).  Mutations in this gene have been implicated in a 
number of cancers including CRC, endometrial cancer (Palles et al., 2013) as well 
as brain tumours in CMMR-D patients (Shlien et al., 2015). 
 
The appearance of novel changes in the POLD1 and POLE genes is notable since 
variants in these genes have previously been associated with cancers of the CNS.  
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The fact that none of the variants identified here and in the various tissues is 
pathogenic ought not to detract from the observation of increased mutagenicity 
especially within this gene i.e. POLD1. As mentioned previously, the mutations in 
this gene have been implicated in a number of cancers, and in the report by 
Shlien et al., (2015), two mutations (POLD1 L606M and C319Y) both of which 
reduced the replication fidelity of this enzyme, were identified as drivers of 
tumours in individuals with CMMRD-syndrome. It is possible that the 
glioblastoma was initiated by a pathogenic mutation, which would have arisen 
‘de novo’ as with the other POLD1 variants described in the various tissues 
analysed in this study.  Unfortunately, at this stage of the work up, there was no 
tumour-material or DNA from tumour remaining from the proband for further 
investigation.  Nonetheless, what the preliminary findings and their 
interpretation represent is the possible accumulation of a range of mutations in a 
range of genes/pathways which may be either directly pathogenic, or whose 
expression may be deleteriously affected – and which either individually or 
collectively expose CMMR-D children to early childhood cancers.  This work will 
be ongoing in the Division of Human Genetics with the Departments of Paediatric 
Oncology and Anatomical Pathology at Red Cross Children’s Hospital in order to 
gather additional cases/familes with Lynch syndrome and CMMR-D. 
 
Furthermore, the above approach and findings provide a strong motivation to 
establish a tumour versus normal tissue bank for all cancers from patients 
admitted to the academic hospitals platform here in Cape Town.  Of particular 
relevance to the present project would be the sequencing (WES, and then whole 
genome sequencing of tumour versus normal tissue) for the range of cancers 
that form the Lynch syndrome phenotype.  The regular surveillance of 
communities carrying the MLH1 c.1528C>T mutation, and their diagnoses with 
cancers of different organs/tissues makes the prospect of identifying 
intersecting pathways and processes for cancers of these different tissues -
perhaps shedding further light on the process of carcinogenesis for Lynch 
syndrome generaly, but for the bigger burden of e.g. non Lynch endometrial, 
breast and other tissues.  
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Chapter 4. General Discussion and Conclusions  
 
4.1 Summary of main findings  
The main aim of this research was to provide a clearer understanding of the 
genetic factors associated with Lynch syndrome on a macro scale, and CMMR-D 
syndrome, on a micro scale. To reach this aim, our first objective was to 
investigate the major clinical features associated with Lynch syndrome within 
our CRC registry in the Division of Human Genetics at UCT, comparing and 
contrasting a relatively large cohort of individuals with a common founder MLH1 
c.1528C>T mutation with the rest of the cohort with a variety of mutations in 
both MLH1 and MSH2.  The second objective was to investigate whether the 
MLH1 c.1528C>T mutation was due to a founder effect – and if it was, to identify 
its possible ‘age’ or date of origin.  The third and final objective was to perform 
an intensive investigation of the status of genomic changes in CMMR-D 
syndrome in a nuclear Lynch syndrome family where both parents were 
heterozygous for the MLH1 c.1528C>T mutation, and who produced a child who 
had inherited the mutation from both her parents towards understanding the 
scale of increased mutagenicity on a genomic scale in individuals who are 
heterozygous and homozygous for the MLH1 c.1528C>T – and how this, in turn, 
might predispose to increased tumorigenicity.   
 
In summary, the Lynch syndrome cohort consisted of 396 mutation positive 
cases (both MLH1 and MSH2 mutation carriers).  The most common mutation, 
MLH1 c.1528C>T, was confirmed in 309 individuals, from 30 families.  CRC was 
the most common cancer observed in both MLH1 and MSH2 carriers.  In 
accordance with what has been previously reported, the age at diagnosis (of 
cancers) is later for MSH2 mutation carriers compared to those with mutations 
in MLH1.  Overall, the most common extra-colonic cancer among males was small 
bowel cancer, while endometrial and breast cancers were the most common in 
females.  No significant difference in the survival period was evident when 
comparing males and females with Lynch syndrome. Although not significant, 
there was an observed trend towards improved survival for individuals with CRC 
versus extra-colonic cancers.  This may be understandable since most of the 
 114 
individuals who are tested for this study have been part of a long standing 
preventative programme involving genetic counselling, genetic testing and 
specifically colonoscopic surveillance of those testing positive for mutations in 
the MMR genes.  The regular colonoscopic surveillance has been shown to 
identify premalignant lesions and their successful removal – thereby preventing 
progression and the associated morbidity and mortality (Stupart et al., 2009), 
which might accompany gynaecological cancers which had not historically been 
actively screened for. 
 
For the investigation of the founder effect of the MLH1 c.1528C>T mutation in a 
group of Lynch syndrome probands, evidence was found suggesting that this 
mutation was indeed due to a founder effect.  Five microsatellite markers 
surrounding the mutations were tested in 30 probands and 98 healthy controls.  
The most common extended haplotype covering all five markers tracked with 
the disease-causing mutation in 25 of the 30 probands and was not observed in 
any of healthy controls.  Following haplotype analysis, the age estimation 
predicted the mutation to have arisen approximately nine generations ago; if 
each generation is considered 25 years, the mutation dates back to between 
1789 and 1814 AD. The time line coincides with the origins and diversification of 
the “Coloured” or Mixed Ancestry population in South Africa in the 1700s. The 
origin of the mutation is still to be determined, this would require testing of the 
haplotype in different populations that have contributed to this admixed 
population such as the indigenous Khoisan, Bantu and immigrant European, and 
Asian populations.   It is reasonably clear however, that because this mutation 
has not been reported in the countries of origin of the original European and 
Asian immigrants (to the knowledge of the investigator)– that the origin is likely 
to be here in Africa.  There is much fieldwork still to be done – tracking families 
beyond the northern borders of South Africa- and perhaps into Namibia, 
especially amongst the native Nama and other indigenous communities.   
 
The work on CMMR-D syndrome focused mainly in identifying genetic factors 
associated with this syndrome. The aim of this section was to investigate the 
level of dynamic change in the genomes of individuals carrying either a single 
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functional copy of the MLH1 gene or no functional copy of the gene.  The goal was 
to identify the underlying genetic features involved in the initiation and 
progression of neoplasia in a hypermutating environment.    It had been 
hypothesised that specific regions within the genome may be more susceptible 
to mutagenesis in the absence of mismatch repair function. We investigated the 
alternative pathways involved in disease manifestation and to identify genetic 
changes/mutations which may drive the premature manifestation of disease in 
CMMR-D, and perhaps also hint at the mechanisms leading to tumorigenesis in 
Lynch syndrome (and perhaps even sporadic cancers). 
   
In the first instance, a range of microsatellite markers were tested on various 
tissues of a proband with CMMR-D and established that MSI testing could not be 
used to diagnose CMMR-D. The purpose of the second part of the CMMR-D study 
was to identify genes which may be prone to mutations, and to link these genes 
to pathways associated with carcinogenesis.  For this section, DNA from the 
proband (NPC569.3), the sibling (NPC569.4) and the parents (NPC569.1 and 
NPC1.77) were subjected to WES. The pathways within genes which had 
embedded the most mutations which were biologically significant because of 
MMR deficiency, included the ‘collagen-related’ and the ‘extracellular matrix 
organisation’ pathways.   The extracellular matrix is one of the most important 
components in the tumour microenvironment and has previously been 
implicated in tumorigenesis.  In the process of mapping protein-protein 
interactions a number of pathways such as, ‘Wnt signalling’, ‘p53 pathway feed-
back’ and ‘TGF-β’ were observed to be the most enriched pathways in the CMMR-
D proband (NPC569.3), while the genome of the sibling, NPC569.4 (heterozygous 
for the MLH1 mutation), reflected variants pertinent to pathways such as 
‘angiogenesis’, ‘integrin-‘ and ‘VEGF- signalling’; all of which have also been 
previously associated with cancer development and progression.  Therefore, 
even though there were no obvious genes and/or identified regions susceptible 
to accumulation of mutations, the data suggests that the variants, although 
seemingly random, occur in or influence specific pathways which are involved in 
the development and spread of cancers. The development of cancers has been 
described as a series of steps starting with the initiating mutation, which often 
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results in a cascade of events that leads to a cell’s ability to disregard the normal 
control of proliferation, evasion of growth suppressors and resisting cell death. 
The data produced in this study shows that the presence of the identified 
variants result in an indirect influence on tumurigenesis thereby contributing, 
indirectly, to the series of events in disease development.  The unfortunate lack 
of adequate amount of tumour tissue, for WES was a major drawback in this 
study. 
 
WES was also performed on DNA samples from diverse tissues from the 
deceased proband (NPC569.3). These tissues included adrenal gland, bowel, 
cerebrum, kidney and saliva. The objective of this experiment was to further 
assess the state of mutagenicity in an individual with CMMR-D, by determining if 
there were differences in number of genetic variants which might be acquired 
between different tissues. There were a number of unique variants present in 
each of the tissues that were subjected to sequencing.  Again, the pathway-based 
analysis for the variants indicated that the extracellular matrix was the most 
enriched pathway, in agreement with the previous analysis.  For further 
validation, targeted sequencing of a panel of 13 most common cancer- related 
genes was done. The results were consistent with those observed in the WES,  
except for one gene, POLD1, which showed an average of 13 variants across the 
series of eight tissue samples (n=8). Interestingly, however, no variants were 
detected in this gene for WES.   This was thought to be due to the ‘on board’ 
filtering which resulted in variants being excluded or discarded during quality 
check processes of the on-board computational sequencing software.  Equally, it 
could be that certain critical regions of POLD1 are not captured during the 
‘amplification/library construction phase’ for WES.   Nonetheless, POLD1 is one 
of the genes that has previously been labelled as a driver in cases of glioblastoma 
in CMMR-D syndrome  (Shlien et al., 2015) – and is very likely to contain the 
disease-causing event in the tumor which resulted in the demise of the subject of 
this study, i.e. Proband NPC569.3. 
Overall, this study of the Lynch syndrome cohort (comprising of individuals with 
mutations in MLH1 and MSH2) has provided an up to date status report of 
cancers in our cohort, and provides data for further analysis of the effectiveness 
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of the surveillance programme.  The range of cancers now recognised to be part 
of Lynch syndrome benefits from data emerging from large cohorts of indviduals 
carrying the same pathogenic MMR gene mutation.  The access to an individual 
with CMMR-D in amongst the large cohort with the MLH1 c.1528C>T requires 
closer investigation of variants in tumors (versus normal tissue) in the range of 
cancers seen in this cohort, and their overlap with varinats seen in the subject 
with CMMR-D.  A considerable amount of effort is being invested in collaboraring 
with the disciplines of Paediatric Oncology and Anatomical Pathology at Red 
Cross Children’s Hospital to molecularly investigate a range of cancers seen in 
CMMR-D patients, starting with e.g. clinical awareness of e.g. signs of  café au lait 
macules, a family history of cancers, and then progressing to 
immunohistochemistry of MMR proteins and then WES (and when affordable 
WGS).    
4.2 Limitations of the study 
Although the MLH1 c.1528C>T cohort is significantly large to investigate disease 
phenomenology- the entire cohort contained relatively small numbers of 
disparate mutations in MLH1 and MSH2 to get an idea of any correlation.  
However, ongoing work – is very likely to yield extensive lineages of founder 
effects amongst CRC patients in S.A. to be able to do this kind of work in future.  
This study is valuable as it analysed the c.1528C>T cohort, and reflects the 
spread of Lynch-spectrum cancers, age at onset/diagnosis, and the success or 
otherwise of Lynch syndrome surveillance in an African setting.   
 
The section on CMMR-D syndrome only focused on a single family, with one 
proband.   This study would be most powerful if there were more families and 
affected individuals included. However, it should be noted that CMMR-D 
syndrome is one of the rare cancer syndromes with less than 200 cases reported 
worldwide, therefore recruitment of families is challenging. There is little doubt, 
however, that many more paediatric cancers may be identified as CMMR-D in the 
future.   
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For the intended list of tissues which were sequenced, unfortunately, no fresh 
tumour tissue was sampled – because of the relatively small size of the tumour.  
Therefore, only preserved material (FFPE) with all of its attendant shortcomings 
(for large scale DNA analysis) was available. Following a series of protocols used 
to extract DNA from the sample, none yielded enough DNA to allow for WES or 
even sequencing of the panel of genes described in Chapter 3. As a last resort, 
whole genome amplification of tumour DNA was attempted, in vain. 
 
Pathway-based analysis was meant to provide a bird’s eye view of the systems 
most impacted by the genes/ variants identified in the proband and sibling, 
however, this information depends greatly on what data is available at the time 
of analysis. Thus, even though the pathway analysis system uses the most 
updated information on specific diseases, it still may change as and when more 
information has been discovered on the genes their interactions and/or 
improved understanding of biological mechanisms. One of the main limitations 
of the pathway based analysis databases is understandable incomplete and 
inaccurate annotations (Khatri et al., 2014) 
 
4.3 Future directions 
The on-going interest in hereditary cancers and notably Lynch syndrome in the 
Division of Human Genetics and the Division of Surgical Gastroenterology at UCT 
and its Affiliated Hospitals – bodes well for identifying larger lineages of families 
and communities affected with Lynch syndrome.  This will add to numbers 
through which one may get an improved idea of the emerging varieties of cancer 
which constitute Lynch syndrome in the African setting.   With the current effort 
– it is likely that individuals with other MMR gene mutations will also be 
identified and add to our knowledge of disease phenomenology – towards 
improved management.  There is currently a major drive to recruit individuals of 
indigenous African origin – especially where there is anecdotal information on 
earlier onset cancers, which are more aggressive.  A visiting co-worker has been 
successful in identifying characteristics of Lynch syndrome in at least 20% of 
cancers in individuals diagnosed with cancer, under the age of 50 years in 
Zimbabwe, which is a neighbouring southern African country (Katsidzira et al., 
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2017a; b).  Of particular interest will be an understanding of whether the 
genetics or environment may contribute to differential manifestation in 
ethnically diverse populations (taking into account the issues of penetrance and 
selection which influence and are influenced by human migration and their 
environmental exposures).  South Africa is an excellent international migratory 
cul-de-sac to study this phenomenon.   
 
There are further aspects of the project which should be considered for the 
future, in the first instance every effort should be made to collect and store fresh 
as well as preserved tumour tissue; WES should be applied to tumours and 
related normal tissue from individuals under 50 years of age in order to identify 
the driver mutations, as well as to compare the acquired mutations; this would 
be equally effective for any child suspected of or identified with CMMR-D 
syndrome. This process requires very careful attention to detail in terms of 
workflows pertinent to patient care, as well as their recruitment for research.   
Although most of this is in place – there needs to be an institutional commitment 
to ethically recruiting all patients for research and ensuring that the resources 
are in place to get this done.  For this to materialise, other FFPE DNA extraction 
methods should be tried in order to yield good quality DNA from samples, 
methods such as the QIAamp FFPE DNA extraction method has been shown to 
yield better quality DNA for downstream exome analysis (Hedengaard et al., 
2014).  
 
Identification of other CMMR-D cases in order to add to the findings of the study 
would be ideal. This would also allow for identification of genetic factors that 
may later be developed as potential biomarkers in persons with CMMR-D 
syndrome.  Relationships have been developed with the Paediatric Oncologists, 
Neuorsurgeons, and Haematologists to consider CMMR-D as a differential 
diagnosis in their patients.    
 
For the current study we were unable to provide evidence for the use of MSI 
testing as a diagnostic tool for CMMR-D. Thus future research should consider 
more sensitive methods, which can be used to diagnose CMMR-D syndrome.  
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The data generated in this study should be compared with other data, such as the 
Cancer Genome Atlas (TCGA) (https://tcga-
data.nci.nih.gov/docs/publications/tcga/) data on childhood brain cancers and 
other Lynch syndrome related cancers, to identify shared variants/genes that 
may be involved in disease manifestation or progression.  
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Appendix A: Example of the consent form 
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Appendix B: Nucleic acid extraction methods 
Preparation of samples for DNA extraction from freshly frozen tissue:  
 
Samples were kept frozen at all times  
**Clear the area to ensure its is RNAse free  
Label 1.5mL tubes and petri-dishes accordingly  
 
For DNA  
Add 600uL of cell lysis buffer into 1.5mL tube  
Add 400uL of cell lysis buffer into the petri dish  
 
Using surgical blades dissect enough tissue into the petri dish (small slices are 
preferred) a slice and a half should be sufficient, however for tissues full of lipids, 
such as the brain, you may need to get more slices.  
 
Break the tissue into the smallest pieces as possible to ensure complete lysis  
Transfer the tissue into the 1.5mL tube  
Leave as much lysis buffer containing blood in the dish as possible 
 
For DNA isolation:  
1. Following the addition of tissues into the 1.5mL tube add 20uL of 10% 
SDS and 5uL of Proteinase-K , keep over night or over 2 days. The lysis 
period depends on the amount of tissue.  
2. Add 200uL of the 6M NaCl and vortex thoroughly  
3. Centrifuge at 3000rpm for 20minutes  
4. Transfer the supernatant into the new 1.5mL tube  
5. Add 1mL of absolute Ethanol to the supernatant and invert the tube 
50times  
6. Centrifuge for 10min at 5000rpm 
7. Discard the supernatant  
8. Ass 500uL ethanol and vortex  
9. Centrifuge at 5000rpm for 10minutes  
10. Decant the supernatant and air-dry the pellet for not more than 2hours  
Add 50 to 100uL of 1XTE buffer to the pellet 
 
Ion Ampliseq FFPE DNA extraction protocol: 
https://tools.thermofisher.com/content/sfs/brochures/ion-ampliseq-direct-ffpe-dna-kit-flyer.pdf  
 
Prepare reagents 
• Equilibrate Transfer Solution to room temperature (15–30°C) before use. 
• Keep Direct Reagent on ice prior to use. 
 
 
Prepare Direct FFPE DNA 
 
The recommended tissue area to be used for this protocol is 4−100 mm2 from a 
5−10 μm thick unstained section mounted on a slide.  
If desired, scrape unwanted tissue from the slide before transfer. 
 
 147 
For each sample,  
 
Pipette 30 μL of Transfer Solution into a single well of a 96-well PCR plate/ 
PCR tube.  
Note: Transfer Solution is viscous, pipet slowly. 
 
Note: Alternatively, label one nuclease-free 1.5-mL Eppendorf LoBindTM 
tube for each FFPE tissue sample and perform incubations in a heated 
block. 
 
Using a single 20-μL pipette tip for each sample: 
 
a. Pipette 2–10 μL of the Transfer Solution from the well onto the region of 
interest of the FFPE tissue section mounted on a slide. 
 
b. Using the same 20-μL-pipette tip, spread the Transfer Solution to ensure 
complete coverage of the region of interest, then scrape and break up the tissue 
with the pipette tip.  
The tissue should be a slurry of fine particles in the Transfer Solution. 
 
c. Pipette the slurry from the slide back into the PCR tube containing Transfer 
Solution. 
 
d. Pipette the slurry up and down at least  five times, leaving as much tissue as 
possible in the PCR tube. 
 
e. If needed, use the same tip to repeat steps b-d, transferring as much of the 
region of interest as possible into the PCR tube.  
 
Note: The total volume of Transfer Solution remaining in the 96-well plate 
may vary, but no volumetric adjustment is required. 
 
f. Add 21 μL of Direct Reagent to each well containing sample in the PCR tube. 
 
g. Set a pipette to 30 μL, then mix the Direct Reagent and slurry by pipetting 
up and down ten times. 
 
h. Seal the tube, then verify that the contents are at the bottom of the tube. 
 
 Note: If necessary, gently tap the tube on a hard at surface to collect the 
contents at the bottom of the wells. 
 
i. Place a compression pad on the plate, load the plate into the thermal cycler, 
then run the following program: 
 
65 degrees Celsius for 15 minutes 
20 degrees Celsius for 30 minutes 
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Appendix C: Gel-electrophoresis    
 
Reagents preparation 
10X TBE buffer 
Tris (MW = 121.134)       108g  
Boric Acid                         55g 
EDTA (pH 8)                    7.4gt 
Made up to 1000ml with distilled water  
  
1X TE buffer  
10mM Tris (121.134)                                                                     12.11g 
1mM Ethylene-diaminetetra-acetic acid (EDTA) (MW 372.24)   1.87g  
Made up to 1000ml with distilled water  
 
Agarose loading dye  
Bromo phenol blue (0.25% w/v)                                                       0.25g  
Sucrose (40% w/v)                                                                               40g 
EDTA, pH 8                                                                                          4ml  
Made up to 100ml distilled water  
 
Gel preparation 
1% , 1.5%  and 2% Agarose gel (100ml) 
1g/ 1.5g/ 2g  Agarose 
100ml 1X TBE 
Heat until the agarose dissolved 
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Allow to cool and poor into the gel tray and allow setting 
 
Molecular weight Marker: 
Gene-Ruler 100pb plus (Fermentas Inqaba) 
 
A 1/10 dilution of the marker solution was made. From the 1:10 solution 
125µl of the marker was added to 125µl of loading dye. 
 
 
 
 
Range:  
14 fragments (in bp): 3000, 2000, 1500, 1200, 1000, 900, 800, 700, 600, 500, 400, 300, 
200, 100 
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Appendix D: Promega MSI analysis protocol 
 
DNA Amplification Using the MSI Analysis System  
https://www.promega.com/resources/protocols/technical-manuals/0/msi-analysis-system-version-12-
protocol/  
 
Materials   
 • thermal cycler [GeneAmp® System 9600 or 9700 (Applied 
Biosystems)]  
 
 • microcentrifuge  
 
 • 0.2ml (thin-walled) microcentrifuge tubes, MicroAmp® reaction 
tube strips or MicroAmp® optical 96-well reaction plates (Applied Biosystems)  
 
 • 1.5ml microcentrifuge tubes  
 
 • aerosol-resistant pipette tips  
 
 • AmpliTaq Gold® DNA polymerase (Life Technologies Cat.# 
N8080242)  
The MSI Analysis System is optimized to amplify 1–2ng of genomic DNA in a 10μl 
reaction volume using the protocols detailed below. However, optimization of 
input DNA amounts should be performed to adjust for variations in DNA yield 
and quality due to differences in samples, DNA isolation methods or both. Using 
excessive amounts of DNA template may result in peak heights exceeding the 
linear detection range of the CE instruments. Use of insufficient DNA template 
can result in low PCR yields, and peak heights may fall below detection limits 
(50RFU). Accurate quantitation of template DNA is highly recommended. We 
recommend quantitating the FFPE template DNA using the Promega 
QuantiFluor® ONE dsDNA System (Cat.# E4870 or E4871) or QuantiFluor® 
dsDNA System (Cat.# E2670). Testing at Promega has shown that DNA 
quantitation using the QuantiFlour® ONE dsDNA System with the QuantusTM 
Fluorometer provided results more similar to those of qPCR from DNA samples 
extracted from three FFPE tissue types as compared to the NanoDrop® 2000 
instrument (1).  
The MSI Analysis System is optimized for use with the GeneAmp® PCR System 
9600 and 9700 thermal cyclers.  
 
4.A. Amplification Setup  
Note: We strongly recommend using gloves and aerosol-resistant pipette tips to 
prevent cross-contamination. We recommend keeping all pre-amplification and 
post-amplification reagents in separate rooms. Prepare ampli cation reactions in 
a room dedicated for reaction setup. Use equipment and supplies dedicated for 
amplification setup.  
Thaw the Gold STHR 10X Bu er, MSI 10X Primer Pair Mix and Nuclease-Free 
Water.  
 
Mix these reagents by vortexing for 5–10 seconds before each use. A precipitate 
may form in the Gold STHR  
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10X Buffer. If this occurs, warm the buffer at 37°C, then vortex until the 
precipitate is in solution.  
 
 
To prepare the Amplification Mix, determine the number of reactions to be set 
up. This should include positive and negative control reactions. Add 1 or 2 
reactions to this number to compensate for losses during pipetting. This 
approach ensures that you will have enough PCR master mix for all samples. It 
also ensures that each reaction contains the same master mix.  
 
Place one 0.2ml micro-centrifuge tube for each reaction into a rack, and label 
appropriately. Alternatively use MicroAmp® optical 96-well reaction plates.  
 
 
Combine the volumes of Nuclease-Free Water, Gold STHR 10X Bu er, MSI 10X 
Primer Pair Mix and AmpliTaq Gold® DNA polymerase in a sterile, 1.5ml tube. 
Mix gently.  
 
Transfer 8μl of Amplification Mix to the bottom of each reaction tube or well. 
Pipet 2μl of template DNA (1–2ng) for each sample into the bottom of the 
appropriate tube or well containing Amplification Mix. Mix by pipetting several 
times.  
Be sure that the template DNA is mixed well before transferring it to the tube or 
well containing Amplification Mix.  
Note: Store DNA templates in nuclease-free water or TE–4 buffer [10mM Tris 
HCl (pH 8.0), 0.1mM EDTA]. If the template DNA is stored in TE buffer that is not 
pH 8.0 or contains a higher EDTA concentration, the volume of DNA sample 
added should not exceed 20% of thermal reaction volume. PCR amplification 
efficiency and quality can be greatly altered by changes in pH (due to added Tris-
HCl), available magnesium concentration (due to chelation by EDTA) or other 
PCR inhibitors, which may be present at low concentrations depending on the 
source of template DNA and the extraction procedure used.  
 
For the positive amplification control, dilute the K562 High Molecular Weight 
DNA 1:10 to 1ng/μl in Nuclease- Free Water. Pipet 2ng of the diluted DNA into 
the bottom of the tube or well containing Amplification Mix. Mix by pipetting 
several times.  
For the negative amplification control, pipet Nuclease-Free Water (instead of 
template DNA) into a microcentrifuge reaction tube or well containing 
Amplification Mix. Mix by pipetting several times.  
 
Protocol for the GeneAmp® PCR System 9600 Thermal Cycler Cycling profile:  
95°C for 11 minutes, then: 96°C for 1 minute, then:  
94°C for 30 seconds ramp, 68 seconds to 58°C, hold for 30 seconds ramp 50 
seconds to 70°C, hold for 1 minute for 10 cycles, then:  
90°C for 30 seconds ramp, 60 seconds to 58°C, hold for 30 seconds ramp 50 
seconds to 70°C, hold for 1 minute for 20 cycles, then:  
60°C for 30 minutes and   
4°C hold  
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